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Oxidative phosphorylation (OXPHOS) has a prominent role in energy metabolism of the cell. 
Embedded in the lipid bilayer of the mitochondrial inner membrane, the OXPHOS system is 
the final biochemical pathway in energy production. The OXPHOS system comprises five 
membrane-bound multiprotein complexes and two mobile electron carriers—ubiquinone 
and cytochrome c—that transfer electrons from NADH and succinate to molecular oxygen. 
While transferring electrons, complexes I, III and IV function as redox pumps using redox 
energy to translocate protons across the membrane into the intermembrane space. The 
resulting proton gradient constitutes a membrane potential that serves as the driving force 
for ATP production by complex V (Fig 1). 
 
 
Figure 1. The OXPHOS system. 
At complex I, one of two entry points of the OXPHOS system, NADH is oxidized and electrons are 
transferred to ubiquinone (Q), while protons (H+) are pumped across the mitochondrial inner 
membrane. Complex II, the second entry point, transfers electrons from succinate into the system, 
using ubiquinone as an electron acceptor. Subsequently, electrons are transferred from ubiquinone to 
complex III, and via the water-soluble electron carrier cytochrome c (cyt c), which shuttles between 
complex III and IV, to complex IV. Complex IV transfers electrons to molecular oxygen (O2), forming 
water (H2O). Simultaneously, the proton gradient build by complexes I, III, and IV is used as a driving 
force by complex V, channeling protons back into the matrix, to convert ADP and inorganic phosphate 
(Pi) into ATP. At the bottom, the total number of subunits, as well as the number of subunits encoded 
by the nuclear (nDNA) and mitochondrial (mtDNA) DNA, are depicted for all five complexes and the 
total OXPHOS system. 
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The aim of this thesis is to expand our understanding of the biogenesis and functioning of 
complex I of the OXPHOS system in health and disease. To date, mutations have been found 
in the genes encoding numerous structural components of complex I, however, a significant 
portion of cases of complex I deficiency cannot be explained by mutations in these 
constituents. 
Alternative candidates for complex I deficiency are the proteins that guide assembly of the 
constituents into a functional complex. The main objectives are 1) identification of new 
genes that are involved in the assembly process of complex I and that are responsible for 
complex I deficiency; and 2) elucidation of the underlying pathological mechanisms. 
Biogenesis and functioning of the OXPHOS system is dependent on the finely tuned 
interaction between the nuclear and the mitochondrial genomes, both contributing to a 
complex build-up that consists of 89 subunits in total. This suggests that disturbances of the 
integrity of the system can be caused by numerous genetic defects and can result in a variety 
of metabolic and biochemical alterations. Consequently, OXPHOS deficiencies manifest in a 
wide variety of clinical symptoms, presenting from infancy to late adulthood and affecting 
many different organs and tissues, either in an organ-specific or multisystemic form (Fig 2). 
Furthermore, OXPHOS deficiencies can either be isolated, with one complex affected, or 
combined, with two or more complexes affected. Four different types of inheritance 
contribute to the heterogeneity of OXPHOS disorders: autosomal recessive or dominant, X-
linked and maternal or mitochondrial. The broad clinical spectrum at which OXPHOS 
deficiencies manifest and their underlying extended genetic background will be reviewed in 
Chapter II. 
Diseases caused by disturbances of the OXPHOS system are amongst the most frequent 
inborn errors of metabolism, with an incidence of 1 in 5,000 live births. Isolated complex I 
deficiency is the most common cause of OXPHOS disorders. Complex I, or 
NADH:ubiquinone oxidoreductase, represents the main entry point of the OXPHOS system, 
as it initiates electron transfer by oxidizing NADH. Mammalian complex I consists of 45 
subunits of which seven are encoded by the mitochondrial DNA (mtDNA) and 38 by the 
nuclear genome. Being accountable for a heterogeneous group of clinical phenotypes, the 
primary defects underlying complex I deficiency are genetically heterogeneous as well. 
Mutations have been found in each of the seven mtDNA-encoded subunits, resulting in 
either single-organ phenotypes, as Leber hereditary optic neuropathy (LHON), or 
multisystemic syndromes, e.g., mitochondrial encephalomyopathy with lactic acidosis and 
stroke-like episodes (MELAS). For mtDNA mutations presentation of the disease often 
occurs in late childhood or adolescence and there is a great variability in clinical course and 
intrafamilial presentation. So far, mutations have been found in twelve of the nuclear genes 
encoding structural components of complex I. Clinical phenotypes caused by mutations in  
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Figure 2. Organs and systems affected in OXPHOS disorders. 
OXPHOS disorders manifest in a great variety of symptoms in many different organs and 
systems of the body. This diagram depicts the most common symptoms that can occur in 
different combinations among patients. 
 
 
nuclear-encoded subunits generally present in infancy and early childhood. Nine of those 
genes (NDUFA1, NDUFA2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8 and 
NDUFV1) are mainly associated with brain and brainstem disorders, mostly Leigh(-like) 
syndrome or leukoencephalopathy, while three others (NDUFA11, NDUFS2 and NDUFV2) 
are exclusively associated with hypertrophic cardiomyopathy and encephalomyopathy. The 
pathology of complex I deficiency as well as the structure, function and biogenesis of 
mitochondrial complex I will be reviewed in Chapter III. 
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In addition to 45 structural components, probably numerous, yet unknown, nuclear factors 
are needed for proper assembly and functioning of complex I, as has been reported 
extensively for complex IV. Identification of these assembly factors will open a new field of 
possible candidates for complex I deficiency. To date, two characterized human complex I 
assembly chaperones have been proved responsible for complex I deficiency. The 
identification of the first human complex I assembly factor, NDUFAF1, as the human 
homologue of the Neurospora crassa assembly chaperone CIA30 will be described in 
Chapter IV. Further characterization of the function of NDUFAF1 in the assembly process 
of complex I and the investigation of its involvement in complex I deficiency will be 
described in Chapter V. Mitochondrial complex I assembly is an intricate process, which is 
nowadays believed to proceed through a series of distinct assembly intermediates by 
combining evolutionarily conserved functional modules in a semi-sequential manner. 
Disturbances of the process by, for instance, mutation of subunits can lead to accumulation 
and/or depletion of several intermediate assemblies, providing so-called assembly profiles. 
The effects of mutations in different complex I subunits on complex I assembly/stability will 
be described in Chapter VI. A second (complex I) assembly factor, NDUFAF2, has been 
found responsible for complex I deficiency in a unique patient with a contiguous gene 
deletion, which will be described in Chapter VII. 
Besides the disturbance of ATP production, complex I deficiency exhibits additional cell 
biological consequences. Increased production of reactive oxygen species (ROS) may have 
deleterious effects on mtDNA, protein complexes and membrane integrity. Alterations in 
mitochondrial morphology, i.e. branching or fragmentation, changes in membrane potential 
and mitochondrial NAD(P)H levels are other examples of disturbances of mitochondrial 
physiology. Some downstream alterations in mitochondrial physiology as a consequence of 
complex I deficiency will be described in Chapter VII. 
Finally, Chapter VIII will summarize the established findings and will give an overview of 
the eminent role for complex I assembly in complex I deficiency. It will also shine a light on 
the directions future research will take concerning complex I deficiency. 
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Abstract 
The oxidative phosphorylation (OXPHOS) system consists of five multiprotein complexes 
and two mobile electron carriers embedded in the lipid bilayer of the mitochondrial inner 
membrane. With the exception of complex II and the mobile carriers, the other parts of the 
OXPHOS system are under dual genetic control. Due to this bigenomic control, the 
inheritance of OXPHOS system defects is either maternal, in the case of mitochondrial DNA 
mutations, autosomal or X-linked, in the case of nuclear gene defects. In this review, our 
current genetic understanding of OXPHOS system enzyme deficiencies will be summarized, 
and future directions that the field might take to unravel so-far genetically unresolved 
OXPHOS system enzyme deficiencies will be described, with special emphasis on complex I 
biogenesis.  
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Introduction 
Deficiencies of the oxidative phosphorylation (OXPHOS) system are phenotypically as well 
as genetically heterogeneous. One of the most common mitochondrial disorders is Leigh 
syndrome. Leigh syndrome is an early-onset progressive neurodegenerative disorder and 
involves encephalopathy with or without lactic acidemia, occasionally complicated by 
cardiomyopathy or a multisystemic presentation[1]. Clinical signs such as motor and/or 
intellectual retardation, as well as other neurological symptoms including ataxia, dystonia, 
hypotonia and optic atrophy, are frequently encountered[2]. Patients with strongly suggestive 
clinical and histochemical features but with an atypical or noninvestigated neuropathology 
are referred to as Leigh-like[2,3]. Combinations of mitochondrial DNA (mtDNA) and nuclear 
DNA mutations, tissue specificity and environmental factors determine the onset and course 
of the disease. Most patients die a few years after first clinical manifestation. Besides Leigh 
and Leigh-like syndrome, many other genetic disorders represent deficiency of the OXPHOS 
system. The underlying biochemical defect can either be isolated, with one OXPHOS 
complex affected, or combined, with two or more OXPHOS complexes affected, in a tissue-
specific manner. Four different types of inheritance contribute to the heterogeneity of 
OXPHOS disorders: autosomal recessive or dominant, X-linked and maternal or 
mitochondrial. As isolated complex I deficiency is most frequently encountered[4], complex I 
will be the main focus of this review. Since the OXPHOS system is under genetic control of 
two interacting genomes, mutations causing OXPHOS deficiency can either be found in 
mitochondrial or nuclear genes.  
 
 
Mitochondrial genes involved in OXPHOS deficiency 
The particular genetic characteristics of mtDNA—maternal inheritance, polyplasmy, 
heteroplasmy, the threshold effect and mitotic segregation—are the features that distinguish 
disorders due to mtDNA defects, which follow the mitochondrial mode of inheritance, from 
disorders due to nuclear gene defects following mendelian inheritance. These characteristics 
also give rise to a broad spectrum of clinical features affecting different organs and tissues 
that can vary from one individual to another. Since mtDNA is maternally inherited, mtDNA 
mutations are only transmitted from mothers to their progeny. Each cell harbors thousands 
of identical copies of mtDNA, which is known as polyplasmy, with up to ten molecules per 
mitochondrion. Heteroplasmy occurs when wild type and mutant mtDNA coexists in cells 
and tissues. When the percentage of wild type mtDNA drops below a certain value, the 
OXPHOS system will be disturbed and clinical manifestation of the disease will take place, 
i.e., the threshold effect. Thresholds for onset of symptoms are tissue specific and are lower 
for tissues with a high demand for OXPHOS metabolism, such as brain, heart, skeletal 
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muscle, retina, renal tubules and the endocrine glands[5]. The degree of heteroplasmy can 
also change during cell division since redistribution of mitochondria occurs randomly, i.e., 
mitotic segregation[5,6]. Thereby, mutation loads can surpass or drop below a certain 
(pathogenic) threshold, altering the phenotype of that particular cell line or tissue. These 
rules of mitochondrial genetics explain the wide variety of symptoms related to age and 
tissue among patients bearing the same mutated gene or even the same specific mutation. 
Different mtDNA mutations may lead to similar clinical phenotypes, as illustrated in the case 
of Leber hereditary optic neuropathy (LHON). Primary mutations leading to LHON have 
been assigned to ND1, ND4 and ND6, and secondary or intermediate mutations have been 
reported for ND1, ND2, ND4, ND4L, ND5, CYB, COI, COII, COIII and ATP6. A T8993G 
mutation in the ATPase 6 gene is the common mutation for neuropathy, ataxia and retinitis 
pigmentosa (NARP) syndrome[7], and this specific mutation has also been associated with 
maternally inherited Leigh syndrome (MILS), provided that percentages of heteroplasmy 
exceed 95% of mutant mtDNA in affected tissues (e.g., fibroblasts, muscle, nerve and 
brain)[8]. Most mutations in the cytochrome b gene are related to progressive exercise 
intolerance[9-11], although some have been reported in cases of cardiomyopathy[12], 
LHON[13,14] and the Parkinsonism/mitochondrial encephalopathy with lactic acidosis and 
stroke-like episodes (MELAS) overlap syndrome[15]. The genes for the mtDNA-encoded 
subunits of cytochrome c oxidase (COX) are, besides LHON[16,17], also associated with 
sideroblastic anemia (COI)[18], isolated motor neuron disease (COI)[19], multisystem 
mitochondrial disorders (COI and COII)[20,21] and recurrent myoglobinuria (COI and 
COIII)[22,23]. 
Due to the unique genetic code and the separate machinery for mitochondrial translation, 
not only mutations in the protein-encoding genes, which encode subunits of the OXPHOS 
complexes, but also the genes encoding transfer RNA (tRNA) and ribosomal RNA (rRNA) 
can, when mutated, lead to OXPHOS deficiency. Since instead of one protein, mitochondrial 
protein synthesis in general is disturbed in these cases, deficiencies of all OXPHOS 
complexes, except complex II, can occur. Mutations in the tRNA Leu(UUR) gene are often 
associated with MELAS[24], another genetic heterogeneous syndrome that can be caused by 
mutations in ND1, ND5, ND6, COIII and tRNA Lys, Gln, Val and Phe. The tRNA Leu(UUR) 
mutations, on the contrary, may also give rise to cardiomyopathy[25], mitochondrial 
myopathy[26], chronic progressive external ophthalmoplegia (CPEO)[27] and diabetes and 
deafness[28]. Mutations in the tRNA Lys gene are the underlying defect in almost all cases of 
myoclonus epilepsy with ragged-red fibers (MERRF) syndrome[29,30], but they can also lead 
to other syndromes. Mutations in the small (12S) rRNA gene cause nonsyndromic 
sensorineural deafness most often[31] and 16S rRNA mutations have been associated with 
cardiomyopathy[32] and with Rett syndrome[33]. 
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In addition to the maternally inherited specific mutations, sporadic rearrangements of 
mtDNA can occur. These deletions and duplications of mtDNA fragments probably originate 
in the germ line, although a few maternally inherited cases have been described[34]. 
Depending on when in oogenesis the deletion occurred, either all three germ layers can bear 
the deleted mtDNA, resulting in multisystemic Kearns-Sayre syndrome (KSS), or 
segregation to the hematopoietic lineage, causing Pearson‘s syndrome, or segregation to the 
muscle, leading to CPEO, can take place[5]. 
Table 1 summarizes the most frequently encountered mtDNA defects, the biochemical 
consequences of these mutations, as well as the associated clinical presentations. 
 
 
Nuclear genes involved in OXPHOS deficiency 
Nuclear genes responsible for disturbance of the OXPHOS system can be categorized on a 
structural and functional level: genes encoding structural components of the OXPHOS 
system; genes encoding assembly factors of the OXPHOS complexes; genes involved in 
biogenesis of the OXPHOS system; genes involved in maintenance of mtDNA; genes 
involved in biogenesis and maintenance of the mitochondrial membranes; and genes 
associated with secondary defects of the OXPHOS system (Tab 2). 
 
Genes encoding structural components of the OXPHOS system 
Complex I—Isolated complex I (or NADH:ubiquinone oxidoreductase; EC 1.6.5.3) deficiency 
is one of the most frequent disturbances of the OXPHOS system and frequently follows an 
autosomal recessive mode of inheritance[4]. Mutations have been identified in twelve of the 
38 nuclear genes encoding structural subunits of complex I. Seven of them, NDUFV1, 
NDUFV2, NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8, encode so-called essential 
or core subunits and are all thought to be involved in the configuration of the iron–sulfur 
clusters. Mutations in these genes apparently affect intramolecular electron transfer. Five 
other genes, NDUFA1, NDUFA2, NDUFA11, NDUFS6 and NDUFS4, encode accessory 
subunits. Clinical presentation, in the majority of cases, involves Leigh or Leigh-like 
syndrome (NDUFS1, NDUFS3, NDUFS4, NDUFS7, NDUFS8, NDUFA1 and NDUFA2)[96-102] 
or leukodystrophy (NDUFS1 and NDUFV1)[97,103], although mutations in the NDUFS2, 
NDUFV2 and NDUFA11 genes have specifically been associated with hypertrophic 
cardiomyopathy and encephalomyopathy[104-106]. 
Complex II—Complex II (or succinate:ubiquinone oxidoreductase; EC 1.3.5.1) consists of 
four nuclear DNA-encoded subunits and functions both as an enzyme complex of the 
OXPHOS system and as an essential enzyme of the tricarboxylic acid (TCA) cycle. The 
peripheral arm consists of a flavoprotein, where the active site containing covalently bound  
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Table 1. Mitochondrial genes involved in oxidative phosphorylation (OXPHOS) deficiency 
Gene (mutation) 
Affected biochemical 
mechanism 
Main clinical presentation Ref. 
Subunits of the OXPHOS system 
MTND1 (G3460A) OXPHOS complex I LHON [35] 
MTND1 (A3796G) OXPHOS complex I 
Adult-onset dystonia, spasticity and core-type 
myopathy 
[36] 
MTND1 (G3697A, G3946A, 
T3949C) 
OXPHOS complex I MELAS [37] 
MTND2 (G5244A) OXPHOS complex I LHON [13] 
MTND2 (T4681C) OXPHOS complex I Leigh syndrome [38] 
MTND3 (T10158C) OXPHOS complex I Leigh syndrome [39] 
MTND3 (T10191C) OXPHOS complex I 
Progressive epilepsy, stroke-like episodes, optic 
atrophy and cognitive decline 
[40] 
MTND3 (G10197A) OXPHOS complex I Leigh syndrome and dystonia [41] 
MTND4 (C11777A) OXPHOS complex I Leigh syndrome [42] 
MTND4 (G11778A) OXPHOS complex I LHON [35] 
MTND4 (G11832A) OXPHOS complex I Exercise intolerance [43] 
MTND4L (T10663C) OXPHOS complex I LHON [44] 
MTND5 (T12706C) OXPHOS complex I Leigh syndrome [45] 
MTND5 (A13084T) OXPHOS complex I Leigh-MELAS overlap syndrome [46] 
MTND5 (G13513A) OXPHOS complex I MELAS [47] 
MTND5 (G13513A) OXPHOS complex I Leigh-like syndrome [48] 
MTND5 (A13514G) OXPHOS complex I MELAS-like [49] 
MTND5 (G13708A) OXPHOS complex I LHON [13] 
MTND6 (G14453A) OXPHOS complex I MELAS [50] 
MTND6 (G14459A) OXPHOS complex I LHON and dystonia [51] 
MTND6 (G14459A) OXPHOS complex I Leigh syndrome [52] 
MTND6 (C14482G, C14482A, 
T14484C, A14495G) 
OXPHOS complex I LHON [35,53,54] 
MTCYB (del14787-14790) OXPHOS complex III Parkinsonism/MELAS overlap syndrome [15] 
MTCYB (G15059A) OXPHOS complex III Exercise muscle intolerance and myoglobinuria [9] 
MTCYB (G15242A) OXPHOS complex III 
Exercise intolerance and mitochondrial 
encephalomyopathy  
[11] 
MTCYB (G15257A) OXPHOS complex III LHON [13,14] 
MTCYB (C15452A) OXPHOS complex III Ischemic cardiomyopathy [12] 
MTCYB (G15615A) OXPHOS complex III Exercise muscle intolerance [10] 
MTCO1 (5-bp del 5‘UTR) OXPHOS complex IV Isolated motor neuron disease [19] 
MTCO1 (T6721C, T6742C) OXPHOS complex IV Sideroblastic anemia [18] 
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MTCO1 (G6930A) OXPHOS complex IV Multisystem mitochondrial disorder [20] 
MTCO1 (G7444A) OXPHOS complex IV LHON [16] 
MTCO1 (G5920A) OXPHOS complex IV Recurrent myoglobinuria [22] 
MTCO2 (G7598A) OXPHOS complex IV LHON [17] 
MTCO2 (T7671A) OXPHOS complex IV Proximal myopathy and lactic acidosis [55] 
MTCO2 (G7706A) OXPHOS complex IV Alpers-Huttenlocher-like syndrome [56] 
MTCO2 (G7896A) OXPHOS complex IV Multisystem mitochondrial disorder [21] 
MTCO2 (del8042AT) OXPHOS complex IV Severe lactic acidosis and hepatic involvement [57] 
MTCO3 (15-bp del) OXPHOS complex IV Recurrent myoglobinuria [23] 
MTCO3 (ins9537C) OXPHOS complex IV Leigh-like syndrome [58] 
MTCO3 (G9804A, G9438A) OXPHOS complex IV LHON [59] 
MTCO3 (T9957C) OXPHOS complex IV MELAS [60] 
MTATP6 (T8993G) OXPHOS complex V NARP [7] 
MTATP6 (T8993G) OXPHOS complex V  MILS [8] 
MTATP6 (T9101C) OXPHOS complex V LHON [61] 
MTATP8 (G8529A) OXPHOS complex V 
Apical hypertrophic cardiomyopathy and 
neuropathy 
[62] 
Transfer RNAs 
MTTL1 Leu(UUR) (A3243G, 
T3271C, T3291C) 
Mitochondrial translation MELAS [24] 
MTTL1 Leu(UUR) (A3243G) Mitochondrial translation MERRF/MELAS overlap syndrome [63] 
MTTL1 Leu(UUR) (A3243G) Mitochondrial translation Diabetes and deafness [28] 
MTTL1 Leu(UUR) (A3243G) Mitochondrial translation CPEO; Kearns-Sayre syndrome [27] 
MTTL1 Leu(UUR) (C3303T) Mitochondrial translation 
Cardiomyopathy and/or mitochondrial 
myopathy 
[25] 
MTTL1 Leu(UUR) (T3250C, 
A3302G) 
Mitochondrial translation Mitochondrial myopathy [26] 
MTTL2 Leu(CUN) (A12320G) Mitochondrial translation Mitochondrial myopathy [64] 
MTTL2 Leu(CUN) (T12297C) Mitochondrial translation Dilated cardiomyopathy [65] 
MTTL2 Leu(CUN) (G12315A) Mitochondrial translation CPEO [66] 
MTTL2 Leu(CUN) (G12301A) Mitochondrial translation Sideroblastic anemia [67] 
MTTK Lys (A8344G, A8296G) Mitochondrial translation MERRF [29,30] 
MTTK Lys (T8316C) Mitochondrial translation MELAS [68] 
MTTK Lys (G8363A) Mitochondrial translation 
Cardiomyopathy and hearing loss; Leigh 
syndrome 
[69] 
MTTK Lys (G8342A) Mitochondrial translation CPEO [70] 
MTTI Ile (A4300G) Mitochondrial translation Hypertrophic cardiomyopathy [71] 
MTTI Ile (A4267G) Mitochondrial translation 
Mitochondrial myopathy, ataxia and 
sensorineural deafness 
[72] 
MTTI Ile (T4285C) Mitochondrial translation CPEO [73] 
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MTTS1 Ser(UCN) (A7445G) Mitochondrial translation Sensorineural deafness [74] 
MTTS1 Ser(UCN) (T7512C) Mitochondrial translation MERFF/MELAS overlap syndrome [75] 
MTTS2 Ser(AGY) (C12258A) Mitochondrial translation Diabetes and deafness [28] 
MTTA Ala (T5628C) Mitochondrial translation CPEO [76] 
MTTC Cys (A5814G) Mitochondrial translation 
Hypertrophic cardiomyopathy; 
encephalomyopathy 
[77] 
MTTD Asp (A7543G) Mitochondrial translation Myoclonic epilepsy [78] 
MTTE Glu (T14687C) Mitochondrial translation 
Mitochondrial myopathy and lactic acidosis, 
retinopathy and respiratory failure 
[79] 
MTTE Glu (T14709C) Mitochondrial translation Mitochondrial myopathy and diabetes mellitus [80] 
MTTF Phe (G583A) Mitochondrial translation MELAS [81] 
MTTF Phe (T618C) Mitochondrial translation Mitochondrial myopathy [82] 
MTTG Gly (T9997C) Mitochondrial translation 
Hypertrophic cardiomyopathy; 
encephalomyopathy 
[83] 
MTTM Met (T4409C) Mitochondrial translation Mitochondrial myopathy [84] 
MTTN Asn (G5703A) Mitochondrial translation CPEO [85] 
MTTP Pro (G15990A) Mitochondrial translation Mitochondrial myopathy [85] 
MTTQ Gln (ins4370A) Mitochondrial translation Myopathy [87] 
MTTQ Gln (G4332A) Mitochondrial translation MELAS [88] 
MTTT Thr (G15915A) Mitochondrial translation Mitochondrial encephalomyopathy [89] 
MTTV Val (G1642A) Mitochondrial translation MELAS [90] 
MTTV Val (G1644C) Mitochondrial translation Leigh syndrome [91] 
MTTW Trp (ins5537T) Mitochondrial translation Leigh syndrome [92] 
MTTY Tyr (G5877A) Mitochondrial translation CPEO [93] 
Ribosomal RNAs 
MTRNR1 12S rRNA (A1555G) Mitochondrial translation Nonsyndromic sensorineural hearing loss [31] 
MTRNR1 12S rRNA (A1555G) Mitochondrial translation Mitochondrial cardiomyopathy [94] 
MTRNR1 12S rRNA (T1095C) Mitochondrial translation 
Sensorineural hearing loss, parkinsonism and 
neuropathy 
[95] 
MTRNR2 16S rRNA (C3093G) Mitochondrial translation 
MELAS, diabetes mellitus, hyperthyroidism and 
cardiomyopathy 
[32] 
MTRNR2 16S rRNA (C2835T) Mitochondrial translation Rett syndrome [33] 
LHON: Leber hereditary optic neuropathy; MELAS: mitochondrial encephalopathy with lactic acidosis and stroke-like 
episodes; NARP: neuropathy ataxia and retinitis pigmentosa; MILS: maternally inherited Leigh syndrome; MERRF: 
myoclonus epilepsy with ragged-red fibers; CPEO: chronic progressive external ophthalmoplegia 
 
 
FAD is located, and an iron–sulfur protein, and is anchored to the membrane by two 
transmembrane proteins. A mutation in the flavoprotein encoding the SDHA gene of a 
patient with Leigh syndrome was the first mutation identified in a nuclear gene causing 
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OXPHOS deficiency[107]. On the contrary, mutations in the genes encoding the iron–sulfur 
protein, SDHB, and the anchor proteins, SDHC and SDHD, manifest in a phenotypically 
different manner; they cause hereditary paragangliomas and/or pheochromocytomas[108-111]. 
Complex III—Complex III (or ubiquinol:cytochrome c oxidoreductase; EC 1.10.2.2) transfers 
electrons from the ubiquinone pool to cytochrome c and is composed of eleven subunits, of 
which ten are nuclear DNA-encoded. Recently, the first mutation in a nuclear DNA-encoded 
subunit of complex III was reported: the ubiquinol–cytochrome c reductase binding protein 
(UQCRB or QP-C) gene[112]. Whereas complex III deficiency is often associated with 
multisystemic and tissue-specific disorders, such as (encephalo)myopathy or 
cardiomyopathy[9-12,15,113], in this case no psychomotor retardation or neurological 
impairment has been observed, although laboratory investigations revealed hypoglycemia 
and lactic acidemia. 
Complex IV & V—To date, no mutations have been reported in the structural nuclear 
components of complex IV (or cytochrome c oxidase; COX; EC 1.9.3.1) or complex V (or 
F0F1-ATPase; EC 3.6.3.14). Most syndromes with isolated complex IV deficiency are caused 
by mutations in genes encoding proteins involved in the proper assembly of this 13-subunit 
rich complex. 
 
Genes encoding assembly factors of the OXPHOS complexes 
Assembly factors are proteins that mediate the assembly process of subunits and 
intermediate complexes into fully assembled OXPHOS complexes and can have chaperone-
like functions. Over the years, a few assembly factors have been identified for complex I and 
III and many for complex IV.  
Two characterized human complex I assembly factors have been proved responsible for 
complex I deficiency. In a patient presenting with an early-onset progressive encephalopathy 
resembling vanishing white matter disease, a null mutation was found in the NDUFAF2 
gene, encoding human complex I assembly factor 2 (also known as human B17.2L), which is 
a paralogue of subunit NDUFA12 of the peripheral arm of complex I[114]. A mutation in the 
gene encoding a second complex I assembly factor, NDUFAF1, has been associated with 
cardioencephalomyopathy[115]. Recently, a third putative complex I assembly factor encoded 
by the C6ORF66 gene has been reported carrying pathogenic mutations in six patients with 
mitochondrial encephalomyopathy or antenatal cardiomyopathy[116]. 
The only known assembly factor gene responsible for isolated complex III deficiency is 
BCS1L[117], encoding a mitochondrial inner membrane protein participating as a chaperone 
in assembly of the Rieske iron–sulfur subunit of complex III[118,119]. Mutations in BCS1L have 
been associated with neonatal proximal tubulopathy, hepatic involvement and 
encephalopathy[120], with a lethal metabolic disorder with iron overload, named GRACILE 
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(growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis and early 
death) syndrome[120], and recently with Björnstad syndrome[121]. 
Complex IV is composed of 13 structural subunits, three of which are encoded by the mtDNA 
and form the catalytic core of the enzyme. The other ten are encoded by the nucleus. A large 
number of accessory factors are necessary for the assembly and maintenance of the active 
holoenzyme complex[122], and several mutations in these factors leading to complex IV 
deficiency have been described. 
The first gene encoding an assembly factor known to be responsible for COX deficiency was 
the SURF-1 gene. SURF-1 is needed for maintenance of COX activity and probably involved 
in the early stages of COX assembly[1,122,123]. Leigh syndrome is the most common clinical 
manifestation observed in SURF-1 patients and is associated with loss of function mutations 
resulting in undetectable protein levels of SURF-1[124,125]. SURF-1 mutations have also been 
described in non-Leigh phenotypes, e.g., isolated leukodystrophy has also been 
described[126,127]. Two other COX assembly genes, SCO1 and SCO2, encode copper ion 
binding proteins that facilitate the insertion of copper into the COX subunits I and II and the 
subsequent incorporation of subunits I and II into the holoenzyme. Mutations in SCO1 and 
SCO2, which are more frequently encountered, correlate with hypertrophic cardiomyopathy 
and encephalopathy[128,129], combined with hepatic failure in a case of a SCO1 patient[130]. The 
COX10 and COX15 genes are involved in the synthesis of heme A, a prosthetic group of COX. 
Mutations in these genes result in a clinical manifestation comparable with that of 
SCO2[131,132]. Mutations in the LRPPRC gene cause Leigh syndrome French Canadian variant 
(LSFC), a variant of Leigh syndrome with additional hepatic involvement[133]. In LSFC 
besides the brain, only the liver exhibits marked reduction in COX activity. LRP130, which is 
encoded by the LRPPRC gene, is a component of a complex that affects numerous processes 
related to energy homeostasis[134]. 
For F0F1-ATPase, complex V of the OXPHOS system, the only pathogenic mutation in a 
nuclear gene encoding an assembly factor (or subunits of the complex itself), so far has been 
found in the ATP12 gene, in a patient presenting with mitochondrial encephalomyopathy 
with lactic acidosis and hepatic involvement[135]. 
 
Genes involved in the biogenesis of the OXPHOS system 
OXPHOS deficiencies can also be due to defects in biogenesis of the OXPHOS system, i.e., 
defects in transcription of mtDNA, or defects in translation of mitochondrial messenger 
RNA (mRNA). The latter defects can occur in the case of defective components of the 
mitochondrial ribosome or the mitochondrial translation system. Mutations in the genes of 
two ribosomal proteins, MRPS16 and MRPS22, have been detected in cases of fatal neonatal 
lactic acidosis, and hypertrophic cardiomyopathy and tubulopathy, respectively[136,137]. 
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Mutations in mitochondrial translation elongation factors EFG1, EFTu and EFTs have been 
encountered in cases of encephalo(myo)pathy with (EFG1)[137] or without (EFTs)[139] hepatic 
involvement,  leukodystrophy (EFTu)[140], but also in a case of hypertrophic cardiomyopathy 
(EFTs)[139]. Another component of the mitochondrial translation machinery, pseudouridine 
synthase 1 (PUS1), is responsible for post-transcriptional pseudouridylation of specific 
mitochondrial tRNAs and mutations in the PUS1 gene are specific for mitochondrial 
myopathy and sideroblastic anemia (MLASA)[141]. 
Genes involved in biosynthesis of ubiquinone—one of the two mobile electron carriers of the 
OXPHOS system—include COQ2, PDSS1, and PDSS2, which form another group of genes, 
when mutated, leading to OXPHOS disorders[142-144]. 
 
Genes involved in mtDNA maintenance 
Mutations in nuclear genes involved in mtDNA maintenance cause disorders that clinically 
resemble those caused by mtDNA mutations, i.e., a primary nuclear gene defect causes 
secondary mtDNA loss or multiple deletion formation but follows a mendelian inheritance 
pattern[145]. The most frequently described disorder is autosomal dominant progressive 
external ophthalmoplegia (adPEO), for which four different disease genes have been 
identified: ANT1, encoding the adenine nucleotide translocator or ADP/ATP 
translocator[146]; POLG1 and POLG2, encoding catalytic subunit A and accessory subunit B, 
respectively, of the mtDNA-specific polymerase gamma[147,148,150]; and PEO1, encoding the 
Twinkle protein, a mtDNA helicase[151-153]. Mutations following a recessive mode of 
inheritance (arPEO) have also been reported for POLG1[149]. Other frequently encountered 
clinical phenotypes observed with POLG1 mutations are Alpers syndrome and Alpers-
Huttenlocher syndrome[154,155]. While mtDNA polymerase gamma and Twinkle are directly 
involved in mtDNA replication, another group of genes is involved in the mitochondrial 
deoxyribonucleoside triphosphate (dNTP) salvage pathway, which supplies the mitochondria 
with dNTP pools needed for mtDNA synthesis. Besides defective mtDNA replication, 
disturbance of the dNTP pools can also cause mitochondrial DNA depletion syndrome 
(MDS). MDS is a clinically heterogeneous group of autosomal recessive disorders 
characterized by tissue-specific reduction in mtDNA copy number. Affected tissues show 
both decreased activity of the mtDNA-encoded OXPHOS complexes (I, III, IV and V) and 
mtDNA depletion. Several tissue-specific forms can be distinguished. The genes encoding 
the salvage-pathway enzymes thymidine kinase 2 (TK2) and deoxyguanosine kinase 
(DGUOK) have specifically been associated with a myopathic form and a hepatocerebral 
form of MDS, respectively[156-158]. A third enzyme involved in the regulation of the 
mitochondrial dNTP pool is thymidine phosphorylase (TP). Deficiency of TP causes multiple 
mtDNA deletions and/or mtDNA depletion leading to mitochondrial neurogastrointestinal 
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encephalomyopathy (MNGIE)[159,160]. Two other genes, SUCLA2 and SUCLG1, encoding the 
β- and α-subunit, respectively, of the TCA-cycle enzyme succinate-coenzyme A ligase (SUCL) 
have been associated with a encephalomyopathic form and fatal infantile lactic acidosis 
(FILA) associated with mtDNA depletion, respectively[161,162]. It is hypothesized that mtDNA 
depletion is caused by decreased mitochondrial nucleoside diphosphate kinase (NDPK) 
activity resulting from the inability of NDPK to form a complex with SUCL[162]. NDPKs are 
protein kinases that are involved in de novo synthesis of dNTPs. Mutations in the MPV17 
gene, of which the function remains unclear, have also been associated with an early-onset 
hepatocerebral form of MDS[163]. Recently, yet another gene, RRM2B, encoding the cytosolic 
tumor suppressor p53-inducible ribonucleotide reductase small subunit (p53R2), has been 
associated with mtDNA depletion, which implies that p53R2 has a crucial role in dNTP 
supply for mtDNA synthesis. Mutations in the RRM2B gene presented with encephalopathy 
and renal failure[164].  
The link between the genetic defects of enzymes of the mitochondrial dNTP salvage pathway 
and mtDNA depletion strongly suggests the involvement of the mitochondrial dNTP pool in 
the pathogenesis of the MDS and underscores the importance of maintaining balanced 
mitochondrial dNTP pools[157]. The identification and interpretation of novel gene defects 
underlying these diseases will provide further understanding of the intergenomic 
communication between the nuclear and mitochondrial genomes[145,159]. 
 
Genes involved in biogenesis and maintenance of the mitochondrial membranes 
Besides defects of genes directly involved in biogenesis of the OXPHOS system, the system 
might also become disturbed by other factors affecting its functioning, such as alterations in 
the lipid composition of the mitochondrial inner membrane. In Barth syndrome, an X-linked 
cardiac and skeletal mitochondrial myopathy, disturbance of cardiolipin metabolism has 
been observed. Mutations of the TAZ gene, encoding tafazzin, a phospholipid acyltransferase 
involved in acyl-specific remodeling of cardiolipin (the specific mitochondrial phospholipid), 
may be responsible for the alterations of mitochondrial lipids leading to changes in 
mitochondrial architecture and function[165-167].  
Several mitochondrial enzymes that are involved in the formation and maintenance of the 
mitochondrial network, called dynamin-related GTPases, have recently been implicated in 
mitochondrial disease. Two of them mediate the mitochondrial fusion process: optic 
atrophy 1 protein (OPA1), which is located in the intermembrane space, is required for 
fusion of the mitochondrial inner membranes and cristae. The OPA1 gene has been 
identified as the gene responsible for autosomal dominant optic atrophy (DOA), the most 
common form of inherited optic neuropathy characterized by early-onset visual 
impairment[168,169]. Mitofusin 2 (MFN2), which is embedded in the mitochondrial outer 
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membrane, mediates the tethering of mitochondria with each other during the fusion 
process. Mutations in the MFN2 gene are the cause of Charcot-Marie-Tooth disease 
type 2A2 (CMT2A2), a peripheral neuropathy characterized by axonal degeneration[170], and 
CMT type 6 (CMT6) also hereditary motor and sensory neuropathy type VI (HMSN VI)[171]. A 
third GTPase, called dynamin-like protein 1 (DLP1) or dynamin-related protein 1 (DRP1), is 
required for mitochondrial fission and mutations in the DLP1 gene have been encountered in 
a case of microcephaly, optic atrophy and metabolic aberrations[172]. 
 
Genes associated with secondary defects of the OXPHOS system 
OXPHOS deficiencies also occur as secondary defects, i.e., as a consequence of defective 
related mechanisms, for instance the import of nuclear DNA-encoded mitochondrial 
proteins (e.g., OXPHOS components) into the mitochondrion. A mutation in the gene for 
subunit 8a of the translocase of the inner mitochondrial membrane, TIMM8A or DDP1, 
causes human deafness dystonia syndrome, also known as Mohr-Tranebjaerg syndrome 
(MTS), a progressive neurodegenerative disorder[173,174]. TIMM8A belongs to a family of 
evolutionarily conserved proteins and is organized in a complex together with the TIM13 
protein in the mitochondrial intermembrane space. This complex mediates the import and 
insertion of nuclear DNA-encoded hydrophobic membrane proteins into the mitochondrial 
inner membrane. Although the involvement of Ddp1 in the import of mitochondrial proteins 
implies that the underlying defect of the MTS is a defect in mitochondrial OXPHOS and 
phenotypes associated with the systemic OXPHOS defects overlap with clinical symptoms of 
MTS[175], enzyme activities of the OXPHOS complexes show normal values in muscle biopsy. 
Therefore, the specific mitochondrial dysfunction in MTS remains to be clarified[176]. 
Two genes encoding mitochondrial solute carriers have been implicated in mitochondrial 
disease. The SLC25A19 gene or DNC encodes a mitochondrial thiamine pyrophosphate 
(ThPP) transporter and the SLC19A2 gene or THTR1 encodes a plasma membrane thiamine 
(or vitamin B1) transporter. Mutations in the SLC25A19 gene lead to lack of mitochondrial 
ThPP—a coenzyme of the pyruvate dehydrogenase and α-ketoglutarate dehydrogenase 
complexes—and concomitant reduction of energy produced by oxidative metabolism, which 
is the cause of Amish lethal microcephaly (MCPHA) and alpha-ketoglutaric aciduria[177,178]. 
Mutations in the SLC19A2 gene cause thiamine-responsive megaloblastic anemia with 
diabetes mellitus and progressive sensorineural deafness (TRMA), also known as Rogers 
syndrome. TRMA is an early-onset autosomal recessive disorder with a severe deficiency of 
pyruvate dehydrogenase and complex I in muscle tissue that responds to thiamine 
treatment[179-181]. 
Friedreich ataxia is an autosomal recessive disorder that is predominantly caused by the 
abnormal expansion of a GAA repeat in the first intron of the FXN gene, which encodes the 
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mitochondrial protein frataxin[182]. Frataxin is a component of the human iron–sulfur cluster 
assembly machinery and plays a role in the maturation of both mitochondrial and cytosolic 
iron–sulfur proteins[183]. The lack of frataxin appears to result in oxidative damage to the 
highly sensitive iron–sulfur protein complexes I, II, III of the OXPHOS system and the TCA 
cycle-enzyme aconitase and should be related to mitochondrial iron accumulation[184]. 
Although significant reductions in the activities of these enzymes are present in the heart[185], 
the deficiencies of the OXPHOS system are presumed to be secondary. 
Hereditary spastic paraplegia (HSP) is a genetically heterogeneous neurodegenerative 
disorder characterized by axonal degeneration and presents with progressive weakness and 
spasticity of the lower limbs. In addition, muscle biopsies from the most severely affected 
HSP patients showed histological evidence of OXPHOS defects, including ragged-red fibers 
and COX-negative fibers, whereas biochemical analysis revealed reduced complex I 
activity[186]. The spastic paraplegia gene, SPG7, encodes a subunit of the m-AAA protease 
termed paraplegin, which has both metallopeptidase and chaperone-like activities at the 
mitochondrial inner membrane. The m-AAA protease has a dual role in protein quality 
control and ribosome assembly in mitochondria. With mitochondrial ribosomal protein 
Mrpl32 as a proteolytic substrate, a crucial function for the control of mitochondrial protein 
synthesis is assigned to the m-AAA protease[187]. Patients with mutations in SPG7, 
expressing a secondary OXPHOS defect, represent one of several subtypes of HSP. 
Ethylmalonic encephalopathy (EE) is a devastating infantile metabolic disorder affecting the 
brain, gastrointestinal tract, and peripheral vessels, and is characterized by high levels of 
ethylmalonic acid in body fluids and decreased cytochrome c oxidase activity in skeletal 
muscle. EE is specifically caused by mutations in the ETHE1 gene, which encodes a 
mitochondrial matrix protein of unknown function[188]. However, the severe consequences of 
its malfunctioning indicate an important role in mitochondrial homeostasis and energy 
metabolism. 
 
 
Expert opinion 
Future directions of research in OXPHOS deficiency 
As the number of genes known to be involved in the biogenesis of the OXPHOS system is 
still growing, mapping and identification of responsible genes for OXPHOS deficiency 
becomes more laborious. Therefore, it is essential to first categorize the biochemical defects 
before further characterization of the genetic defects can take place. Traditional approaches 
to the diagnosis of mitochondrial disorders have been based on enzymatic activity assays, 
which are time consuming and often require large patient samples. Capaldi‘s group 
developed an immunocytochemical assay to aid in the detection of mitochondrial disorders 
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Table 2. Nuclear genes involved in oxidative phosphorylation (OXPHOS) deficiency 
Gene (protein 
name) 
Affected biochemical 
mechanism 
Main clinical presentation Ref. 
Subunits of the OXPHOS system 
NDUFS1 OXPHOS complex I Leigh syndrome and leukodystrophy [97] 
NDUFS2 OXPHOS complex I 
Hypertrophic cardiomyopathy and 
encephalomyopathy 
[104] 
NDUFS3 OXPHOS complex I Leigh syndrome [98] 
NDUFS4 OXPHOS complex I Leigh syndrome [96, 189] 
NDUFS4 OXPHOS complex I Leigh-like syndrome [190,191] 
NDUFS6 OXPHOS complex I Unspecified mitochondrial encephalomyopathy [192] 
NDUFS7 OXPHOS complex I Leigh syndrome [99] 
NDUFS8 OXPHOS complex I Leigh syndrome [100] 
NDUFV1 OXPHOS complex I Leukodystrophy and myoclonic epilepsy [97, 103] 
NDUFV2 OXPHOS complex I 
Hypertrophic cardiomyopathy and 
encephalomyopathy 
[105] 
NDUFA1 OXPHOS complex I Leigh syndrome [101] 
NDUFA1 OXPHOS complex I Myoclonic epilepsy and developmental delay [101] 
NDUFA2 OXPHOS complex I Leigh syndrome [102] 
NDUFA8, NDUFS2 OXPHOS complex I Mitochondrial encephalopathy [193] 
NDUFA11 OXPHOS complex I Encephalocardiomyopathy [106] 
NDUFA11 OXPHOS complex I FILA [106] 
SDHA OXPHOS complex II Leigh syndrome [107] 
SDHA OXPHOS complex II Late-onset optic atrophy, ataxia and myopathy [194] 
SDHB OXPHOS complex II 
Hereditary paraganglioma/ pheochromocytoma 
(PGL4) 
[108,109] 
SDHC OXPHOS complex II Hereditary paraganglioma (PGL3) [110] 
SDHD OXPHOS complex II 
Hereditary paraganglioma/ pheochromocytoma 
(PGL1) 
[111] 
UQCRB OXPHOS complex III Hypoglycemia and lactic academia [112] 
Assembly factors of the OXPHOS complexes 
NDUFAF1 OXPHOS complex I 
Hypertrophic cardiomyopathy and 
encephalomyopathy 
[115] 
NDUFAF2 OXPHOS complex I Leukoencephalopathy [114] 
NDUFAF2 OXPHOS complex I 
Mitochondrial encephalopathy and hepatic 
involvement 
[195] 
C6ORF66 OXPHOS complex I Mitochondrial encephalomyopathy [116] 
C6ORF66 OXPHOS complex I Antenatal cardiomyopathy [116] 
BCS1L OXPHOS complex III 
Neonatal proximal tubulopathy, hepatic involvement 
and encephalopathy 
[117] 
BCS1L OXPHOS complex III GRACILE syndrome [120] 
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BCS1L OXPHOS complex III Björnstad syndrome [121] 
SURF-1 OXPHOS complex IV Leigh syndrome [124,125] 
SURF-1 OXPHOS complex IV Leukodystrophy [126] 
SURF-1 OXPHOS complex IV 
Villous atrophy, hypertrichosis and mild neurological 
involvement 
[127] 
SCO1 OXPHOS complex IV Neonatal-onset hepatic failure and encephalopathy [129] 
SCO2 OXPHOS complex IV Encephalopathy and hypertrophic cardiomyopathy [128,129] 
COX10 OXPHOS complex IV 
Mitochondrial encephalopathy, hypotonia ataxia and 
seizures 
[131] 
COX15 OXPHOS complex IV Fatal infantile hypertrophic cardiomyopathy [132] 
LRPPRC OXPHOS complex IV Leigh syndrome French Canadian [133] 
ATP12 OXPHOS complex V 
Lactic acidosis, mitochondrial encephalomyopathy 
and hepatic involvement 
[135] 
OXPHOS system biogenesis 
MRPS16 Mitochondrial translation Agenesis of corpus callosum, dysmorphism and FILA [136] 
MRPS22 Mitochondrial translation Hypertrophic cardiomyopathy and tubulopathy [137] 
EFG1 (GFM1) Mitochondrial translation Hepatoencephalopathy [138] 
EFTs (TSFM) Mitochondrial translation Mitochondrial encephalomyopathy [139] 
EFTs (TSFM) Mitochondrial translation Hypertrophic cardiomyopathy [139] 
EFTu (TUFM) Mitochondrial translation Macrocystic leukodystrophy with micropolygyria [140] 
PUS1 Mitochondrial translation MLASA [141] 
COQ2 
Ubiquinone (CoQ10) 
biosynthesis 
Encephalomyopathy and nephropathy [142] 
PDSS1 
Ubiquinone (CoQ10) 
biosynthesis 
Encephaloneuropathy and deafness [143] 
PDSS2 
Ubiquinone (CoQ10) 
biosynthesis 
Leigh syndrome and nephropathy [144] 
Mitochondrial DNA maintenance 
POLG1 (polymerase γA) mtDNA replication adPEO; arPEO [147-149] 
POLG1 (polymerase γA) mtDNA replication Alpers syndrome [154] 
POLG1 (polymerase γA) mtDNA replication Alpers-Huttenlocher syndrome [155] 
POLG2 (polymerase γB) mtDNA replication adPEO [150] 
PEO1 (twinkle) mtDNA replication adPEO [151-153] 
PEO1 (twinkle) mtDNA replication IOSCA [196] 
PEO1 (twinkle) mtDNA replication MDS - hepatocerebral form [197] 
ANT1 
Mitochondrial dNTP salvage 
pathway 
adPEO [146] 
TK2 
Mitochondrial dNTP salvage 
pathway 
MDS - myopathic form [156] 
DGUOK 
Mitochondrial dNTP salvage 
pathway 
MDS - hepatocerebral form [157,158] 
ECGF1 or TP 
Mitochondrial dNTP salvage 
pathway 
MDS - MNGIE [159,160] 
SUCLA2 
Mitochondrial dNTP salvage 
pathway 
MDS - encephalomyopathic form [161] 
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SUCLG1 
Mitochondrial dNTP salvage 
pathway 
MDS - FILA [162] 
MPV17 
Mitochondrial dNTP salvage 
pathway 
MDS - hepatocerebral form [163] 
RRM2B 
Mitochondrial dNTP salvage 
pathway 
MDS - nephrocerebral form [164] 
Mitochondrial membrane biogenesis and maintenance 
TAZ (tafazzin) Cardiolipin metabolism Barth syndrome [165,166] 
OPA1 
Mitochondrial inner 
membrane maintenance 
Autosomal dominant optic atrophy [168,169] 
MFN2 Mitochondrial fusion CMT2A2  [170] 
MFN2 Mitochondrial fusion CMT6 or HMSN VI [171] 
DPL1 or DRP1 Mitochondrial fission 
Microcephaly, optic atrophy and metabolic 
aberrations 
[172] 
Secondary defects of the OXPHOS system 
TIMM8A 
Mitochondrial protein 
import 
Deafness dystonia syndrome or Mohr-Tranebjaerg 
syndrome 
[173,174] 
SLC25A19 or DNC or 
TPC  
Mitochondrial ThPP 
transport 
Amish lethal microcephaly (MCPHA) [177,178] 
THTR1 or SLC19A2 Thiamine transport TRMA or Rogers syndrome [179-181] 
FXN (frataxin) 
Iron-sulfur cluster 
biogenesis 
Friedreich ataxia [182] 
SPG7 (paraplegin) 
Mitochondrial protein 
processing/quality control 
and ribosome assembly 
Hereditary spastic paraplegia [186] 
ETHE1 unknown Ethylmalonic encephalopathy [188] 
FILA: fatal infantile lactic acidosis; GRACILE: growth retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis 
and early death; MLASA: myopathy, lactic acidosis and sideroblastic anemia; adPEO: autosomal dominant progressive 
external ophthalmoplegia; arPEO: autosomal recessive PEO; IOSCA: infantile onset spinocerebellar ataxia; MDS: mtDNA 
depletion syndrome; MNGIE: mitochondrial neurogastrointestinal encephalomyopathy; CMT2A2: Charcot-Marie-Tooth 
disease type 2A2; CMT6: CMT type 6; HMSN VI: hereditary motor and sensory neuropathy type VI; ThPP: thiamine 
pyrophosphate; TRMA: thiamine-responsive megaloblastic anemia 
 
 
by identifying the defective complex using monoclonal antibodies to subunits of each of the 
OXPHOS complexes[198]. Both mtDNA- and nuclear DNA-encoded defects can be 
distinguished. This test could be performed quickly and uses less sample material. 
Different strategies are used for elucidation of nuclear gene defects in biogenesis of the 
OXPHOS system. With the chromosome transfer technique, chromosomes or parts of 
chromosomes can be identified which can complement the unknown defective (responsible) 
gene. In order to identify the chromosome harboring the mutated gene, microcell-mediated 
transfer of human chromosome (fragments) into OXPHOS-deficient cultured patient 
fibroblasts is performed. Functional complementation of the mitochondrial defect can be 
established with a complementation test based on restoration of the complex enzyme activity 
or the complex assembly[125,199]. In the past this technique has revealed the SURF-1 gene as a 
mutational hotspot for Leigh syndrome with COX deficiency[125]. 
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Five-year view 
As it is the largest of the five OXPHOS complexes, deficiency of complex I is a major 
contributor to the total of deficiencies of the OXPHOS system. With a total of 45 subunits, 
complex I is the most complicated multisubunit protein of the mitochondrial inner 
membrane[200-202]. Over the years, bovine heart complex I has been studied extensively by 
the Walker group[203]. With the almost complete characterization of all structural subunits 
enabling mutational analysis in complex I-deficient patients, the focus on complex I 
research, with regard to the pathogenesis of complex I deficiency, has now shifted towards 
the biogenesis of complex I and especially the understanding of the assembly process of the 
complex, which is still a black box. One human gene, CIA30 (currently known as NDUFAF1), 
which encodes a nonstructural protein and is involved in assembly of human complex I, has 
been characterized[204]. The gene product CIA30 is a homologue of a yeast protein found to 
be transiently associated with a 350-kDa complex I intermediate[205]. Another yeast complex 
I intermediate-associated protein, CIA84, has not been identified in humans. As for complex 
IV, for which many assembly factors are known at present, more assembly factors are 
expected to be identified for complex I in the near future. 
The availability of an increasing number of antibodies directed against subunits of complex I 
significantly contributes to the elucidation of the composition of subcomplexes and will 
eventually lead to a greater understanding of the assembly process. More and more 
techniques are becoming available to characterize different intermediate subcomplexes in 
subsequent steps of the assembly process. Capaldi‘s group is developing a complex I 
immunocapture assay analogous to a recently developed complex V assay[206], in which fully 
assembled and functionally active complex I, as well as partially assembled subcomplexes, 
can be purified and measured in terms of activity. Walker‘s group distinguished three major 
subcomplexes that can be obtained by treatment of intact complex I from bovine heart 
mitochondria with mildly chaotropic detergents[200]. Recently, Antonicka and coworkers 
proposed a model in which seven distinct intermediate subcomplexes can be identified[207]. 
With the characterization of the intermediate subcomplexes and subsequent exploration of 
the assembly process, the understanding of complex I biogenesis will become clearer in the 
near future, thereby opening doors to the identification of new (assembly) factors involved in 
the process and increasing the number of candidate genes for complex I deficiency. 
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Key issues 
• Deficiencies of the oxidative phosphorylation (OXPHOS) system are phenotypically and 
genetically heterogeneous. 
• Since the OXPHOS system is under genetic control by two interacting genomes, mutations 
causing OXPHOS deficiency can either be found in the mitochondrial DNA or nuclear genes. 
• Due to the unique genetic code and the separate machinery for mitochondrial translation, 
mutations in the protein-encoding genes, encoding subunits of the OXPHOS complexes, as 
well as mutations in the genes encoding transfer RNA and ribosomal RNA, can lead to 
OXPHOS deficiency. 
• Nuclear genes responsible for disturbance of the OXPHOS system can be categorized on a 
structural and functional level: genes encoding structural components of the OXPHOS 
system; genes encoding assembly factors of the OXPHOS complexes; genes involved in the 
biogenesis of the OXPHOS system; genes involved in the maintenance of mitochondrial 
DNA; genes involved in biogenesis and maintenance of the mitochondrial membranes; and 
genes associated with secondary defects of the OXPHOS system. 
• Isolated complex I deficiency is the most common disturbance of the OXPHOS system and 
frequently follows an autosomal recessive mode of inheritance. Mutations have been 
identified in twelve nuclear genes encoding structural subunits of complex I: NDUFV1-2, 
NDUFS1-4, NDUFS6-8 and NDUFA1-2, NDUFA11, and three genes encoding (putative) 
complex I assembly chaperones: NDUFAF1, NDUFAF2 and C6ORF66. 
• With the exploration of the assembly process, the understanding of complex I biogenesis 
will become more clear in the near future, opening doors to the identification of new 
(assembly) factors involved in the process and increasing the number of candidate genes for 
complex I deficiency. 
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Abstract 
Oxidative phosphorylation (OXPHOS) has a prominent role in energy metabolism of the cell. 
Being under bigenomic control, correct biogenesis and functioning of the OXPHOS system is 
dependent on the finely tuned interaction between the nuclear and the mitochondrial 
genome. This suggests that disturbances of the system can be caused by numerous genetic 
defects and can result in a variety of metabolic and biochemical alterations. Consequently, 
OXPHOS deficiencies manifest as a broad clinical spectrum. Complex I, the biggest and most 
complicated enzyme complex of the OXPHOS system, has been subjected to thorough 
investigation in recent years. Significant progress has been made in the field of structure, 
composition, assembly and pathology. Important gains in the understanding of the Goliath 
of the OXPHOS system are: exposing the electron transfer mechanism and solving the 
crystal structure of the peripheral arm, characterization of almost all subunits and some of 
their functions, and creating models to elucidate the assembly process with concomitant 
identification of assembly chaperones. Unraveling the intricate mechanisms underlying the 
functioning of this membrane-bound enzyme complex in health and disease will pave the 
way for developing adequate diagnostic procedures and advanced therapeutic treatment 
strategies. 
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Introduction 
Embedded in the lipid bilayer of the mitochondrial inner membrane, the oxidative 
phosphorylation (OXPHOS) system is the final biochemical pathway in energy production of 
the cell. Five multisubunit enzyme complexes, together with two mobile electron 
carriers ubiquinone (Q) and cytochrome c (cyt c) constitute the mitochondrial OXPHOS 
system. By transferring electrons from complex to complex, via Q and cyt c, complexes I, III 
and IV function as redox pumps using redox energy to translocate protons across the 
membrane. As a result of the build-up of a proton gradient, a membrane potential is created. 
At the end of the chain, complex IV reduces the final electron acceptor molecular oxygen to 
water, while complex V, or F1F0-ATP synthase, uses the membrane potential as a driving 
force to produce ATP. 
 
Subcellular functioning of complex I in the oxidative phosphorylation system 
NADH:ubiquinone oxidoreductase (complex I; EC 1.6.5.3), the first and largest (and most 
complicated) of the five complexes, is one of the two entry points of the OXPHOS system, 
succinate:ubiquinone oxidoreductase (complex II; EC 1.3.5.1) being the other. It initiates 
electron transfer by oxidizing NADH and using the lipid-soluble ubiquinone as the electron 
acceptor. In an exergonic redox reaction, following upon binding of NADH to complex I, the 
transfer of two electrons from NADH to ubiquinone in the mitochondrial inner membrane is 
coupled to the translocation of four protons from the negative matrix side to the positive side 
of the intermembrane space: 
 
 NADH + H+ + Q + 4H+matrix    NAD+ + QH2 + 4H+intermembrane space 
 
The two electrons provided by the oxidation of NADH are transferred to the primary 
electron acceptor of complex I, a noncovalently bound flavin mononucleotide (FMN). 
Subsequently, electrons are transduced through redox centers represented by eight iron-
sulfur (FeS) clusters two binuclear, N1a and N1b, and six tetranuclear clusters, N2, N3-
N6a, N6b to the final acceptor ubiquinone (Q), which then is reduced to ubiquinol (QH2). 
Bacterial complex I (e.g. complex I of Escherichia coli, Thermus thermophilus, and others), 
referred to as NDH-1, has a ninth, tetranuclear, iron-sulfur cluster, N7, which is not part of 
the conserved electron transfer pathway from FMN to ubiquinone. 
The redox reactions are tightly linked to the pumping of protons across the mitochondrial 
inner membrane; the transfer of two electrons is coupled to the translocation of four 
protons. Because of its complexity and the lack of available high-resolution crystallographic 
three-dimensional (3D) structures, little is known about the mechanisms underlying 
enzymatic functioning of mitochondrial complex I. Unlike for the other OXPHOS complexes, 
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high-resolution 3D structures have not been solved for complex I yet. It has been generally 
accepted from low-resolution 3D structures revealed by electron microscopy[1,2] that the 
mitochondrial as well as the bacterial complex I have an ‗L‘-shaped or ‗boot‘ structure, as has 
been demonstrated for the enzyme of Neurospora crassa[3], Yarrowia lipolytica[4], 
Escherichia coli[5] and bovine heart mitochondria[1]. This structure is constituted of two arms 
that are perpendicular to each other[6]: a hydrophobic arm embedded in the lipid membrane 
and a hydrophilic, peripheral arm protruding into the matrix or bacterial cytoplasm. Sazanov 
and colleagues provided the first structural information of bacterial complex I in a native 
membrane environment by showing that intact complex I is L-shaped in a lipid bilayer, and 
confirmed this for the active enzyme in solution[7]. This supports the view of an L-shaped 
conformation in vivo and contradicts the view of a ‗horseshoe‘ conformation (the two 
complex arms arranged side by side) of the active enzyme in vivo proposed by Bottcher et 
al.[8]. It is proposed that the latter conformation is mistaken for dimers of complex I with a 
horseshoe-like appearance by lack of, or by inadequately staining of peripheral arms[7]. In a 
recent study, Hirst and coworkers underlined the importance of native lipids for the 
stabilization as well as the activation of complex I, by developing a method of preparing fully 
active complex I from bovine heart mitochondria[9]. Different classes of interactions between 
phospholipids and complex I have been defined: tightly bound cardiolipin may be required 
for structural integrity of the complex (but also a functional role has not been ruled out), 
while the amounts of the more weakly bound phosphatidylcholine and 
phosphatidylethanolamine are determinant for catalytic activity[10]. 
An important step in elucidating the enzymatic mechanisms of energy transduction in 
complex I has been made recently by the group of Sazanov. The atomic structure of the 
hydrophilic peripheral arm, including the arrangement of iron-sulfur clusters, has been 
determined for complex I from Thermus thermophilus with the use of x-ray 
crystallography[11,12]. Seven clusters are arranged in a continuous chain connecting the two 
catalytic sites of the enzyme. The first cluster in the chain is the tetranuclear cluster N3 
located in the 51-kDa metalloprotein (NDUFV1),1 which also contains the NADH-binding 
site and the primary electron acceptor FMN. Clusters N1b, N4, N5 and the distal tetranuclear 
cluster N7 are located in the 75-kDa subunit (NDUFS1). Clusters N6a and N6b are located in 
                                                                    
 
 
1For consistency, the following rules have been applied concerning the subunit nomenclature: the 
bovine nomenclature is used (with the human nomenclature in parentheses) when referring to 
subunits of bovine complex I, or homologous subunits of T. thermophilus, or N. crassa. The human 
nomenclature is used (with the bovine nomenclature in parentheses) when referring to subunits of the 
human enzyme or all eukaryotic homologues in general. 
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the TYKY subunit (NDUFS8) in the connecting domain, close to the interface with the 
membrane arm. The last cluster in the chain is likely to be N2, which is in the PSST subunit 
(NDUFS7), and it has been suggested that it reduces ubiquinone at the interface with the 
membrane domain. The likely pathway of electron transfer from FMN to ubiquinone follows 
the shortest route: FMN-N3-N1b-N4-N5-N6a-N6b-N2-Q. The binuclear cluster N1a, which 
is in the 24-kDa subunit (NDUFV2), is unlikely to participate directly in the electron transfer 
from FMN to ubiquinone. N1a can accept electrons from FMN but cannot pass them directly 
to the nearest cluster of the main redox chain. A role as antioxidant has been suggested for 
cluster N1a: by accepting electrons from the more exposed FMN, excessive generation of 
reactive oxygen species (ROS) can be prevented[12]. 
The mechanisms of proton pumping by complex I discussed in literature are based on two 
main models: direct (redox-driven) and indirect (conformation-driven) coupling between 
electron transfer and proton translocation. In the first model, referred to as the Q-cycle 
mechanism, it is assumed that the quinone-binding sites and proton translocation 
components, located in the membrane, are in close contact with the redox centers in the 
peripheral arm, allowing direct interaction. In the second model, the redox centers of the 
peripheral arm are coupled to distal proton translocating components that are located at the 
end of the membrane arm, through long-range conformational changes[13]. A combination of 
both mechanisms has also been discussed. In the latter situation, two modules are suggested 
to participate in proton pumping: the hydrogenase module acts as a redox-driven proton 
pump and the transporter module acts as a conformation-driven proton pump. This implies 
that complex I contains two energy-coupling sites[14,15]. Recently, a novel complex I-proton 
pumping mechanism has been proposed by Ohnishi and Salerno based on redox-driven 
conformational changes of the quinone-binding site[16]. Two distinct ubiquinone-binding 
sites were assigned within the membrane domain of complex I. 
 
The subunits of mitochondrial complex I 
Evolutionary conservation and subunit composition of mammalian complex I 
Bacterial complex I, or NDH-1, consists of 14 different subunits, which all have homologues 
in the mitochondrial or eukaryotic enzyme. These 14 mitochondrial homologues, referred to 
as ‗core subunits‘, are essential for catalysis of electron transfer from NADH to ubiquinone 
and for generation of the membrane potential, and are therefore together considered as the 
‗minimal‘ constitution of the enzyme. Because of its minimal subunit composition, NDH-1 
can be used as a model for the more complex mammalian enzyme. Half of the core subunits 
are encoded by the nuclear genome and half by the mitochondrial genome, with both 
genomes representing subunits of distinct parts of the complex. The seven nuclear DNA-
encoded core subunits (NDUFS1-3, NDUFS7-8, NDUFV1-2) are the most conserved among 
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the eukaryotic subunits. They constitute the peripheral domain, comprising all redox 
centers, while the seven subunits of the mitochondrial genome (ND1-6, ND4L) form the 
membrane domain[9]. 
Because of extensive analyses over many years of the subunit composition of complex I from 
bovine heart mitochondria, it has become the best-characterized eukaryotic complex I[9,17-21]. 
To date, identification of all structural components of mammalian complex I is assumed to 
be completed and has resulted in a total number of 45 subunits that have all been assigned to 
well-characterized genes. Homologues of all bovine complex I subunits have been identified 
in human complex I, and the human genes have been identified by homology with the bovine 
sequences. Because of high sequence identity between bovine and human subunits, the 
bovine enzyme can be adopted as a model for human complex I. Assuming there is one copy 
of each subunit present in complex I, its molecular mass is 980 kDa[9]. 
 
The mitochondrial DNA-encoded subunits 
With the exception of complex II and the mobile electron carriers, the OXPHOS system is 
subjected to dual genetic control, i.e. the OXPHOS constituents are encoded by two 
physically separate genomes: the mitochondrial and the nuclear genomes. The 
mitochondrial DNA (mtDNA) codes for 13 polypeptides, i.e. structural components for 
complex I (7), complex III (1), complex IV (3) and complex V (2), two ribosomal RNAs, and 
22 transfer RNAs. The seven mtDNA-encoded subunits of complex I, ND1-6 and ND4L, are 
all hydrophobic and bear a number of transmembrane helices. Together with ~20 integral 
membrane proteins in total, they form the membrane arm of the enzyme, contributing >60 
transmembrane segments[22]. 
The subunits ND2, ND4, and ND5 seem to originate from one common ancestor. From 
sequence comparisons it has been suggested that they are related to subunits of K+ or 
Na+/H+ antiporters, which makes them good candidates for components of the proton 
translocation machinery[15]. Because of its quinone-binding site, subunit ND1 is proposed to 
be involved in ubiquinone binding. 
 
The nuclear DNA-encoded subunits 
Thirty-eight of the 45 subunits of mammalian complex I are encoded by the nuclear genome. 
Eighteen subunits have N-terminal precursor mitochondrial targeting sequences (MTSs) 
that are cleaved upon import into the mitochondrial inner membrane or the matrix (Tab 1). 
The 20 remaining characterized subunits lack precursor import sequences and are somehow 
imported into the mitochondria by internal signals within the mature protein. Post-
translational modifications of individual subunits have been identified by electrospray 
ionization mass spectrometry (ESI-MS). Fourteen subunits have post-translationally 
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Table 1. The subunits of human complex I 
Human gene 
Bovine 
homologue 
Subcomplex a 
Post-translational 
modification 
(N-terminal)b 
N. crassa homologued 
E. coli 
homologue 
Predicted mass 
mature proteing 
Biochemical features (EPR signal) 
ND1 ND1 I  - ND1 NuoH 35.7  
ND2 ND2 I  - ND2 NuoN 39.0  
ND3 ND3 I  - ND3 NuoA 13.2  
ND4 ND4 I  - ND4 NuoM 51.6  
ND4L ND4L I  - ND4L NuoK 10.7  
ND5 ND5 I  - ND5 NuoL 67.0  
ND6 ND6 I  - ND6 NuoJ 18.7  
NDUFV1 51 kDa I   MTS 1-20 51 kDa NuoF 48.6 FMN; [4Fe-4S] (N3) 
NDUFV2 24 kDa I  MTS 1-32 24 kDa NuoE 23.7 [2Fe-2S] (N1a) 
NDUFV3 10 kDa I  MTS 1-34 -  8.4  
NDUFS1 75 kDa I  MTS 1-23 78 kDa NuoG 77.0 [2Fe-2S] (N1b); 2 x [4Fe-4S] (N4, N5) 
NDUFS2 49 kDa I  MTS 1-33 49 kDa NuoCDf 49.1  
NDUFS3 30 kDa I  MTS 1-36 30.4 kDa NuoCDf 26.4  
NDUFS4 18 kDa (AQDQ) I  MTS 1-42 21 kDa  15.4  
NDUFS5 15 kDa I  Met predicted orthologuee  12.4  
NDUFS6 13 kDa I  MTS 1-28 28.7 kDa  10.7  
NDUFS7 PSST I  MTS 1-38 19.3 kDa NuoB 19.8 [4Fe-4S] (N2) 
NDUFS8 TYKY I  MTS 1-34 21.3c kDa NuoI 20.3 2 x [4Fe-4S] (N6a, N6b) 
NDUFA1 MWFE I  - 9.8 kDa  8.0  
NDUFA2 B8 I  Met; N-acetyl 10.5 kDa  10.8  
NDUFA3 B9 I  Met; N-acetyl 9.3 kDa  9.3  
NDUFA4 MLRQ nd - -  9.4  
NDUFA5 B13 I  Met; N-acetyl 29.9 kDa  13.3  
NDUFA6 B14 I  Met; N-acetyl 14.8 kDa  15.0  
NDUFA7 B14.5a I  Met; N-acetyl -  12.4  
NDUFA8 PGIV I  Met 20.8 kDa  20.0  
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NDUFA9 39 kDa I  MTS 1-35 40 kDa  38.9 NADPH  
NDUFA10 42 kDa I  (loosely) MTS 1-35 -  37.1  
NDUFA11 B14.7 I  Met; N-acetyl 21.3b kDa  14.9  
NDUFA12 B17.2 I  N-acetyl 13.4 kDa  17.1  
NDUFA13 B16.6 I  Met; N-acetyl predicted orthologuee  16.6  
NDUFB1 MNLL I  Met -  7.0  
NDUFB2 AGGG I  MTS 1-33 predicted orthologuee  8.6  
NDUFB3 B12 I  Met; N-acetylc -  11.3 His-methylated 
NDUFB4 B15 I  & I  Met; N-acetyl predicted orthologuee  15.1  
NDUFB5 SGDH I  MTS 1-46 -  17.0  
NDUFB6 B17 I  Met; N-acetyl -  15.4  
NDUFB7 B18 I  Met; N-myristoyl predicted orthologuee  16.3  
NDUFB8 ASHI I  MTS 1-28 19 kDa  18.8  
NDUFB9 B22 I  Met; N-acetyl predicted orthologuee  21.7  
NDUFB10 PDSW I  Met 12.3 kDa  20.7  
NDUFB11 ESSS I  MTS 1-29 predicted orthologuee  17.3  
NDUFAB1 SDAP I  & I  MTS 1-68 9.6 kDa ACP  10.2 Ser-phosphopantetheine 
NDUFC1 KFYI I  MTS 1-27 -  5.9  
NDUFC2 B14.5b I  N-acetylc -  14.2  
    21.3 kDa    
    21.3a kDa    
    20.9 kDa    
    17.8 kDa    
a Subunit distribution over subcomplexes according to reanalysis of the resolution of bovine complex I into subcomplexes by Carroll et al.[21] 
b MTS: cleavage of mitochondrial targeting sequence (number of amino acids from human sequences acquired from the NCBI protein database: www.ncbi.nlm.nih.gov); Met: cleavage of 
N-terminal methionine; N-acetyl: acetylation of N-terminal residue; N-myristoyl: myristoylation of N-terminal residue 
c Subunits B14.5b and B12 are partially acetylated 
d Adopted from Videira and Duarte[23] 
e Predicted orthologue by Gabaldon et al.[24] 
f In E. coli both subunits are fused 
g Predicted masses of the human mature proteins in kDa adopted from Murray et al.[25]. NDUFC1, ND4L, and ND6 were not detected by Murray et al.[25] 
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modified N-termini, the so-called B-subunits of the bovine enzyme (Tab 1). Modifications 
mostly concern acetylation of the first residue after removal of the N-terminal methionine, 
although for some subunits acetylation of the initiator methionine occurs. In one case, the 
B18 subunit (NDUFB7), myristoylation occurs instead of acetylation. Six subunits either 
with or without N-terminal methionine removal remain unmodified[26]. The function of N-
terminal acetylation of complex I subunits is not known, although a role in post-translational 
transfer of the respective subunits into mitochondria is proposed. The mirystoyl group of the 
B18 subunit, which is part of the membrane arm, has been assumed to bind the subunit to 
the mitochondrial inner membrane[26]. 
Besides the permanent N-terminal modifications, several other types of post-translational 
modifications have been identified in the extensively analyzed bovine and human 
mitochondrial complex I. In addition to the incorporation of eight iron-sulfur clusters, a few 
other post-translational modifications occur in complex I subunits. Methylation of several 
histidine residues takes place in the B12 subunit (NDUFB3), and the SDAP subunit 
(NDUFAB1) carries a phosphopantetheine prosthetic group[26]. In contrast to N-acetylation, 
protein methylation is reversible by demethylases, and methylation-demethylation reactions 
are thought to have regulatory functions[26]. The phosphopantetheine cofactor is important 
for the function of the protein in a soluble state, in type II mitochondrial fatty acid synthesis, 
but its significance in the complex I-bound state is less clear[27]. 
In addition, several complex I subunits are known to undergo additional post-translational 
phosphorylation, for instance the 39-kDa bovine subunit (NDUFA9) and an 18-kDa subunit 
of complex I. Reversible phosphorylation of complex I subunits has been implicated in 
regulation of enzymatic activity and possibly affects electron transfer and superoxide 
production[28]. The 39-kDa subunit of complex I was phosphorylated at a tyrosine residue 
and putative tyrosine-phosphorylated subunits for the other complexes have been identified. 
From these findings it has been hypothesized that tyrosine kinases and phosphatases are 
involved in the regulation of oxidative phosphorylation[29]. The phosphorylated 18-kDa 
subunit of complex I was assigned by Papa and colleagues as the AQDQ subunit (NDUFS4) 
and they demonstrated that cAMP-dependent phosphorylation of the 18-kDa subunit can 
regulate complex I activity and overall respiratory activity[30,31]. Later, by a combination of 
Edman sequencing and mass spectrometric analysis, Walker and colleagues identified the 
phosphorylated 18-kDa subunit as the ESSS subunit (NDUFB11) with the phosphorylation 
site at serine-20, and demonstrated that it is was not the AQDQ subunit (NDUFS4) that was 
phosphorylated[32]. They also found a second phosphorylated protein, the MWFE subunit 
(NDUFA1), with a phosphorylation site at serine-55. Both sites conform to the standard 
motifs for cAMP-dependent phosphorylation sites[33]. A third phosphorylated subunit is the 
bovine 42-kDa subunit (NDUFA10), located in the hydrophobic membrane arm[34]. In 
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contrast to the phosphorylation sites in the ESSS and MWFE subunits, serine-59 of the 42-
kDa subunit appeared to be phosphorylated when isolated directly from mitochondria, i.e. 
without prior kinase treatment[28]. 
 
Topology of complex I 
Over the years, the group of Walker obtained considerable information about the subunit 
topology of bovine complex I. Extensive analyses of the intact complex and various 
subcomplexes from bovine heart mitochondria have played an important role in defining the 
subunit composition of complex I, and resulted in the localization of the individual subunits 
to structurally and functionally distinct parts of the complex (Fig 1). With mildly chaotropic 
detergents (LDAO), intact complex I can be resolved into four subcomplexes: I , I , I , and 
I [20,21,36]. Separation of the subunits has been carried out by three independent methods (1D 
SDS-PAGE, 2D IEF/SDS-PAGE, and reversed-phase HPLC) and subsequent analysis of the 
individual subunits has been done by tryptic peptide mass fingerprinting and tandem mass 
spectrometry[21]. Subcomplex I  consists of the hydrophilic peripheral arm plus part of the 
hydrophobic membrane arm, as subcomplex I  contains the main part of the membrane 
arm. However, some subunits are not found in either subcomplex I  or I  and can together 
be considered as subcomplex I . Under slightly different conditions subcomplex I  
dissociates to produce subcomplex I  representing the hydrophilic or peripheral arm. I  
contains 15 subunits including the seven nuclear DNA-encoded core subunits carrying all 
redox cofactors: the FMN and eight iron-sulfur clusters (Fig 1). These subunits, which are 
present in apparently stoichiometric amounts[9], are predominantly hydrophilic; only one 
subunit, B16.6 (NDUFA13), carries a transmembrane helix. Subcomplex I  consists of the 
subunits of I  and nine additional subunits in apparently stoichiometric amounts. 
Containing several transmembrane helices, these subunits are likely to anchor subcomplex 
I  to the inner membrane. Since the subcomplex I  B14.7 subunit (NDUFA11) is also 
predicted to contain transmembrane helices and is detected in trace amounts in subcomplex 
I , it can be assumed that the B14.7 subunit together with the B16.6 subunit is located in the 
small connection between the peripheral arm and the membrane arm of complex I. The 42-
kDa subunit is weakly associated with the complex and probably bound to subcomplex I . 
Subcomplex I , consisting of twelve subunits in apparently stoichiometric amounts (and a 
thirteenth, the B14.5b subunit, in substoichiometric amounts), contains most 
transmembrane helices of all subcomplexes and constitutes the major part of the membrane 
arm. Two subunits, the SDAP (NDUFAB1) and B15 subunits (NDUFB4), are present in both 
subcomplexes I  and I  in substoichiometric amounts, and are probably located at the 
boundary between the two subcomplexes[21]. The MLRQ subunit (NDUFA4) was not  
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Figure 1. Subunit composition of mammalian complex I. 
Subunits have been grouped by the subcomplex they have been identified in, after complex I 
fractionation according to Walker and coworkers[21]. The human subunit nomenclature is 
shown in blue, the bovine subunit nomenclature is shown in grey. Subunits that have been 
reported harboring pathogenic mutations causing complex I deficiency are depicted with an *. 
(Figure adapted from Nijtmans et al.[35]). 
 
 
detected in any of the subcomplexes; its presence in complex I is proposed to be dependent 
on the presence of cardiolipin. The remaining five subunits, KFYI (NDUFC1), ND1, ND2, 
ND3, and ND4L reside in subcomplex I . 
Subunits ND1 and ND2 are grouped together, as are subunits ND4 and ND5. Together with 
the PSST subunit (NDUFS7), carrier of iron-sulfur cluster N2, which is generally assumed to 
be the immediate electron donor for ubiquinone, and the 49-kDa subunit (NDUFS2), ND1 
has implicated in the formation of the ubiquinone binding pocket. With the N2 cluster 
placed in or close to the centre of the connecting domain, ND1 and proton translocating 
subunit ND2 are therefore supposed to be located near the thin stalk of the complex, 
connecting the peripheral and membrane arms[37]. In contrast, the other suspected proton 
translocating subunits, ND4 and ND5, are believed to be located at the distal part of the 
membrane domain[2], as has been proved for E. coli complex I[13]. These findings are 
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indicative of a combined, i.e. redox-driven and conformational-driven, mechanism of energy 
transduction. 
For the human enzyme, Murray and colleagues identified 42 homologues of the 45 bovine 
heart complex I subunits by mass spectrometry analysis of complex I from human heart 
mitochondria isolated by means of an immunocapture method[25]. Keeping in mind that all 
characterized bovine genes encoding complex I subunits have homologues in the human 
genome (Tab 1; Fig 1), together with the high degree of subunit homology between the 
bovine and the human species, the bovine enzyme can be regarded as a bona fide model for 
human complex I. 
 
Function of individual subunits 
While for the 14 core subunits of complex I, containing all redox centers and substrate-
binding sites, primary roles in electron transfer and proton translocation have been 
established, the functions of the remaining 31 accessory or supernumerary subunits is less 
understood. They may have general roles in preventing ROS generation and protection 
against oxidative damage by shielding redox groups from reaction with oxygen, in binding of 
the complex to the membrane, and in the stabilization of the enzyme by forming a scaffold 
around the core subunits[9,38]. Also more specific functions in the regulation of activity or the 
assembly of other subunits into the holocomplex have been implied. However, some 
subunits are known to carry out an additional function besides their role in energy 
transduction. They are involved in distinct biochemical processes in the same or even 
another subcompartment of the cell. Others show homology to protein families suggesting 
specific functions that have yet to be substantiated by experimental evidence (see below)[9].  
Two nucleotide-binding sites, one for NADH and one for NADPH, have been established in 
mitochondrial complex I. The first, NADH-binding site, is found in the 51-kDa core subunit 
(NDUFV1), which also binds the FMN, providing the conversion of the 2-electron donor 
NADH to the 1-electron transferring iron-sulfur clusters[39]. Together with the 24-kDa 
subunit (NDUFV2) and the 10-kDa subunit (NDUFV3), the 51-kDa subunit forms the 
flavoprotein part of the enzyme. The other nucleotide-binding site, NADPH is assigned to 
the 39-kDa accessory subunit (NDUFA9). This subunit shows a considerably higher 
sequence homology between mammals and fungi than most of the accessory subunits. The 
conserved nucleotide-binding site of the 39-kDa subunit is characteristic of a heterogeneous 
family of reductases/isomerases, all biosynthetic enzymes with NADH or NADPH 
cofactors[38]. In N. crassa complex I, the tightly bound NADPH is shielded from the other 
redox groups, not participating in the electron transfer chain. Interestingly, lack of the 
subunit leads to loss of complex I activity[38].  
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Analogous to known interactions between members of the reductase/isomerase family, and 
acyl carrier proteins (ACPs), it has been hypothesized that the 39-kDa subunit may form a 
‗biosynthetic module‘ with the SDAP subunit (NDUFAB1), another highly conserved 
accessory subunit with a putative biosynthetic function[9]. The bovine SDAP subunit and its 
N. crassa homologue are ACPs with a phosphopantetheine prosthetic group and are closely 
related to the ACPs involved in fatty acid biosynthesis in bacteria and chloroplasts. A 
possible role for the ACP/SDAP subunit of complex I in mitochondrial de novo fatty acid 
synthesis, elongation, or desaturation has been suggested. Recently, it was found that most 
of the SDAP subunit is present as a soluble protein in the mitochondrial matrix of bovine 
heart mitochondria, and thus available to carry the intermediates of the type II fatty acid 
synthesis. Its significance as a complex I-bound subunit, however, is less clear[27].  
The MWFE subunit (NDUFA1), being an integral membrane protein of the I  subcomplex, is 
probably located in the membrane domain close to the stalk of the complex, and has a key 
function in complex I assembly. It has been suggested that presence of the MWFE protein is 
required for the synthesis of the mtDNA-encoded ND subunits and their incorporation into 
the complex[40,41]. Since MWFE has been identified as one of the complex I subunits that can 
be phosphorylated, functional activation upon phosphorylation can be speculated.  
The NDUFA13 subunit (B16.6), the only hydrophobic subunit of the peripheral domain, is 
also known as GRIM-19, for gene associated with retinoid-interferon-induced mortality 19 
protein, and is the product of a cell death regulatory gene induced by interferon-  and 
retinoic acid which promotes apoptosis[42]. By biochemical and cellular studies, a dual 
function for GRIM-19 has been implicated: one involved in the OXPHOS system as a 
structural component of complex I, the other playing a key role in initiation of 
apoptosis[43,44]. The question arises whether GRIM-19 is involved in independent cellular 
processes in different subcellular compartments, or whether GRIM-19 is the next link 
connecting mitochondria and apoptosis[9]. 
The nuclear DNA-encoded subunit B14.7 (NDUFA11) shows homology to Tim proteins 
(Tim17, Tim22 and Tim23) of the translocase of the inner membrane 17/22 (TIM17/22) 
family, which are involved in protein import from the cytosol into the mitochondrial matrix 
and inner membrane[20,24]. A related protein import mechanism may be operating for 
proteins synthesized in the mitochondrial matrix. It has therefore been proposed that the 
B14.7 subunit may be involved in the incorporation of the mtDNA-encoded ND subunits into 
the mitochondrial inner membrane. 
Two other subunits, NDUFA2 (B8) and NDUFA10 (42 kDa), have shown homology to 
mitochondrial ribosomal proteins L43 and S25, and to mitochondrial thymidine kinase 2 
(TK2), respectively[24], suggesting a possible connection between complex I and 
mitochondrial protein synthesis that has to be subjected to thorough functional analysis. 
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Homology studies like these can provide useful clues in determining the functions of the 
many accessory subunits of mitochondrial complex I. 
 
 
The assembly process of mitochondrial complex I 
The Neurospora crassa model 
The complex I assembly process has been studied in detail in the aerobic fungus Neurospora 
crassa[45]. The hydrophilic peripheral arm and the hydrophobic membrane arm are formed 
independently. A small (~200 kDa) and a large (~350 kDa) intermediate membrane-bound 
subcomplex are joined together to form the membrane arm[46]. In N. crassa mutants 
obtained by gene disruption, the lack of single subunits causes a complete block in the 
assembly pathway. In some mutants of a subunit of the peripheral arm, a complex I lacking 
only that single subunit is assembled (51 kDa; 39 kDa; 24 kDa). In most cases, however, 
owing to loss of one of its subunits, the peripheral arm remains unstable, leading to 
accumulation of only the membrane arm. In its turn, lacking a subunit of the membrane 
arm, the peripheral arm is still assembled, and accumulates together with the small and 
large assembly intermediate complexes of the membrane arm. One subunit of the peripheral 
arm, the acyl carrier protein (SDAP) represents an exception. Loss of this subunit not only 
prevents peripheral arm assembly but also disturbs formation of the membrane arm[47,48]. 
In N. crassa, two complex I intermediate associated proteins, CIA30 and CIA84, play an 
essential role in the assembly of the membrane arm. Since they are transiently associated 
with the large membrane arm assembly intermediate and are not part of holocomplex I, both 
are thought to function as chaperones. Travelling back and forth between a pool of 
monomers and the assembly intermediates the CIA proteins participate in many assembly 
cycles[46]. Loss of either CIA protein will prevent the formation of the large membrane arm 
assembly intermediate, leading to accumulation of the small assembly intermediate and the 
peripheral arm. Functioning as chaperones, it has been suggested that they might maintain 
the assembly-competent state of the large membrane arm intermediate, preventing 
aggregation and misfolding[49]. 
 
The assembly process of mammalian complex I 
Several recent studies of disturbed assembly processes, investigating the accumulation of 
assembly intermediates, have provided some insights in the assembly process of 
mammalian, and especially human, complex I[50,51]. Some subunits are shown to be essential 
for the assembly of others into the complex. For instance, the hydrophobic subunits ND4 
and ND6 have been shown to be essential for the assembly of other ND subunits into the 
complex[52-54]. Loss of the ND4 subunit will prevent the formation of the complex I 
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membrane arm[55] and mutation of subunits ND6 and ND1 will lead to a severe reduction of 
holocomplex I levels[56]. Subunit ND2 is also needed for the assembly and/or stability of 
complex I. In a patient with a mutation in ND2, complex I assembly is compromised, leading 
to the formation of subcomplexes without NADH dehydrogenase activity[50]. In contrast, 
subunit ND5 is not essential for assembly of the other ND subunits into the complex, and 
loss of ND5 leads only to a lower efficiency of assembly or to instability of the membrane 
arm. ND5 is likely to be located at the periphery of the membrane arm, and therefore may be 
the last of the ND subunits to be assembled into the complex[55]. Nevertheless, since 
synthesis of ND5 is rate limiting, ND5 is essential for complex I activity[52]. In addition, loss 
of subunit ND3 will also lead to a relatively normal assembly profile[57]. 
The MWFE (NDUFA1) subunit also has a key role in the process of complex I assembly. With 
the development of a conditional complex I assembly system in Chinese hamster fibroblasts, 
Scheffler and coworkers showed that the insertion and stabilization of some ND subunits is 
dependent on the presence of MWFE and some other nuclear DNA-encoded subunits. The 
simultaneous insertion of the ND subunits and MWFE into the membrane and interaction 
with some other nuclear DNA-encoded subunits, resulting in the formation of an assembly 
intermediate, appears to be a crucial step in assembly of mammalian complex I[41]. 
Loss of one or all seven of the ND subunits encoded by the mitochondrial genome, in 
contrast, has no effect on the protein levels of the nuclear DNA-encoded complex I subunits 
of the peripheral arm[55]. The majority of the subunits of the peripheral arm are most likely 
already associated in an assembly intermediate subcomplex[22]. The PSST subunit, which is 
absent in this subcomplex, forms an exception. The localization of the PSST subunit near the 
membrane domain may explain its dependence on the presence of these integral membrane 
proteins, i.e. the ND subunits. Several accumulated subcomplexes contained the NDUFS2 
(49 kDa), NDUFS3 (30 kDa) and NDUFS8 (TYKY) subunits, which are thought to constitute 
the complex I connecting module between the membrane arm and the peripheral arm[22]. 
Lack of the TYKY subunit (NDUFS8), another subunit of the peripheral domain that is in 
close contact with the PSST subunit, also reduces the levels of subunits NDUFV1 (51 kDa), 
NDUFA10 (42 kDa), and NDUFA9 (39 kDa). The suggested interaction with these subunits 
underlines the proposed function of subunit NDUFS8 in assembly or stability of complex I, 
specifically in connecting the membrane and peripheral domains of complex I[58,59]. 
Recently, this has been confirmed in a patient with mutations in the NDUFS8 gene, for 
which assembly of the complex I holoenzyme was prevented almost completely[60]. 
 
The human complex I assembly pathway 
In 2003, a possible pathway for human complex I assembly was proposed[50] that differs 
significantly from the N. crassa model[46]: many more assembly intermediates are 
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encountered in the human pathway. For the human enzyme, at least seven distinct 
intermediate subcomplexes are identified, as was observed in a cohort of four patients with 
complex I deficiency. Some of the subcomplexes contain both peripheral and membrane arm 
subunits, suggesting that the peripheral and membrane arms are not assembled in separate, 
independent pathways[50]. Since different genetic defects underlying complex I deficiency 
reveal a common set of subcomplexes, these subcomplexes most likely represent 
intermediate complexes of the assembly pathway. Similar intermediate subcomplexes were 
observed in an additional study of patients with mutations in nuclear DNA-encoded 
subunits[60]. Nevertheless, we must take into account that the accumulation of lower-
molecular weight subcomplexes in complex I-deficient patients could be due not only to an 
assembly defect but also to disturbance of stability of the complex[60]. 
Accumulation of an additional intermediate subcomplex of approximately 800 kDa (referred 
to as ~830 kDa by Antonicka et al.[50]) has been observed in patients with a mutation in the 
NDUFS4 subunit[31], indicative of defects in complex I assembly or stability. The existence of 
this relatively large subcomplex of ~800 kDa, suggests that NDUFS4 will be incorporated at 
a late stage in the assembly process[60]. It contains subunits of the peripheral domain, 
NDUFS3, NDUFS5, and NDUFA9, but shows no NADH dehydrogenase activity in a complex 
I in-gel activity assay. Moreover, this intermediate subcomplex has particularly been found 
in patients with mutations in the NDUFS4 and NDUFV1 genes, but not in other complex I-
deficient patients or normal controls[50]. The accumulation of an approximately 750-kDa 
intermediate subcomplex observed in patients with mutations in the peripheral arm subunit 
NDUFS6[57] possibly resembles the assembly profile of the NDUFS4 and NDUFV1 patients. 
Therefore, NDUFS6 is also likely to play an essential role in complex I assembly or 
stability[57]. 
Regarding the distribution of eleven studied subunits over the seven distinguishable 
subcomplexes, the following groups of subunits can be considered to follow similar assembly 
routes: NDUFS2, NDUFS3, and NDUFA9; NDUFV2, NDUFS4, and NDUFS7; ND1 and 
NDUFA2; and NDUFS5 and NDUFA6. Combining these findings, the following assembly 
pathway has been proposed. First, subunits of the peripheral arm, including the 49-, 39-, 
and 30-kDa subunits, are assembled together and associated with some other subunits of the 
peripheral arm, resulting in a second assembly intermediate. Second, the partially assembled 
peripheral arm is coupled to several subunits of the membrane arm, including ND1, to form 
a membrane-bound complex. Subsequently, a subcomplex including the PSST, 24-, and 18-
kDa subunits is associated with the peripheral arm; and finally the membrane arm is 
completed[50,61]. The second assumption is in conflict with the semi-sequential human 
complex I assembly pathway proposed by Ugalde and colleagues[51], which states that the 
membrane arm subunits ND1, ND6, and B17, are assembled into a ~700-kDa membrane 
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arm subcomplex before association with a ~600-kDa peripheral arm subcomplex takes 
place. This model more or less resembles the N. crassa model, for which it is suggested that 
complex I follows a modular assembly pathway, i.e. complex I is formed by combining three 
different evolutionarily conserved modules: an NADH-dehydrogenase module, a 
hydrogenase module, and a transporter module[14,62]. 
 
Involvement of assembly chaperones 
For at least half of the patients with a complex I deficiency caused by disturbed assembly of 
the holocomplex, the primary defect cannot be assigned to the structural components of the 
complex. While assembly chaperones have been described for the other complexes of the 
OXPHOS system, proteins required for assembly of mammalian complex I long remained 
unknown. However, four years ago, the human homologue of the N. crassa CIA30, 
NDUFAF1, was characterized[63] and recently its functioning in complex I assembly has been 
investigated[64]. Reduction in the amount of NDUFAF1, achieved by means of RNA 
interference, leads to a reduced amount of fully assembled complex I and complex I activity, 
whereas overexpression of NDUFAF1 leads to an increase of fully assembled complex I. 
Furthermore, NDUFAF1 associates with two high-molecular weight assembly intermediate 
complexes of approximately 600 kDa and 700 kDa. Expression of NDUFAF1 has been 
investigated in a conditional complex I assembly system, comprising inhibition and recovery 
of mitochondrial protein synthesis, and in patients with a disturbed complex I assembly, 
caused by mutations in one of the subunits. When the assembly of the membrane arm is 
either disturbed (as shown for a patient with an ND5 mutation) or induced (in the 
conditional complex I assembly system), NDUFAF1 becomes more predominant in the 
~700-kDa complex. Therefore, it has been concluded that NDUFAF1 is an important protein 
for the assembly and/or stability of human complex I, and might act as a chaperone by 
preventing misfolding or degradation of assembly intermediates[64]. 
The predicted human homologue of the other assembly chaperone of N. crassa complex I, 
CIA84, which has been identified by means of comparative genomics (PTCD1, GenBank 
accession number: NM_015545)[24], is still awaiting functional characterization. 
A third assembly chaperone for mitochondrial complex I has also been identified and 
characterized recently[65]. By comparing genomes of yeast species that do (aerobic yeasts) 
and do not (fermentative yeasts) express complex I, several candidate genes for complex I 
assembly factors were selected. Among them is the NDUFAF2 gene that encodes complex I 
assembly factor 2 (also known as B17.2L for B17.2-Like protein), a paralogue of the small 
subunit of the peripheral arm NDUFA12 (B17.2). Mutation of the NDUFAF2 gene leads to 
complex I assembly defects, as both the amount of holocomplex I and the catalytic activity 
are compromised, and assembly intermediates of 380 and 480 kDa are accumulated. The 
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NDUFAF2 protein associates specifically with the accumulating 830-kDa intermediate 
subcomplex observed in patients with mutations in the NDUFS4 and NDUFV1 genes. The 
830-kDa subcomplex, co-immunoprecipitated by anti-NDUFAF2 antibody, contained 
subunits of both the peripheral (NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFV1) and 
membrane (ND1) arms. While a chaperone function in the late stages of complex I assembly 
has been proposed, further functioning of the protein needs to be investigated. The same 
protein has been studied earlier, under the name mimitin, for myc-induced mitochondrial 
protein, and has been assigned to function in myc-dependent cell proliferation in tumor cell 
lines[66]. 
Another mitochondrial protein interacting with complex I subcomplexes was detected by 
Bourges and colleagues. In human cells lacking ND subunits, mitochondrial prohibitin was 
detected in a subcomplex containing subunits NDUFS2 (49 kDa), NDUFS3 (30 kDa) and 
NDUFS8 (TYKY), which are thought to constitute the complex I connecting module between 
the membrane arm and the peripheral arm[55]. Prohibitin is a mitochondrial inner 
membrane protein, which is known in yeast to interact with complex IV subunits to prevent 
their proteolysis by m-AAA proteases. By stabilizing newly synthesized mitochondrial 
translation products, prohibitin is now proposed to act as a chaperone not only for complex 
IV assembly[67] but also for complex I assembly[55]. 
 
 
Supercomplex formation 
The arrangement of the OXPHOS complexes into higher supramolecular structures, called 
supercomplexes, seems to be well established in various organisms, as bacteria[68], lower 
eukaryotes and mammals[69]. By the use of different solubilization detergents (e.g. lauryl 
maltoside, digitonin, Triton X-100) supercomplexes with varying stoichiometries have been 
demonstrated in bacterial as well as mitochondrial membranes[70]. Supercomplexes 
comprising complexes I, III and IV are also called respirasomes. 
Supercomplexes containing monomeric complex I, dimeric complex III, and up to four 
complexes IV (I1 III2 IV0-4) have been reported for bovine mitochondria. In bovine 
mitochondria nearly all complex I associates with dimeric complex III, while association of 
complex IV seems to be more detergent-sensitive[70]. The largest of the supercomplexes, 
I1III2IV4, has been proposed to constitute a complete respirasome[69]. Schägger proposed a 
model for the mammalian OXPHOS system consisting of two supercomplexes with and 
without complex I (I1III2IV4 and III2IV4) accompanied by monomeric complex II and 
dimeric complex V in a 2:1:3:3 ratio[70]. 
The functional significance of supercomplex formation can be supported by the following 
characteristics: channeling of the substrates ubiquinol and cytochrome c, preventing 
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competition from other enzymes; catalytic enhancement as a result of reduction of the 
diffusion time of substrates; sequestration of the reactive intermediate ubisemiquinone, 
preventing the generation of the pathogenic superoxide by reaction with oxygen[69]; and 
stabilization of the individual OXPHOS complexes[71,72]. 
Supercomplex formation is essential for the assembly and/or stability of complex I. For 
instance, decreased amounts of membrane-bound complex I have been shown for 
Paracoccus denitrificans mutants lacking complexes III and IV, suggesting a decreased 
stability of complex I when not assembled into a supercomplex[68]. For human mitochondria 
it has also been established that complex I is stabilized by the association with dimeric 
complex III in a supercomplex.  
Primary genetic defects affecting complex III assembly, e.g. mutations in the mtDNA 
cytochrome b gene, result in secondary complex I deficiency by failing to form 
supercomplexes[71]. Since complex I assembly is not compromised, it has been concluded 
that the stability of complex I is severely affected. Additionally, cytochrome b mutations 
affecting complex III activity, while not disturbing complex III assembly, have no effect on 
complex I and result in an isolated complex III deficiency[71]. There are also examples of 
mutations in nuclear genes encoding the QP-C subunit of complex III[73] and the complex 
III assembly factor BCS1L[74] that disturb complex III assembly and present with a 
combined complex I + III deficiency, supporting the significance of supercomplex formation 
for complex I stability. Conversely, primary complex I defects affecting the stability of 
complex III have also been reported for patients with mutations in the NDUFS2 and 
NDUFS4 genes[60,75]. It has to be further investigated whether the physical interaction 
between complexes I and III is mediated through these subunits NDUFS2 and NDUFS4. 
 
 
Clinical manifestation and genetic heterogeneity 
Mitochondrial disorders, or more specifically diseases caused by disturbances in the 
mitochondrial OXPHOS system, are the most frequent inborn errors of metabolism, with an 
incidence of 1 in 5,000 live births[76,77]. Owing to dual genetic control, with both nuclear and 
mitochondrial genomes contributing to the complexity of the OXPHOS system (which 
consists of 89 structural components in total), defects in oxidative phosphorylation result in 
a wide variety of clinical phenotypes, presenting from infancy to late adulthood. OXPHOS 
disorders can involve many different organs and tissues, in an organ-specific or 
multisystemic form. However, tissues with a high energy demand, such as brain, heart and 
skeletal muscle, are more dependent on OXPHOS, and therefore more vulnerable to defects 
than others. Heredity patterns can vary from maternal, autosomal dominant or recessive, to 
X-linked and sporadic. Especially for mtDNA mutations, there is no clear genotype-
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phenotype relation: different mtDNA mutations either in the same or in different 
mitochondrial genes may lead to similar clinical phenotypes, whereas the same 
mutations or different mutations in the same gene may result in several distinct 
phenotypes. Clinical manifestation of pathogenic mutations in the mitochondrial DNA is 
often associated with onset in late childhood or adulthood, although some cases of mtDNA 
mutations with an early onset are described. Variability in clinical course and intrafamilial 
presentation are important characteristics of mtDNA mutations[78]. 
Particular features of mitochondrial genetics contributing to the heterogeneous nature of 
OXPHOS disorders are maternal inheritance, heteroplasmy and the threshold effect, and 
mitotic segregation. Mitochondria are exclusively maternally inherited, so primary mtDNA 
mutations and their respective phenotypes are transmitted only from mothers to their 
progeny. Since hundreds or thousands of copies of mtDNA are present in each cell (called 
polyplasmy), different populations of wild-type and mutant mtDNA can occur in cells and 
tissues, a feature known as heteroplasmy. The threshold for a pathogenic mtDNA mutation 
is the minimum percentage of mutant mtDNA that is needed for biochemical expression and 
clinical manifestation of the disease. The threshold of a certain mutation can vary between 
tissues, in relation to their dependence on oxidative metabolism. We speak of mitotic 
segregation when, as a consequence of the redistribution of mitochondria, the degree of 
heteroplasmy changes during cell division. As a result, the pathogenic threshold can be 
crossed, altering the phenotype of that particular cell line or tissue. 
Among the group of OXPHOS disorders, isolated complex I deficiency is the most common 
cause of OXPHOS dysfunction[78-80]. Although complex I deficiency is the responsible 
biochemical defect for a heterogeneous group of diseases, some distinction can be made. 
Clinical phenotypes of complex I deficiency caused by mutations in nuclear DNA-encoded 
subunits generally present in infancy and early childhood, while presentation of the disease 
due to mutations in the mtDNA often occurs in late childhood or adolescence. Among the 
latter group there is a great variability in clinical course and intrafamilial presentation. 
mtDNA mutations have been identified in each of the seven ND genes, expressing various 
clinical symptoms, either restricted to a single organ or tissue, e.g. Leber hereditary optic 
neuropathy (LHON; MIM 535000), or presenting in a multisystemic manner, e.g. 
mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS; 
MIM 540000). 
LHON is a common cause of central vision loss in young adults. It is a maternally inherited 
disorder characterized by bilateral, usually sequential, optic neuropathy, presenting in late 
adolescence or early adulthood. In some patients a more widespread neuromuscular disease 
is seen with cardiac involvement or encephalopathic features, particularly dystonia[81,82]. Co-
occurrence of multiple sclerosis-like white-matter lesions has also been reported[83]. Three 
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common point mutations are responsible for the majority of the LHON cases; these are 
G3460A in ND1, G11778A in ND4, and T14484C in ND6. A few other mutations associated 
with LHON have been described in the ND2, ND5[84], and ND4L[85] genes, but the ND1 and 
ND6 genes are considered as mutational hot spots for LHON[86,87]. The combination of 
LHON and dystonia has also been assigned to mutations in ND6[88]. 
MELAS syndrome is probably the most common mitochondrial encephalomyopathy, and is 
characterized by mental retardation, psychomotor deterioration, migraine, seizures, 
convulsions and lactic acidosis in serum or cerebrospinal fluid (CSF). Presentation is usually 
during childhood or adolescence and in some cases deafness and diabetes can develop at a 
later stage. Mutations have been found in the ND1[56], ND5[89], and ND6[90] genes. The ND5 
gene appeared to be a hot spot for mutations associated with MELAS, but also for several 
overlap syndromes. Many MELAS overlap syndromes have been described with features 
typical of other mitochondrial diseases, such as cardiomyopathy, myoclonus and ragged-red 
fibers, and ataxia[81]. For instance, LHON/MELAS[91], MELAS/MERRF[92], and even 
Leigh/MELAS[93] overlap syndromes, all associated with ND5 mutations, have been 
reported[94]. LHON/MELAS overlap syndrome associated with mutations in ND1 has also 
been reported[95]. 
 
Nuclear genes associated with complex I deficiency 
When isolated complex I deficiency presents in the neonatal period, infancy or early 
childhood, most probably the genetic defect must be sought in the nuclear genes. Also 
mendelian inheritance patterns indicate nuclear gene defects, mostly being autosomal 
recessive. A diversity of clinical phenotypes has been described to occur in complex I-
deficient patients, which can be classified into five main clinical phenotypes: severe neonatal 
lactic acidosis, also known as fatal infantile lactic acidosis (FILA), Leigh syndrome, neonatal 
cardiomyopathy with lactic acidosis, leukodystrophy with macrocephaly, and hepatopathy 
with renal tubulopathy[78,96]. Finally, there is a group of unspecified mitochondrial 
encephalomyopathies that present a combination of neuromuscular symptoms that could 
not be assigned to a specific phenotype. 
The most common clinical phenotype associated with early-onset complex I deficiency is 
Leigh syndrome, first described as subacute necrotizing encephalomyelopathy[97]. Leigh 
syndrome is an early-onset, progressive neurological disorder characterized by motor and 
intellectual developmental delay, signs of brainstem and basal ganglia involvement, and 
increased lactate levels in blood and/or CSF[98]. Further clinical features are optic atrophy, 
ophthalmoparesis, hypotonia, ataxia and dystonia[76]. Mutations causing complex I 
deficiency associated with Leigh syndrome have been found in seven nuclear genes encoding 
complex I subunits: NDUFA1[99], NDUFA2[100], NDUFS1[101,102], NDUFS3[103], NDUFS4[104], 
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NDUFS7[105], and NDUFS8[58,106]. Mutations in NDUFS4 have also been described for Leigh-
like syndrome[75,107,108]. Whereas most cases of Leigh syndrome are caused by autosomal 
recessive nuclear gene defects, recently an increasing number of cases of maternally 
inherited Leigh syndrome (MILS) have been reported, associated with mutations in the 
mitochondrial complex I genes: ND2[109], ND3[110,111], ND4[112], ND5[113,114], and ND6[54,112,115]. 
Severe neonatal lactic acidosis, also known as FILA, is characterized by extremely high 
lactate levels in blood and CSF and high lactate/pyruvate ratios, resulting in severe 
metabolic crisis with secondary cardiac and respiratory failure[78,112]. Just recently, the first 
mutation in a gene encoding a complex I subunit, NDUFA11, causing FILA has been 
described[116]. 
Leukoencephalopathy or leukodystrophy with macrocephaly is an early-onset progressive 
neurological disorder characterized by progressive cerebral white-matter deterioration 
accompanied by enlargement of the head. Mutations have been described for the complex I 
genes NDUFV1[101,117] and NDUFS1[101,112]. 
Neonatal cardiomyopathy with lactic acidosis comprises early-onset, progressive 
hypertrophic cardiomyopathy, possibly accompanied by prominent neurological symptoms 
such as hypotonia, psychomotor retardation, microcephaly and cataract. Hypertrophic 
cardiomyopathy and encephalopathy has been associated with mutations in the complex I 
genes NDUFS2[118], NDUFV2[119] as well as NDUFA11[116]. 
Two cases of other, unspecified, mitochondrial encephalomyopathies have been described 
recently. Kirby and colleagues reported two cases diagnosed as lethal infantile mitochondrial 
disease in patients presenting with hypotonia, lethargy, seizures and a persistent lactic 
acidosis[57]. The responsible pathogenic mutations were located in the NDUFS6 gene, 
causing a complex I assembly or stability defect. Bugiani and colleagues described another 
interesting case of mitochondrial encephalopathy in a patient presenting with severe 
neonatal hypotonia, dysmorphic features, epilepsy and signs of brainstem involvement, 
associated with a markedly reduced residual complex I activity in muscle[112]. Interestingly, 
two heterozygous missense mutations were found in two different genes: NDUFS2 
(paternally inherited) and NDUFA8 (maternally inherited), indicating digenic inheritance. It 
has been suggested that the pathogenesis of the biochemical defect could be the consequence 
of two dominant-negative mutations in different genes. 
In conclusion, complex I deficiency-causing mutations have been found in twelve nuclear 
genes encoding complex I subunits. Mutations in nine of these genes, i.e. NDUFA1, 
NDUFA2, NDUFS1, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8 and NDUFV1, cause 
brain and brainstem disorders, mostly Leigh(-like) syndrome or leukoencephalopathy, while 
mutations in the NDUFS2, NDUFV2 and NDUFA11 genes have exclusively been linked to 
hypertrophic cardiomyopathy and encephalomyopathy[116,118,119]. Although some mutations 
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have a great share in a certain clinical phenotype, a genotype-phenotype relation is not 
clearly apparent. Expanding our knowledge of complex I biogenesis and functioning will aid 
in finding an explanation for the clinical variability and underlying genetic heterogeneity of 
complex I deficiency. 
In addition, probably numerous, yet unknown, nuclear factors are needed for proper 
assembly and functioning of complex I. Identification of these assembly factors will open a 
new field of possible candidates for complex I deficiency. The first mutation in a complex I 
assembly factor gene was found in the NDUFAF2 gene in a complex I-deficient patient with 
early-onset progressive encephalopathy. The clinical presentation resembles that of 
leukoencephalopathy with vanishing white matter[65]. Later, pathogenic mutations have been 
found in the NDUFAF1 gene of a patient presenting with cardioencephalomyopathy[120] and 
in the C6ORF66 gene, encoding a third putative complex I assembly factor, in six patients 
with mitochondrial encephalomyopathy or antenatal cardiomyopathy[121]. 
 
Neurodegeneration and secondary complex I deficiency 
Recently, complex I deficiency has been clearly associated with the pathogenesis of many 
devastating neurodegenerative disorders, including Parkinson disease[122,123]. It has become 
clear that the OXPHOS system may be impaired by mutation of many more mitochondrial 
and even non-mitochondrial proteins, or may be disturbed as a secondary effect of other 
biochemical defects of intracellular metabolism[124]. 
OXPHOS defects caused by genes encoding non-OXPHOS mitochondrial proteins, e.g. 
frataxin and paraplegin, are responsible for Friedreich ataxia and hereditary spastic 
paraparesis, respectively. Friedreich ataxia is an autosomal recessive neurodegenerative 
disease characterized by progressive ataxia, neuropathy, skeletal abnormalities and 
cardiomyopathy. Mutations in the nuclear gene encoding frataxin, which is involved in iron 
homeostasis in mitochondria, result in severe deficiencies of iron-sulfur cluster-containing 
complexes I-III and of the Krebs cycle enzyme aconitase[124]. Hereditary spastic paraparesis 
(HSP) is characterized by progressive spasticity and weakness of the lower limbs, possibly 
accompanied by neurological signs as retinopathy, optic atrophy, ataxia, dementia, and 
mental retardation. One of the genes responsible for HSP is the gene encoding paraplegin, 
an m-AAA metalloprotease, which has a proteolytic and chaperone-like function in the 
folding process of mitochondrial inner membrane proteins. Mutations in this gene have been 
associated with a reduced complex I activity and an increased sensitivity to oxidative stress, 
resulting in an autosomal recessive form of HSP[125]. Recently, it has been demonstrated in 
both yeast and mouse models that the m-AAA protease is directly involved in the proteolytic 
control of the mitochondrial ribosome assembly process by processing MrpL32, a subunit of 
the large ribosomal particle. Affecting mitochondrial protein synthesis, impairment of m-
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AAA protease activity has been proposed to not only disturb the assembly of complex I but 
also that of the other components of the OXPHOS system[126]. 
In Huntington disease (HD) and motor neuron disease (or amyotrophic lateral sclerosis), 
OXPHOS deficiency, and complex I deficiency in particular, is secondary to free radical 
generation, which is induced by mutations in a gene encoding a non-mitochondrial 
protein[124]. In Huntington disease, the responsible mutations are in a nuclear gene encoding 
a non-mitochondrial protein of unknown function, named huntingtin. In a HD patient with 
severe complex I deficiency, multiple mtDNA deletions were found indicating the 
involvement of OXPHOS defects and oxidative damage[127]. Similar complex I and other 
complex deficiencies secondary to oxidative damage by ROS have been implicated in Wilson 
disease[124]. 
For Parkinson disease (PD) it is known that accumulation of oxidative damage caused by 
reactive oxygen and nitrogen species, particularly to complex I, is responsible for the 
degeneration of dopaminergic neurons of the substantia nigra[25]. Recently, it has been 
shown that reduced complex I function in PD brain mitochondria arises from oxidation of its 
catalytic subunits from internal processes, rather than from external oxidative stress, and 
correlates with complex I misassembly[122]. A possible explanation may be provided by two 
other recent studies[128,129]. They independently linked clonal expansion of somatic mtDNA 
mutations, resulting in high levels of mtDNA deletions in individual cells, to the observed 
OXPHOS deficiency, specifically in neurons of the substantia nigra. 
Determining the primary defect underlying the mtDNA deletions in PD brain remains 
complicated. The high oxidative capacity and increased oxidative stress of the substantia 
nigra neurons may contribute to the accumulation of mtDNA deletions and impairment of 
the OXPHOS system, but also impaired mtDNA replication has been proposed as a possible 
cause[128]. However, the question whether additional mtDNA-[130] or nuclear DNA-encoded 
abnormalities in combination with environmental factors are required to cause 
dopaminergic neuronal loss needs to be addressed[82,112]. 
Furthermore, complex I deficiency has been implicated in Alzheimer disease (AD), Down 
syndrome (DS), schizophrenia and bipolar disorder[131]. A reduction in the protein levels of 
complex I subunits encoding genes NDUFV2 and NDUFS1 has been established in several 
brain regions from patients with Down syndrome and Alzheimer disease[132]; however, the 
relationship of the defect to the pathogenesis of the disease is not known. Mutations in the 
mtDNA ND1 gene[133] and polymorphisms in the promoter region of the nuclear NDUFV2 
gene[134,135] associated with complex I deficiency, have both been suggested as genetic risk 
factors for bipolar disorder. 
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Concluding remarks 
Mitochondrial complex I is one of the most complicated enzymes of the eukaryotic cell. 
Forty-five subunits originating from two separate genomes and a number of cofactors 
constitute a membrane-bound enzyme complex that operates within a large respirasome 
structure. Owing to its bigenomic control, deficiency of complex I will lead to a broad 
spectrum of clinical symptoms and biochemical changes in various tissues. Many devastating 
neurodegenerative disorders have been associated with complex I deficiency, emphasizing 
the need to elucidate the molecular mechanisms underlying the functioning of complex I in 
energy transduction. 
The characterization of the 45 genes encoding complex I subunits has been an important 
first step in determining the structure of complex I. Establishing the subunit composition of 
complex I from bovine and human heart mitochondria and the assignment of the cofactors 
to their respective subunits has been important for our knowledge of its enzymatic function. 
Determining the arrangement of the iron-sulfur clusters with the X-ray crystallographic 
structure of the peripheral domain of complex I from T. thermophilus has been a further 
important step, providing more insight in the electron transfer mechanism and the subunits 
involved. When additional crystallographic structures of the membrane domain and 
holocomplex I become available, the coupling mechanism between electron transfer and 
proton translocation will be clarified. 
Characterization of the functions of individual subunits will also be needed to gain insight in 
the enzymatic function of complex I. The presence of some subunits raised questions about 
their function in complex I and their link to other biochemical processes. For instance, the 
NDUFA13 subunit (GRIM-19) provides a link between complex I and apoptotic cell death, 
and the NDUFAB1 subunit (SDAP), the acyl carrier protein, has been suggested to be 
involved in mitochondrial fatty acid synthesis. However, the functions of most of the 
accessory subunits remain to be explored. 
Although, all the structural components of complex I have been identified, little is known 
about the biogenesis of complex I and how its interaction with other complexes of the 
OXPHOS system is regulated. The first models of the human complex I assembly pathway 
are a step in the right direction towards solving the assembly process and need to be further 
investigated. Analysis of the complex I assembly status of patients with a complex I 
deficiency will provide more information on the mechanisms of complex I assembly and/or 
stabilization and on the consequences in a disturbed situation. In at least half of the patients, 
complex I deficiency is caused by disturbance of assembly of the holocomplex; however, little 
is known about the chaperones that guide the assembly process. 
The recent identification of the first complex I assembly chaperone associated with complex 
I deficiency is the beginning of exploring a new direction in the pathogenesis of complex I 
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deficiency. In a comprehensive comparative genomics analysis of the evolution of eukaryotic 
complex I, several paralogous groups resulting from gene duplications were detected for 
some complex I subunits. These paralogues of complex I subunits may have retained their 
functional interaction with complex I and may now be considered as candidates for complex 
I assembly factors[24]. In the future, more complex I-related proteins will be identified by 
means of a bioinformatics approach comparing whole genomes. 
Elucidating the mechanisms underlying the biogenesis and functioning of complex I and 
expanding our knowledge of the pathogenesis of complex I deficiency will be of utmost 
importance for performing adequate diagnostics and the development of future therapeutic 
treatment. 
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Abstract 
The human mitochondrial NADH:ubiquinone oxidoreductase (complex I), the first complex 
of the oxidative phosphorylation system, is composed of at least 42 subunits. Little is known 
about the assembly process of these subunits into the mature complex. Recently, two 
proteins in Neurospora crassa have been found to be involved in the assembly of complex I. 
These proteins are not constituent parts of the mature complex but are associated with 
smaller intermediate complexes of the assembly process and have a chaperone-like function. 
We have characterized the human homologue of one of these two complex I intermediate 
associated proteins, named CIA30, and show that expression of the human CIA30 protein2 is 
ubiquitous with a slightly higher expression in various heart tissues, kidney, lung and liver. 
As deletion of the Neurospora crassa CIA genes results in severe disruption of the assembly 
process, human CIA30 can be considered as a candidate gene related to complex I 
deficiency. Thirteen patients with an isolated complex I deficiency, but who were ruled out 
for mutations in the mtDNA and the 35 nuclear genes of the complex, were subjected to 
mutational analysis of the gene coding for the human CIA30 protein. Four new single 
nucleotide polymorphisms (SNPs) were detected but no functional mutation was found. 
                                                                    
 
 
2 Human CIA30 is currently known as NDUFAF1, complex I assembly factor 1 
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Introduction 
Isolated complex I deficiency is the most frequently encountered defect of disturbances of 
the mitochondrial oxidative phosphorylation (OXPHOS) system[1,2]. Human complex I, 
NADH:ubiquinone oxidoreductase, is a multiprotein complex known to be composed of (at 
least) 42 subunits, seven of which are encoded by mitochondrial DNA (mtDNA). Based on 
homology with the bovine complex, it is assumed that the human complex is L-shaped, 
partly located in the mitochondrial inner membrane and partly protruding into the matrix[3]. 
The main function of the complex is the transportation of electrons from NADH to 
ubiquinone, simultaneously accompanied by the transfer of protons across the 
mitochondrial inner membrane to the intermembrane space. 
Complex I deficiency has been related to mutations in genes of mtDNA-encoded subunits[1,4-
6], mtDNA-encoded tRNAs[1,7] and nuclear DNA-encoded subunits[1,8-12]. In a group of 24 
patients with an isolated complex I deficiency in skeletal muscle tissue and cultured skin 
fibroblasts, eleven patients were screened positive for nuclear encoded defects of complex I 
subunits[1,8,19]. As no mitochondrial or nuclear DNA mutations were found in the remaining 
13 patients, candidates should be sought among additional genes encoding proteins required 
for the assembly of a functional complex I. Recently, in collaboration with Capaldi and 
colleagues, we have reported a new approach for detecting and characterizing complex I 
deficiencies[20]. By using monoclonal antibodies directed against several complex I subunits 
in conjunction with western blotting and sucrose gradient studies, differences in assembly 
patterns can be distinguished[20]. The aberrant patterns are indicative of a possible defect in 
a complex I assembly factor. To date, little is known about the assembly process of the 
subunits into the mature complex and no evidence of a complex-I-specific assembly protein 
has been found in humans as yet. Küffner et al.[21] have reported the involvement of two 
chaperone proteins in the assembly of complex I of the fungus Neurospora crassa. During 
the assembly process, these complex I intermediate associated proteins (CIA30 and CIA84) 
are transiently associated with a complex I assembly intermediate[21]. Since the correct 
assembly is a prerequisite for a functional complex, genes encoding human homologues of 
these two proteins are logical candidates for complex I deficiency. 
Here, we report the genomic sequence of the human homologue of CIA30 together with 
homologues of mouse, Caenorhabditis elegans, Drosophila melanogaster and Aspergillus 
nidulans, the tissue distribution of gene expression, and a mutational detection study. 
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Patients, materials and methods 
Patient group 
Our patient study group consisted of 13 children with an isolated decreased activity of 
complex I in skeletal muscle tissue and cultured skin fibroblasts (male:female ratio of 11:2). 
The clinical characteristics of these patients were described previously by Loeffen et al.[1,13,15]. 
In previous studies, no mtDNA rearrangements (deletions, insertions or duplications), 
common mtDNA point mutations or mutations in any of the 35 nuclear genes and the seven 
mitochondrial ND genes of complex I were found in these patients. 
 
Elucidation of the human CIA30 genomic sequence 
The protein and nucleotide databases of the National Center for Biotechnology Information 
(NCBI; http://www.ncbi.nlm.nih.gov) were subjected to a basic local alignment search tool 
(BLAST) search with the cDNA and amino acid sequence of the Neurospora crassa CIA30 
gene (accession numbers: AJ001726 and CAA04954). Human Genome BLAST was 
performed with the discovered human cDNA sequence. 
 
Tissue distribution of human CIA30 expression 
A human multiple tissue expression (MTE) array (CLONTECH Laboratories), carrying 
poly A+ RNA from 72 different human tissues, was hybridized with a [α-32P]-dCTP labeled 
cDNA probe encompassing the human CIA30 open reading frame at 65°C for 24 h by using 
standard hybridization solutions according to manufacturer‘s protocol. Subsequently, the 
MTE Array was analyzed by autoradiography. 
 
Mutational detection 
Total RNA isolated from cultured skin fibroblasts was used for first-strand cDNA synthesis 
with SuperScript II RNase H- reverse transcriptase (Gibco BRL Life Technologies). A total 
volume of 40 µl reaction mixture, containing 50 mM Tris-HCl, 75 mM KCl, 3 mM MgCl2, 
0.01 M dithiothreitole, 1.25 mM dNTP mix, 0.625 µg oligo(dT), 0.625 µg random hexamer 
primers and 60 U RNasin ribonuclease inhibitor (oligo(dT), primers and inhibitor, all from 
Promega), was incubated at 42°C for 1 h. The reaction was stopped by heating at 96°C for 
5 min, followed by direct cooling on ice. 
Amplification of the human CIA30 cDNA sequence was carried out in three overlapping 
polymerase chain reaction (PCR) fragments covering the entire open reading frame by using 
sense and antisense primers mentioned in Table 1. Primers were constructed based on the 
cDNA sequence of an unknown human protein from NCBI GenBank (accession 
numbers: BC000780 and AAH00780), a result of the BLAST search. 
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Table 1. Primers used for PCR on human CIA30 cDNA 
Primer name Primer sequence (5′ 3′) Location 3’end 
Sense primer 1 CGTCAGTGAAACACTTAGAGC cDNA position 264 
Antisense primer 1 CGGTCCTCTCCAATGATCC cDNA position 666 
Sense primer 2 GAAGCAATATACCATTTTAGGC cDNA position 646 
Antisense primer 2 GATATTCACCATCCAAGGCC cDNA position 1010 
Sense primer 3 AGATGTCTTACGATTGGTCCC cDNA position 950 
Antisense primer 3 TATCATTGTAGATGCTAGTACCC cDNA position 1378 
 
 
The following PCR conditions were used: 35 cycles of 30 s at 92°C, 30 s at 54°C (fragments 1 
and 2) or 57.5°C (fragment 3) and 1 min at 72°C. The cycles were preceded by an initial 
denaturation step of 2 min at 92°C and were followed by a final extension of 7 min at 72°C. 
PCR fragments were separated on a 1.5% agarose gel and bands were made visible by 
ethidium bromide staining. After purification, PCR products were cycle-sequenced, by using 
the same primers mentioned above, and analyzed on an automated ABI Prism 377 DNA 
sequencer (Applied Biosystems), according to the manufacturer's protocol. 
 
 
Results 
Characterization of the human CIA30 gene 
A BLAST search of the NCBI protein and nucleotide databases with the amino acid sequence 
of the Neurospora crassa CIA30 gene revealed a putative human CIA30 homologue, i.e. a 
sequence encoding an unknown human hypothetical protein (CGI-65, accession 
numbers: BC000780 and AAH00780) with an E value of 1*e-08. Subsequently, a Human 
Genome BLAST with this sequence led to the localization of the entire gene on a genomic 
contig (NT_010194) corresponding to chromosome 15. 
The human CIA30 gene has been localized to chromosome 15q13.3 (LOC51103) and 
encompasses ~15 kb. The gene is composed of five exons and has a coding sequence of 
984 bp with the translation initiation codon located in the second exon. A TATA-box 
sequence at position -39 to -36 and a CG-box sequence at position -54 to -49, calculated 
backwards from the transcription initiation site, are present in the promoter region (Fig 1). 
Approximately 1 kb of the promoter region has been examined for sequence motifs 
suggesting the binding of transcription factors. Several potential sites for known 
transcription factors have been identified, including a site for nuclear respiratory factor 2 
(NRF-2) at position -100 to -91[22]. A large number of CpG residues can be observed around 
the transcriptional start site. 
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acacacctgt aatcccagct acttgggagg ctgaggcagg agaattgctc caacccagga gtcggaggtt gcagatcgcg ccactgcact acagcctggg 
caacagagtg agactccgtc tcaaaaaaaa aaagtgcttt aagagaggtg tgcacaaggt acaaacagat gccctgagca actggcgacc gtgtggggcg
agactcggga agggctggta ggaggggctg ctgtccaggt gcgtggtggt cctcaagaat tcatgggggc aattccagca gaatcggcct tttgaggcct 
caggcagttc ttgtggggac cgaggcgaca gataaggaag gaagggatac aggcgcgtta gcaataactg ggttctattt gaaagacgca gggggccggg 
cttggtggct cgcgcctgta atctcagcac tttgggaggc cgaggcgggt ggatcacgag gtcaggagat cgagatcatc ccggctaaca tggtgaaacc 
ccgtctctac taaaaataca aaaattagtc gggcatgatg gcgcgcacct gtaatcccag ctactcggga ggctgaggca ggagaatcgc ttgaatctgg 
gaggcagagg ttgtagtgag ccgagatcgc gccactgcac tccagcctgg gcgacagagc gagaatccgt ctcaaaaaaa aaaaaaaaaa aaaagacgca 
gggatggagt ttgccgcctg aaaggataca ggaaggagag gcgaaaaact tatctgaatt ctcactgctt ccttacaact ggcgaccaag tggaccaaaa 
acctccaaaa acctcagttg gctgggctac ggggtccttg ctgtccttcc tgggcttctg tactcggccg gaactttggt gttctgacgc cttgtttggc 
atcggaaggg aaaagcagat ggacctatac gggtaaagtg gcttctgggc ggaaggtaca ctataggctc ggggaggtaa gcggcggcag gccggcggtt
ggtgtgtccc gggtgtgggg aggcgacaga gccctggcac ttgagggttg agggggcctc cccagcgcgg cgaaccgtct agcctccgga ggccaggccg
tgagtgcggg aggtatacgc caaggcggaa gaattttgcc actcactacc tgtgtgacct cgggtaaatt agccttggaa cgtcagtttc ttcgtctcta 
taattgaaat aataatagta cctctctcag gattgttgtg agccgtcagt gaaacactta gagcagtttc tggcacatgg taaggcatgg >>>IVS1<<<
ctgttatagg tagaattggg ctatttgctg aagcttcttg gtggcccttg ctagcccagg aagaaactta cattttgatt tttttgtacc ATGGCTTTGG
M  A  L
TTCACAAATT GCTGCGTGGT ACTTATTTTC TCAGAAAATT CTCTAAGCCA ACTTCTGCCT TGTATCCATT TTTGGGTATT CGCTTTGCAG AGTATTCCAG 
V  H  K  L  L  R  G  T  Y  F  L  R  K  F  S  K  P  T  S  A  L  Y  P  F L  G  I  R  F  A  E  Y  S  S
TAGTCTTCAG AAACCAGTGG CTTCTCCTGG CAAAGCCTCC TCACAGAGGA AGACTGAAGG GGATTTGCAA GGAGATCACC AGAAAGAAGT TGCTTTGGAT 
S  L  Q  K  P  V  A  S  P G  K  A  S S  Q  R  K  T  E G D  L  Q G  D  H  Q  K  E  V   A  L  D
ATAACTTCTT CTGAGGAGAA GCCTGATGTT AGTTTCGATA AAGCAATTAG AGATGAAGCA ATATACCATT TTAGGCTTTT GAAGGATGAA ATTGTGGATC 
I  T  S  S  E  E  K P  D  V  S  F  D  K  A  I R D  E  A  I  Y  H  F  R  L  L K  D  E  I  V  D
ATTGGAGAGG ACCGGAAGGC CACCCTCTGC ATGAGGTCTT GCTGGAACAA GCCAAGGTTG TCTGGCAATT CCGGGGGAAA GAAGATTTGG ATAAGTGGAC 
H  W  R  G P  E  G  H  P  L  H  E  V  L   L  E  Q  A  K  V  V  W  Q  F R  G  K E D  L   D  K  W  T
AGTGACTTCT GATAAGACGA TTGGAGGCAG AAGTGAAGTG TTTTTGAAAA TGGGCAAGAA TAACCAAAGT GCACTGCTAT ATGGAACTCT GAGCTCTGAG 
V  T  S   D  K  T   I  G  G  R S  E  V   F  L  K   M  G  K  N   N  Q  S   A  L  L  Y  G  T  L S  S  E
GCGCCTCAGG ACGGGGAGTC TACCCGAAGT GGGTACTGTG CAATGATATC CAGGATTCCA AGGgtaggtg aggcccagga >>>IVS2<<< ttcaatatct
A  P  Q  D  G  E S T  R  S   G  Y  C   A  M  I  S  R  I  P   R
tagGGTGCTT TTGAGAGGAA GATGTCTTAC GATTGGTCCC AGTTCAATAC TCTGTATCTC CGTGTACGTG GGGATGGTCG GCCTTGGATG GTGAATATCA 
G  A   F  E  R K M  S  Y  D  W  S  Q  F  N  T  L  Y  L R  V  R  G  D  G R P  W  M V  N  I
AGGAGGACAC AGATTTCTTC CAGAGGACGA ATCAGATGTA TAGTTACTTC ATGTTCACCC GCGGGGGACC CTACTGGCAG GAGGTCAAGg taacagcata
K  E  D  T D  F  F   Q  R  T   N  Q  M  Y S  Y  F   M  F  T   R  G  G  P Y  W  Q   E  V  K
>>>IVS3<<< ttctttcagA TTCCTTTTTC CAAATTTTTC TTCTCTAATC GAGGAAGAAT CCGGGATGTT CAGCATGAGC TTCCGCTTGA TAAGgtaaca
I  P  F  S   K  F  F F  S  N   R  G  R  I R  D  V Q  H  E L  P  L D   K
tattcctgta >>>IVS4<<< tattttaaat ttagATCTCT TCTATAGGAT TCACCTTGGC TGATAAAGTG GATGGTCCAT TCTTCCTGGA GATAGATTTT 
I  S S  I  G   F  T  L  A   D  K  V   D  G  P   F  F  L  E   I  D F
ATTGGCGTGT TTACTGATCC AGCTCATACA GAAGAATTTG CCTATGAAAA TTCTCCAGAG CTTAACCCAA GGCTTTTTAA ATAAagatca tatggtagtt 
I  G  V   F  T  D  P A  H  T   E  E  F   A  Y  E  N S  P  E   L  N  P   R  L  F  K
ttgttttact aatctaaggg tactagcatc tacaatgata tagacaaaat aaaatatttc tttaatggca tccaac
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Figure 1. Genomic and deduced amino acid sequence of human CIA30 (page 95). 
The genomic sequence of human CIA30 including 1 kb of promoter region, five exons of 279, 654, 186, 
75 and 242 bp in length, respectively, and the exon-intron boundaries of the intervening sequences 
(IVSs). The lengths of IVS1, IVS2, IVS3 and IVS4 are 5002, 1416, 6336 and 854 bp, respectively (not 
shown). IVSs, TATA box (position -39), CG box (position -54), NRF-2 site (position -100) and poly A 
signal (position 1408) are depicted in bold, CG elements are underlined. The deduced amino acid 
sequence is placed directly underneath the coding sequence, which is depicted in capitals. cDNA 
numbering is depicted left, amino acid numbering right. 
 
 
Chromosome 19 bears a putative pseudogene of human CIA30 (localization 19p12), which 
consists of the coding sequence of the gene not interrupted by any intervening sequences 
and which is 90% identical to the CIA30 gene. 
 
Primary structure of the human CIA30 protein 
The protein is composed of 327 amino acids and has a predicted (N-terminal) mitochondrial 
targeting sequence composed of the first 24 amino acids of which six are positively charged 
and five are hydroxylated residues. This leader sequence has a probability of export to 
mitochondria of 0.9838 (MITOPROT: prediction of mitochondrial targeting sequences; 
MITOP database; http://www.mips.biochem.mpg.de/proj/medgen/mitop/). The protein 
including the leader sequence has a calculated molecular mass of 37.7 kDa. 
A search for protein patterns and domains at the PROSITE database of the ExPASy 
proteomics server (http://www.expasy.org/tools/scnpsite.html) shows the presence of 
several often-occurring patterns. Among them are two possible cAMP- and cGMP-dependent 
protein kinase phosphorylation sites: an RKFS amino acid sequence located in the leader 
sequence at amino acid positions 15-18 and an RKMS amino acid sequence located at amino 
acid positions 196-199. 
 
Homology studies 
A BLAST search of protein and nucleotide databases revealed putative CIA30 homologues 
(accession numbers given in parentheses) of Mus musculus (AK010328, BAB26855), 
Caenorhabditis elegans (CEC50B8, CAB01129), Drosophila melanogaster (AC007892, 
AAF56928), and the known Aspergillus nidulans CiaA gene (AF236661, AAK14054). The 
CIA30 protein is moderately conserved among species and exhibits the highest homology in 
the C-terminal part of the protein. A multiple alignment of the CIA30 homologues together 
with the human and Neurospora crassa protein is depicted in Figure 2. 
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Figure 2. Comparison of CIA30 homologues (page 97). 
Alignment of CIA30 homologues of Homo sapiens, Mus musculus, Caenorhabditis elegans, Drosophila 
melanogaster, Neurospora crassa and Aspergillus nidulans. Identical amino acids in all six organisms 
are shaded darkly, identical amino acids in four or five of the six organisms are shaded lightly. 
 
 
Tissue distribution of human CIA30 expression 
To obtain more information concerning the expression of human CIA30 in a wide range of 
human tissues, a human MTE array was used for screening with radioactively labeled CIA30 
cDNA. All human tissues revealed expression of human CIA30 mRNA. Dots with a slightly 
higher intensity were seen for various heart tissues (left and right atrium and ventricle and 
interventricular septum), kidney, lung and liver, indicative of a higher expression of CIA30 
mRNA in these tissues (Fig 3). High intensity dots of hybridization with human DNA can be 
explained by the presence of a pseudogene. Thus, expression of the human CIA30 protein is 
ubiquitous with a slightly higher expression in various heart tissues, kidney, lung and liver. 
 
Mutational analysis of the human CIA30 gene 
Direct sequencing of the human CIA30 open reading frame of 13 patients with an isolated 
complex I deficiency in skeletal muscle tissue and cultured skin fibroblasts and who were 
ruled out for mutations in all 42 nuclear and mitochondrial genes of the complex and 
common mtDNA alterations revealed five heterozygous nucleotide substitutions, four of 
which resulted in amino acid substitutions (Tab 2). One of them, the R9H substitution, is a 
known polymorphism recorded in the NCBI SNP database (Reference SNP Id: rs1899). Since 
the other four nucleotide substitutions frequently occur in expressed sequence tags (ESTs), 
they should be characterized as polymorphisms or silent mutations. 
 
 
Table 2. Polymorphisms of human CIA30 
Nucleotide substitutiona Amino acid substitution Reference SNP Id 
G386A R9H rs1899 
G452T R31L - 
G886A E176 K - 
G1269A V303 V - 
C1301G A314G - 
acDNA numbering 
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Figure 3. Tissue distribution of human CIA30 expression. 
Autoradiogram of the human MTE array hybridized with the radiolabeled CIA30 cDNA probe. 
The key to the type and position of poly A+ RNA and control DNA dotted onto the membrane is 
depicted beneath the autoradiogram. 
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Discussion 
Isolated complex I deficiency is the most frequently observed OXPHOS disorder. Genetic 
causes have been found in mtDNA-encoded tRNAs[1,7], in genes of mtDNA-encoded 
subunits[1,4-6] and in nuclear DNA-encoded subunits of complex I[1,8-12]. In contrast to, for 
example, OXPHOS complex IV[23,24], no defects of the assembly of complex I have been 
described as yet. Complex I consists of a membrane arm and a matrix arm that assemble 
independently in separate pathways[25]. Assembly of the membrane arm requires two 
intermediates, called the large and small membrane arm assembly intermediates. In 
Neurospora crassa, two proteins are transiently associated with the large membrane arm 
assembly intermediate but are not associated with the other assembly intermediates or the 
fully assembled complex[21]. Deletion of the genes encoding these proteins, i.e., CIA30 and 
CIA84, results in the disruption of the assembly process by prevention of the formation of 
the large membrane arm intermediate[21]. Neurospora crassa CIA30 and CIA84 function as 
specific chaperones in the formation of complex I. 
We present the genomic sequence of the first human complex I assembly factor, a 
homologue of Neurospora crassa CIA30. The putative mitochondrial targeting sequence 
and the presence of a NRF-2 site indicate that the gene product is presumably a 
mitochondrial protein. NRF-2 has been shown to contribute to the transcriptional regulation 
of a number of nuclear genes that code for subunits of respiratory chain complexes, 
including cytochrome c oxidase, and for other mitochondrial proteins, such as the β-subunit 
of ATP synthase and the mitochondrial transcription factor[22,26]. 
Expression of the human CIA30 protein is ubiquitous with a slightly higher expression in 
various heart tissues, kidney, lung and liver. This finding and the high occurrence of CpG 
elements around the transcription initiation start, which could indicate the presence of a 
CpG island, suggest that CIA30 is a housekeeping gene, as are most genes of the OXPHOS 
system. 
In contrast to mouse with which human CIA30 is nearly 80% identical, there is a moderate 
level of homology between human CIA30 and homologues of Caenorhabditis elegans, 
Drosophila melanogaster, Neurospora crassa and Aspergillus nidulans. No large stretches 
of conservation have been identified but some residues are conserved among all six species. 
The primary structure of the CIA30 protein shows no similarity to known proteins and 
CIA30 cannot be classified as a member of one of the chaperone families, which makes it 
plausible that CIA30 is a single-target chaperone specific for complex I[21]. Further 
investigations are needed to elucidate the role of the putative phosphorylation sites of 
CIA30. A cAMP-dependent protein kinase phosphorylation site, located on the 18-kDa 
subunit of complex I, has been shown to be involved in the activation of the complex[27]. 
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Subjection of our patient group of 13 patients with isolated complex I deficiency in skeletal 
muscle tissue and cultured skin fibroblasts to mutational analysis of the human CIA30 gene 
revealed four new DNA alterations resulting in three amino acid substitutions. Since none of 
these substitutions concerned highly conserved amino acid residues, and since the 
corresponding nucleotide alterations occurred in ESTs, no pathogenic consequences can be 
ascribed to any of them. Although no pathogenic mutations in the human CIA30 gene were 
found in 13 patients of this investigation, this number is too low to allow any speculation 
about the importance of human CIA30 in relation to isolated complex I deficiency. In our 
patient group, candidate genes for isolated complex I deficiency should be sought among 
other, as yet uncharacterized genes encoding complex I specific assembly factors. A human 
(or other organism's) homologue(s) of Neurospora crassa CIA84, for instance, has not been 
identified to date. 
Recently, Triepels et al.[20] have described a promising method for selecting patients by the 
examination of complex I assembly profiles. Western blotting with the use of a set of 
monoclonal antibodies directed against various subunits of complex I in conjunction with 
sucrose gradient studies can reveal aberrant assembly patterns suggesting a possible defect 
in a complex I assembly factor. 
One option for tracking down the defective gene is the chromosome transfer technique. 
Since most of our patients are male, the X-chromosome might be the carrier of a defective 
gene. 
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Abstract 
Complex I (NADH:ubiquinone oxidoreductase) is the largest multiprotein enzyme of the 
oxidative phosphorylation system. Its assembly in human cells is poorly understood and no 
proteins assisting this process have yet been described. A good candidate is NDUFAF1, the 
human homologue of Neurospora crassa complex I chaperone CIA30. Here, we 
demonstrate that NDUFAF1 is a mitochondrial protein that is involved in the complex I 
assembly process. Modulating the intramitochondrial amount of NDUFAF1 by knocking 
down its expression using RNA interference leads to a reduced amount and activity of 
complex I. NDUFAF1 is associated with two complexes of 600 and 700 kDa in size of which 
the relative distribution is altered in two complex I-deficient patients. Analysis of NDUFAF1 
expression in a conditional complex I assembly system shows that the 700-kDa complex may 
represent a key step in the complex I assembly process. Based on these data, we propose that 
NDUFAF1 is an important protein for the assembly/stability of complex I. 
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Introduction 
The failure to assemble a properly functioning complex I (NADH:ubiquinone 
oxidoreductase, EC 1.6.5.3) results in complex I deficiency. This is a major contributor to 
mitochondrial disease and frequently results in early childhood death[1]. As complex IV 
(cytochrome c oxidase) deficiency is frequently caused by mutations in an assembly factor[2], 
it is likely that a similar situation holds for complex I. However, in contrast to the 15 
assembly chaperones already found for complex IV, so far no assembly proteins have been 
described for mammalian complex I. Given the complexity of the enzyme, many assembly 
factors are likely to be needed and still await detection. We have described a candidate gene, 
NDUFAF1, which has 28% homology with Neurospora crassa complex I assembly 
chaperone CIA30[3]. The present study is the first to investigate the possible role of 
NDUFAF1 in the assembly of complex I in human cells. 
Complex I is the first of five multiprotein complexes which together constitute the oxidative 
phosphorylation system. In this system NADH is oxidized by complex I, after which 
electrons are transferred via electron carriers (ubiquinone and cytochrome c) and via 
complexes III and IV to the final electron acceptor molecular oxygen. The energy of this 
transfer is used to translocate protons across the mitochondrial inner membrane. The thus 
generated proton gradient is used by complex V (ATP synthase) to generate ATP. 
Mammalian complex I is an L-shaped structure consisting of at least 45 subunits[4-6] of which 
seven are encoded by the mitochondrial genome. The complex can be subdivided into three 
functionally distinct fragments. The NADH dehydrogenase segment includes the redox 
cofactor flavin mononucleotide, which is involved in the oxidation of the NADH substrate. 
The hydrogenase part contains several iron-sulfur clusters which are involved in electron 
transfer to the electron transporter ubiquinone. The membrane-bound transporter part of 
complex I is involved in proton translocation. Whether and how electron transport and 
proton translocation are coupled is yet uncertain[7]. 
Assembly of complex I is an intricate process which has been studied in several organisms[8-
10]. The most extended investigation of complex I assembly was performed for the fungus 
Neurospora crassa[11,12]. In the proposed model, the hydrophilic peripheral arm and the 
hydrophobic membrane arm of complex I are assembled independently before being joined 
together. The search for a more detailed description of the assembly pathway has recently 
resulted in the publication of the first models for human complex I assembly[13,14]. Both 
models differ considerably, illustrating the fact that the complex I assembly pathway is far 
from solved. The model we describe shows considerable homology to N. crassa complex I 
assembly. We propose that, analogous to the situation in N. crassa, complex I is assembled 
semi-sequentially: discrete functional modules are assembled independently and are joined 
in several steps to form a peripheral arm and a membrane arm assembly intermediate. In 
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more detail, this entails the formation of peripheral arm assembly intermediate D (600 kDa) 
from intermediates H (80 kDa), G (150 kDa) and F (250 kDa) and the formation of 
membrane arm assembly intermediate C (700 kDa) from the combination of membrane 
proteins with intermediate E (400 kDa). Peripheral arm intermediate D consists of a core or 
highly conserved hydrophilic subunits (such as the 49-kDa, 39-kDa and 30-kDa subunits), 
while membrane arm intermediate C consists of highly conserved hydrophobic subunits 
(such as ND1 and ND6). These two key intermediates are combined to form assembly 
intermediate B (950 kDa) and finally holocomplex I (A, 1 MDa)[14]. 
Two candidate assembly proteins for complex I were found in N. crassa: complex I 
intermediate associated proteins CIA30 and CIA84[15]. Knockouts of the cia genes in 
N. crassa resulted in membrane arm subunit knockout phenotypes. The CIA proteins are 
thought to chaperone the combination of the small and large membrane arm intermediates 
of complex I via binding to the large membrane arm intermediate. The binding of CIA84 is 
transient as the protein cycles between a bound and unbound state. Immunoprecipitations 
using a CIA84 antibody have resulted in the identification of associated subunits in the 
membrane arm[15]. 
So far nothing is known about the possible involvement of CIA30 homologue NDUFAF1 in 
human complex I assembly. In this paper, we demonstrate that NDUFAF1 acts as an 
assembly protein for complex I in human cells, in line with the proposed function of its 
homologue CIA30 in the fungus N. crassa. 
 
 
Materials and methods 
Generating the NDUFAF1 antibody 
To produce antibodies against NDUFAF1, two oligopeptides were selected. The first peptide 
corresponds to the mid-portion of the NDUFAF1 sequence, amino acids 43V-57G; the 
second peptide corresponds to the C-terminus of the protein, amino acids 314F-327K. A 
mixture of both peptides was coupled to keyhole limpet hemocyanin, serving as an 
immunogenic carrier. Rabbits were immunized with an injection of the antigen-carrier 
conjugate, followed by three subsequent boosters, one every three weeks. The two antisera 
were collected from a final bleeding and tested for specific detection of the NDUFAF1 protein 
by western blotting. Both antisera displayed comparable specificity. 
 
Cell cultures 
JM109 E. coli cells (Promega, Madison, WI, USA) were cultured in Luria Burtani (LB) 
medium and the appropriate antibiotic was added to the medium. 143B206 ρ0 cells were 
cultured in Dulbecco's Modified Eagle Medium (DMEM, Biowhitaker, Walkersville, MD, 
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USA) supplemented with 5% (v/v) fetal bovine serum (FBS), antibiotics, 1 mM uridine and 
100 µg/mL bromodeoxyuridine. HeLa cells and 143B osteosarcoma cells were cultured in 
DMEM supplemented with 10% (v/v) FBS, penicillin and streptomycin (Gibco, Paisley, UK). 
HEK293 T-REx™ cells without the TO/NDUFAF1 construct were cultured in the same 
medium to which 5 µg/mL blasticidin (Invitrogen, Carlsbad, CA, USA) was added to 
maintain the repressor construct. To HEK293 T-REx™ cells containing the TO/NDUFAF1 
construct additionally 300 µg/mL Zeocin™ (Invitrogen) was added to maintain the 
inducible construct. 
 
siRNA transfection 
For transfection, HeLa cells were plated in DMEM supplemented with 10% (v/v) FBS 
(without antibiotic) in 24-well plates with a cell density of 1.5*104 cells per well. The next 
day, cells were transfected with siRNA duplex (control: Cyclophilin B (Dharmacon, 
Lafayette, CO, USA), NDUFAF1#1 antisense strand: 5‘-ACUAACAUCAGGCUUCUCCdTdT-
3‘, NDUFAF1#2 antisense strand: 5‘-UAACUAUACAUCUGAUUCGdTdT-3‘) in 3 µL 
oligofectamine (Invitrogen) to achieve a final concentration of 10 nM siRNA per well. Cells 
were incubated at 37 °C in a CO2 incubator for 48-72 h until they were ready to assay for 
protein knockdown or to perform a second transfection. 
 
Cellular fractionation 
Approximately 5*106 HEK293 cells were harvested, washed in NaCl/Pi, resuspended in an 
appropriate isotonic buffer [0.25 M sucrose, 5 mM Tris/HCl, pH 7.5, and 0.1 mM 
phenylmethylsulfonylfluoride (PMSF)] and homogenized using a glass Teflon homogenizer. 
Unbroken cells and nuclei were pelleted by centrifugation at 600 g for 15 min. Supernatants 
were centrifuged at 10,000 g for 25 min. The resulting supernatant was isolated as the 
cytoplasmic fraction and the mitochondrial pellet was washed once with the isotonic buffer 
containing 1 mM EDTA, pH 8. 
 
Creating the inducible NDUFAF1 construct and transfection into HEK293 T-REx™ cells 
A PCR of total cell cDNA was performed to specifically amplify NDUFAF1 cDNA using 
Native Pfu DNA polymerase (Stratagene, La Jolla, CA, USA). Primer sequences are (5‘ 3‘): 
NDUFAF1 forward: 5‘-CGCGGAATTCATGGCTTTGGTTCACAAATTGC-3‘, NDUFAF1 
reverse: 5‘-CGCGTCTAGATTTAAAAAGCCTTGGGTTAAGCTC-3‘. 
The amplified fragment and pcDNA4/TO/myc-His A (Invitrogen) (TO) were digested with 
EcoRI and XbaI restriction enzymes (Gibco, Paisley, UK) and subsequently ligated using T4 
DNA Ligase (Invitrogen) and transformed into JM109 competent E. coli cells (Promega). 
Clones containing the plasmid were obtained by kanamycin (Sigma Aldrich, St Louis, MO, 
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USA) selection and were cultured to obtain sufficient construct for transfection. After 
sequence verification, transfection of the construct was performed on HEK293 T-REx™ cells 
(Invitrogen), which stably express the tetracycline repressor operon, using the Superfect® 
Transfection Reagent (Qiagen). Cells were grown to a confluency of 60-70% in a 6-well plate 
and cells in each well were transfected by adding 2 µg of the construct according to the 
protocols described in the Superfect® Transfection Reagent Handbook (Qiagen). Stable 
clones were obtained by culturing under selective pressure of 300 µg/mL Zeocin™ 
(Invitrogen). HEK293 T-REx™ clones containing the TO/NDUFAF1 construct were induced 
for expression of the transgene by adding 0.1-1 µg/mL doxycycline to the growth medium for 
the times indicated in the results section. 
 
Immunofluorescence assay 
A culture of a TO/NDUFAF1 containing HEK293 T-REx™ clone was seeded onto a coverslip 
in a 24-wells plate and grown overnight to achieve a confluency of 50% on the day of the 
assay. Cells were prestained with Mitotracker Red (Molecular Probes, Eugene, OR, USA) 
prior to paraformaldehyde fixation. For fluorescence imaging, cell preparates were attached 
to the stage of an inverted microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany) 
equipped with a 63×/1.25 NA Plan NeoFluar objective (Carl Zeiss). Alexa Fluor® 488 and 
Mitotracker Red were excited at 488 nm and 570 nm, respectively, using a monochromator 
(Polychrome IV, TILL Photonics, Gräfelfing, Germany). Fluorescence emission light was 
either directed by a 505DRLPXR dichroic mirror (Omega Optical Inc., Brattleboro, VT, USA) 
through a 535AF26 emission filter (Alexa Fluor® 488) or by a 595DRLP dichroic mirror 
through a 645AF75 emission filter (Mitotracker Red) onto a CoolSNAP HQ monochrome 
CCD-camera (Roper Scientific, Vianen, The Netherlands). All hardware was controlled with 
METAFLUOR 6.0 software (Universal Imaging Corporation, Downingtown, PA, USA) 
running on a PC equipped with 1 Gb RAM running WINDOWS XP Professional. 
 
Digitonin isolation and solubilization of mitochondria 
Approximately 1*106 trypsin-harvested cells were pelleted and resuspended in 100 µL of cold 
NaCl/Pi to which 100 µL of 4% digitonin (w/v) was added to achieve a final concentration of 
2% (w/v) digitonin. This sample was shortly vortexed and incubated on ice for 10 min to 
solubilize cell membranes. After this, 1 mL of cold NaCl/Pi was added and the sample was 
centrifuged at 10,000 g for 10 min at 4 °C to obtain a mitochondria-enriched organelle 
pellet. To remove traces of digitonin, this pellet was washed twice with 1 mL of cold NaCl/Pi. 
Mitochondrial proteins were solubilized by the addition of 100 µL of AC/BT (1.5 M 
aminocaproic acid, 75 mM bis-tris pH 7.0) and 20 µL of 10% (w/v) n-dodecyl-β-D-maltoside 
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and incubation on ice for 10 min. The solubilized proteins are retained in the supernatant 
after centrifugation at 10,000 g for 25 min at 4 °C, which was used for further analysis. 
 
Gel electrophoresis and in-gel activity assays 
The protein concentration for blue native polyacrylamide gel electrophoresis (BN-PAGE) 
and SDS-PAGE was determined in the n-dodecyl-β-D-maltoside solubilized supernatants 
before adding coomassie blue containing sample buffer, using a MicroBCA protein assay kit 
(Pierce). Blue native 5-15% gradient gels were loaded with 40 µg of digitonin-isolated 
mitochondria and, after electrophoresis, were further processed for western blotting, second 
dimension 10% SDS-PAGE or in-gel activity assays as described earlier[18]. SDS-PAGE 
analysis was performed by loading 40 µg of protein per lane on 10% SDS-PAGE gels as 
described before[14]. 
 
Blotting and detection 
Blue native and SDS gels were blotted onto PROTRAN® nitrocellulose transfer membrane 
(Schleicher and Schuell BioScience) according to standard procedures. Primary antibodies 
used are against the following proteins: NDUFA9 (39 kDa; Molecular Probes), ND1 (a gift 
from A. Lombes, INSERM, Paris, France), Complex II 70-kDa subunit, COXII (both 
Molecular Probes), GADPH,  porin, HSP70 (all Abcam, Cambridge, UK), c-myc (Invitrogen) 
and NDUFAF1 (our laboratory). Secondary antibodies used are swine anti-rabbit IgG 
horseradish peroxidase (SWARPO), goat anti-rabbit IgG horseradish peroxidase (GARPO) 
and goat anti-mouse IgG horseradish peroxidase (GAMPO) (Molecular Probes). Signal 
detection was performed using the ECL® plus Western Blotting Detection System 
(Amersham Biosciences). After ECL, the blots were exposed to X-OMAT UV film (KODAK). 
ECL signals were quantified using the IMAGEPRO-PLUS 4.1 image analysis software (Media 
Cybernetics, Silver Spring, MD, USA). 
 
 
Results 
NDUFAF1 localizes in the mitochondrion 
To analyze the subcellular localization of NDUFAF1 we harvested HEK293 cells at 90% 
confluency, prepared protein samples of total cell lysate, isolated mitochondria and the 
cytoplasmic fraction and performed SDS polyacrylamide gel electrophoresis (PAGE). A 
western blot of this SDS gel was incubated with antibodies against NDUFAF1, a cytoplasmic 
marker (GAPDH), a marker for the mitochondrial inner membrane (COXII), a marker for 
the mitochondrial outer membrane (porin) and a marker for both cytoplasm and the 
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mitochondrial matrix (HSP70) (Fig 1). NDUFAF1 is clearly more abundant in isolated 
mitochondria than in the total cell protein extract and is absent in the cytoplasmic protein 
extract. These data show a specific localization of NDUFAF1 in the mitochondrion. 
 
 
 
To confirm this result and to use another antibody for localization studies, we decided to 
create a construct in which the NDUFAF1 gene was tagged with an immunogenic epitope. 
We cloned NDUFAF1 into an inducible vector in-frame with a c-myc and His6 tag and 
transfected this construct into a human embryonic kidney cell line (HEK293), which stably 
expresses the tetracycline repressor gene. Stable clones were selected and induction of 
protein expression was tested using western blot analysis. Digitonin-isolated mitochondria 
were obtained from cultures of an inducible clone after 0, 1, 2, 4, 24, 48 and 72 h of 
induction with 0.1 µg/mL of doxycycline and analyzed by western blotting (Fig 2). This 
concentration of doxycyline does not interfere with mitochondrial protein translation[14]. 
Using both the NDUFAF1 and the c-myc antibodies both the endogenous and the induced 
(slightly larger than the endogenous protein due to the C-terminal tags) NDUFAF1 could be 
observed after induction. 
To investigate the cellular localization of the NDUFAF1-c-myc fusion protein we used a 
monoclonal c-myc antibody in an immunohistochemical experiment, further incubated with 
a secondary antibody to which a fluorescent Alexa probe was coupled. The overlay of the 
Alexa dye staining with mitochondrial control Mitotracker Red shows that induced 
NDUFAF1 indeed migrates to the mitochondrion (Fig 3). Biochemical fractionation of the 
NDUFAF1-c-myc expressing cells indicates that this fusion protein also exclusively localizes 
in mitochondria (results not shown). 
Figure 1. Western blot analysis of cellular 
fractionation of HEK293 cells. 
An SDS-PAGE (10%) gel was loaded with 40 μg 
protein per lane as follows: lane 1, total cell 
protein extract; lane 2, cytoplasmic protein 
extract; lane 3, mitochondrial protein extract. 
The western blot of this gel was treated with 
antibodies against NDUFAF1, GAPDH 
(cytoplasmic marker), COXII and porin 
(mitochondrial markers) and HSP70 (loading 
control). 
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Figure 2. Western blot analysis of induction of NDUFAF1 in HEK293 cells. 
An SDS-PAGE (10%) gel was loaded with 40 μg protein per lane of a mitochondrial 
protein extract of an inducible HEK293 clone and blotted. Cells were induced with 
0.1 μg/mL of doxycycline for 0 (control), 1, 2, 4, 24, 48 and 72 h. Antibodies used are 
against NDUFAF1 and complex I membrane arm subunit ND1. Induced and 
endogenous NDUFAF1 and ND1 signals are indicated on the right. Quantification of 
the ECL signals is shown in the histogram below, each bar corresponding to the lane 
above. The signal is expressed as percentage of the 0 h time point signal for both 
endogenous NDUFAF1 (white bars) and induced NDUFAF1 (black bars). 
 
 
NDUFAF1 knock down reduces the complex I level and activity 
Based on its homology with alleged complex I chaperone CIA30 in N. crassa, NDUFAF1 is 
an interesting candidate assembly protein for human complex I. The possible involvement of 
NDUFAF1 in complex I assembly/stability was investigated by performing RNA interference 
experiments. To knock down NDUFAF1 protein expression, two different small interfering 
RNA (siRNA) oligonucleotides were designed for targeting NDUFAF1 mRNA. Both siRNAs 
displayed similar knock down effects. Figure 4 shows a transfection of 48 h, followed by 
consecutive transfections of 48, 72 or 96 h with 10 nM of siRNA #2 (data for siRNA #1 not 
shown). RNA interference effects are analyzed for NDUFAF1 protein (Fig 4A), fully 
assembled complex I (Fig 4B) and complex I in-gel activity (Fig 4C). NDUFAF1 expression 
can be knocked down to less than 30% of the control signal (Fig 4A, lanes 4 and 5). This 
leads to a 40% decrease of fully assembled complex I (Fig 4B, lane 5). Complex I activity is  
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Figure 3. Immunofluorescence mitochondrial localization 
of induced NDUFAF1. 
Cells that are induced for NDUFAF1 expression by 1 μg/mL of 
doxycycline for 24 h were treated with either anti-c-myc IgG coupled 
to Alexa Fluor 488 to verify the presence of induced NDUFAF1 (top 
panel) or mitochondrial control Mitotracker Red (middle panel). The 
bottom panel shows an overlay of the two signals. 
 
 
compromised as well, as can be seen by the 50% decrease of signal in Figure 4C (lane 5). 
Interestingly, longer second incubations with siRNA lead to a greater inhibitory effect. 
Control transfections with an siRNA targeting cyclophilin B performed under the same 
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circumstances did not lead to a reduction of the NDUFAF1 signal, or to a reduction in the 
amount of fully assembled complex I (data not shown). This analysis shows that knockdown 
of NDUFAF1 protein leads to a decrease in the amount and activity of fully assembled 
complex I. Conversely, preliminary evidence suggests that overexpression of NDUFAF1 leads 
to an increase in the expression of complex I (data not shown). 
 
NDUFAF1 is present in two high-molecular weight protein complexes 
To investigate whether NDUFAF1 is present in high-molecular weight protein complexes, its 
expression pattern was analyzed by means of two-dimensional blue native/SDS-PAGE (2D 
BN/SDS-PAGE) and western blotting. Control HEK293 cells were harvested at 90% 
confluency and lysates of digitonin-isolated mitochondria were run on 2D BN/SDS gels 
before blotting and antibody detection (Fig 5). Two NDUFAF1-containing high-molecular 
weight complexes of about 600 and 700 kDa can be observed (Fig 5, complexes 2 and 1, 
respectively). As a size reference, complex I (1 MDa) is shown by using an antibody against 
the NDUFA9 (39 kDa) subunit of complex I. The expression pattern of NDUFAF1 when it is 
overexpressed was analyzed by using the doxycycline inducible expression system in 
combination with 2D BN/SDS-PAGE. After 4 h of induction (Fig 6), induced NDUFAF1 can 
be seen to migrate from its monomeric form towards the complexes of 600 and 700 kDa, 
confirming the data observed for endogenous NDUFAF1 in the control situation. 
 
NDUFAF1 expression pattern changes in patients with mutations leading to complex I 
assembly defects 
Our complex I assembly model[14] confirms the separate assembly of membrane and 
peripheral arms described in previous assembly models in N. crassa. A clue about the stage 
at which NDUFAF1 may operate in this human model can be obtained by screening for the 
NDUFAF1 expression pattern in complex I-deficient patients. For this study, we have used 
fibroblasts from an NDUFS8 (TYKY) patient (L. van den Heuvel, manuscript in preparation) 
and an ND5 patient cybrid cell line with 90% of heteroplasmy (D393G)[19] as representatives 
of both a peripheral arm and a membrane arm subunit mutation. Cells were harvested to 
obtain mitochondrial lysates which were run on 2D BN/SDS gels for western blotting and 
antibody incubation (Fig 7). The NDUFS8 (TYKY) patient cell line is represented in 
Figure 7A and the ND5 cybrid cell line is represented in Figure 7B. 
For both patients, complex I expression analysis using NDUFA9 (39 kDa) antibody reveals a 
decrease in the amount of holocomplex I (represented by Figure 7A, see also Ugalde et al.[14] 
for detailed description of the composition of complex I assembly intermediates). Less 
NDUFAF1 is observed in the control fibroblast cell line used for the NDUFS8 (TYKY) patient 
compared to the cybrid control cell line, and the 700-kDa complex seems absent (Fig 7A,  
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Figure 4. RNA interference of 
NDUFAF1 in HeLa cells. 
A, B and E, HeLa cells were transiently 
transfected twice for 48 and 48 h, 48 
and 72 h, and 48 and 96 h, respectively. 
Quantification of the signals is 
represented in the histograms below 
each panel. Each bar corresponds to the 
lane above it, representing the 
percentage of signal compared to the 
‘untreated signal’, corrected for the 
loading control signal (CoII). A. Western 
blot of SDS gel. B. Western blot of blue 
native gel. C. In-gel activity assay. For 
these panels: lane 1, untreated cells; lane 
2, mock transfection (no siRNA); lane 3, 
transfection with NDUFAF1 siRNA #2 
for 48 and 48 h, consecutively; lane 4, 
transfection with NDUFAF1 siRNA #2 
for 48 and 72 h, consecutively; lane 5, 
transfection with NDUFAF1 siRNA #2 
for 48 and 96 h, consecutively. 
Antibodies used are against NDUFAF1, 
NDUFA9 (complex I) and CoII-70 kDa 
(complex II, loading control). In-gel 
activity results are indicated with IGA, 
western blot results are indicated with 
WB. 
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Figure 5. 2D BN/SDS-PAGE expression analysis of a 
mitochondrial protein extract from HEK293 cells. 
40 µg protein per lane was loaded on a blue native 5-15% gradient gel 
(1st dimension) followed by 2nd dimension separation using SDS-
PAGE (10%) gels and western blotting. Antibodies used are against 
NDUFAF1 and NDUFA9 (39 kDa), indicated at the left of each panel. 
CI refers to fully assembled complex I (complex A in Ugalde et al.[14]). 
Numbers 1 and 2 refer to NDUFAF1 complexes of 700 and 600 kDa, 
respectively. 
 
 
 
 
Figure 6. 2D BN/SDS-PAGE expression analysis of mitochondrial protein extracts 
from HEK293 control cells and an NDUFAF1 inducible HEK293 clone. 
The inducible clone was induced for NDUFAF1 expression for 1, 2 and 4 h with 1 μg/mL of 
doxycycline. 40 μg protein per lane was loaded on a blue native 5-15% gradient gel (1st 
dimension) followed by 2nd dimension separation using SDS-PAGE (10%) gels and western 
blotting. Anti-NDUFAF1 antibody was used for immunoblot detection. NDUFAF1 containing 
intermediates are indicated with 1 (700 kDa) and 2 (600 kDa). Induced and endogenously 
expressed NDUFAF1 are indicated on the right with ‘induced’ and ‘endogenous’, respectively, to 
differentiate between the endogenous protein and the slightly larger tagged induced protein. 
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NDUFAF1 panels). This difference in expression intensity is observed more often and 
appears to be cell type dependent[14]. Irrespective of this, what can clearly be seen is the 
strong increase of NDUFAF1 in the 600-kDa complex in the patient compared to the control. 
So, interestingly, complex I and its assembly intermediates are less abundant whereas more 
NDUFAF1 is present in the 600-kDa complex. 
Additionally, the ND5 patient displays a different relative distribution of NDUFAF1 between 
the 600- and 700-kDa complexes compared to the control (Fig 7A, complexes 2 and 1). 
NDUFAF1 is more prominently present at 700 kDa in the 90% cybrid compared to the 
control. As the observed effects are the consequence of complex I membrane arm subunit 
mutation, this allows the possibility that NDUFAF1 is involved in membrane arm assembly. 
 
NDUFAF1 expression pattern changes in a conditional complex I assembly system 
To further investigate this, we used a conditional complex I assembly system. A high 
concentration (10 µg/mL or more) of doxycycline results in the inhibition of mitochondrial 
protein synthesis. Releasing this inhibition allows investigation of the complex I assembly 
process and has recently been used in our group to establish a human complex I assembly 
model[14]. Using this system in combination with 2D BN/SDS-PAGE analysis of NDUFAF1 
expression allows investigation of the possible involvement of NDUFAF1 with complex I 
membrane arm assembly intermediates (Fig 7C). The ratio of the 600- and 700-kDa 
complexes (Fig 7C, complexes 2 and 1, respectively), shows a remarkable change after the 
resumption of mitochondrial protein synthesis. In control 143B osteosarcoma cells, 
NDUFAF1 is predominantly present in the 600-kDa complex (Fig 7C, complex 2). After five 
days of inhibition of mitochondrial protein synthesis (Fig 7C, t = 0 h), a minor amount of 
NDUFAF1 is still present in this complex. At 12 h after release of inhibition, NDUFAF1 
becomes more predominant in the 700-kDa complex (Fig 7C, complex 1) up to 48 h after 
release of inhibition. After this time, the amount of NDUFAF1 in the 700-kDa complex 
decreases and finally returns to the wild-type state in the 600-kDa complex after five days. It 
seems that NDUFAF1 appears in the 700-kDa complex while complex I assembly proceeds 
and releases when the control complex I amount is assembled (Fig 7C, complex A). These 
kinetics are not displayed for the 600-kDa NDUFAF1 complex, which is still present after 
5 days of doxycycline inhibition and increases gradually while complex I assembly proceeds 
(Fig 7C, complex 2). The expression kinetics described above support the notion that when 
complex I membrane arm assembly is either disturbed or induced, NDUFAF1 becomes more 
abundant in the 700-kDa complex. 
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Figure 7. NDUFAF1 expression in two complex I-deficient patients (A and B) and in a 
conditional complex I assembly system (C). 
Mitochondrial pellets were solubilized and 40 µg of protein was loaded onto a blue native 5-15% 
gradient gel. Expression profiles were analyzed by 2D BN/SDS-PAGE, western blotting and antibody 
incubation. Antibodies used are against NDUFAF1 and NDUFA9 (39 kDa). Assembly stages described 
in[14] are indicated at the top by A, B and D. NDUFAF1 containing complexes are indicated by 1 
(700 kDa) and 2 (600 kDa). A. Expression analysis of control 143B osteosarcoma cells and a complex I 
peripheral arm subunit patient cell line [NDUFS8 mutation, (L. van den Heuvel, unpublished data)]. 
B. Expression analysis of control cybrids (cybrid control) and a complex I membrane arm subunit 
patient cell line (ND5 mutation D393G)[19] with heteroplasmy level of 90%. C. Expression analysis of 
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mitochondrial protein extracts from 143B osteosarcoma cells inhibited for mitochondrial protein 
synthesis by treatment with 15 μg/mL of doxycycline for 5 days. Samples were taken at 0, 3, 6, 12, 24, 
48 h and 5 days after release of doxycycline inhibition. Control (143B osteosarcoma cells) panel is at 
the top. 
 
 
Discussion 
Studying complex I assembly factors will not only aid the development of an accurate 
assembly pathway but will also contribute to the elucidation of the molecular mechanism 
responsible for many of the genetically unexplained complex I deficiencies. Analogous to the 
numerous complex III and IV assembly proteins which are not part of the structural 
framework of these complexes, it is to be expected that such proteins also exist for complex I. 
However, so far only two candidate complex I assembly factors were found in the fungus 
Neurospora crassa: CIA30 and CIA84[15]. The human homologue of CIA30, named 
NDUFAF1, could be identified[3], but has remained unstudied since its discovery. 
The mitochondrial localization of NDUFAF1 shown by cellular fractionation (Fig 1) and 
immunofluorescence microscopy (Fig 3) is consistent with the in silico prediction of an N-
terminal mitochondrial targeting sequence and the distribution pattern of expression in 
different tissues[3]. 
Our findings support the role of NDUFAF1 in the regulation of assembly/stability of human 
complex I. Firstly, the knockdown of NDUFAF1 expression by RNA interference shows that 
the protein is required for correct complex I assembly and/or stabilization (Fig 4). After 
knockdown of NDUFAF1, the amount of fully assembled complex I is reduced and enzymatic 
activity is impaired. Surprisingly, no accumulation of assembly intermediates is observed in 
the NDUFAF1 RNAi experiments on 2D BN/SDS gels, suggesting that NDUFAF1 may be 
involved in the stabilization of these intermediates rather than in active combination of 
assembly intermediates (R. Janssen, unpublished results). Secondly, prolonged 
overexpression of NDUFAF1 in HEK293 cells leads to an increased amount of fully 
assembled complex I. 
NDUFAF1 occurs in two high-molecular weight protein complexes of 600 and 700 kDa. Its 
expression in two complex I-deficient patient cell lines differs greatly when either membrane 
arm or peripheral arm assembly is compromised by mutation (Fig 7A,B). Mutation in 
membrane subunit ND5 results in a relative increase of the 700-kDa NDUFAF1 complex 
very similar to the shift in the conditional assembly system. Peripheral arm subunit NDUFS8 
mutation results in a completely different expression profile. While in this patient complex I 
and its assembly intermediates are diminished, more NDUFAF1 is present at 600 kDa. This 
indicates that despite the comigration of this complex with peripheral arm assembly 
intermediate D[14], they are different complexes. 
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Additional support for the involvement of NDUFAF1 in complex I assembly/stability comes 
from analysis of its 2D BN/SDS assembly profiles in a conditional complex I assembly 
system (Fig 7C). Absence of NDUFAF1 from the 700-kDa complex after inhibition of 
assembly shows that association of NDUFAF1 with the complex is hampered. As after 
doxycycline inhibition of mitochondrial protein synthesis no mitochondrial protein can be 
produced, this suggests that NDUFAF1 is bound to a mtDNA-encoded protein. The transient 
shift of NDUFAF1 to the 700-kDa complex after assembly resumes, suggests that NDUFAF1 
is required in this complex while assembly proceeds. This is supported by the fact that when 
after five days the complex I amount is restored, the amount of associated NDUFAF1 in this 
complex is also reduced to control levels. The 700-kDa NDUFAF1 complex may therefore 
represent an important step in the process of complex I assembly. 
The model for complex I assembly in humans proposed by our group supports the idea that 
complex I assembly occurs in a modular fashion, and is largely compatible with the 
N. crassa model for complex I assembly[14]. In this system, complex I is assembled via the 
combination of preassembled evolutionarily conserved modules like the bricks of a Lego 
system. In more detail, this entails that the membrane arm appears to be assembled in 
several steps by combining a small and large intermediate. The peripheral arm is assembled 
independently and is joined to the complete membrane arm in a later stage. Based on the 
results presented in this paper, we propose that NDUFAF1 modulates this process. An active 
role in assembly may serve to ease the combination of assembly intermediates while, 
alternatively, a stabilizing or scaffolding role may serve to prevent misfolding or degradation 
of assembly intermediates. 
This function for NDUFAF1 is in line with the proposed mechanism described for the 
N. crassa homologue CIA30[15]. In this study CIA30 was suggested to aid the combination of 
the small and large membrane arm intermediates in complex I assembly by exclusive 
binding to the large membrane arm intermediate[12,16]. Knockout of the cia genes in 
N. crassa resulted in a block in complex I assembly, characterized by the absence of the large 
membrane arm intermediate and the accumulation of the small membrane arm intermediate 
and the peripheral arm[15]. The acquired data do not conflict with this idea. Both disturbance 
of membrane arm assembly (ND5 cybrid) and pressurizing the assembly system by releasing 
doxycycline inhibition of mitochondrial translation result in accumulation of the 700-kDa 
NDUFAF1 complex. However, to ascertain direct involvement in complex I membrane arm 
assembly, the exact composition of the NDUFAF1 intermediates is a prerequisite. In 
addition, the observed changes in NDUFAF1 assembly status in complex I-deficient patients 
can be indicative for the possible gene defect and we are currently investigating more 
patients to test this. 
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It is quite conceivable that, analogous to NDUFAF1, many more proteins are involved in the 
stabilization of complex I assembly intermediates. A recent example is the possible function 
of apoptosis-inducing factor (AIF) in intramitochondrial assembly/maintenance of 
respiratory chain complexes in a mouse model system[17]. Future investigation of the exact 
composition of complex I assembly intermediates will be a great step forward in studying the 
function of NDUFAF1 and finding new complex I assembly chaperones. 
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Abstract 
NADH:ubiquinone oxidoreductase (complex I) deficiency is amongst the most encountered 
defects of the mitochondrial oxidative phosphorylation (OXPHOS) system and is associated 
with a wide variety of clinical signs and symptoms. Mutations in complex I nuclear structural 
genes are the most common cause of isolated complex I enzyme deficiencies. The cell 
biological consequences of such mutations are poorly understood. In this paper we have used 
blue native polyacrylamide gel electrophoresis in order to study how different nuclear 
mutations affect the integrity of mitochondrial OXPHOS complexes in fibroblasts from 15 
complex I-deficient patients. Our results show an important decrease in the levels of intact 
complex I in patients harboring mutations in nuclear-encoded complex I subunits, 
indicating that complex I assembly and/or stability is compromised. Different patterns of 
low-molecular weight subcomplexes are present in these patients, suggesting that the 
formation of the peripheral arm is affected at an early assembly stage. Mutations in complex 
I genes can also affect the stability of other mitochondrial complexes, with a specific 
decrease of fully assembled complex III in patients with mutations in NDUFS2 and 
NDUFS4. We have extended this analysis to patients with an isolated complex I deficiency in 
which no mutations in structural subunits have been found. In this group, we can 
discriminate between complex I assembly and catalytic defects attending to the fact whether 
there is a correlation between assembly/activity levels or not. This will help us to point more 
selectively to candidate genes for pathogenic mutations that could lead to an isolated 
complex I defect. 
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Introduction 
Mitochondrial diseases are a heterogeneous group of multisystemic disorders mostly caused 
by the dysfunction of one or more enzyme complexes of the oxidative phosphorylation 
(OXPHOS) system. NADH:ubiquinone oxidoreductase (complex I) deficiency is a frequently 
diagnosed defect of the mitochondrial OXPHOS system generally associated with severe 
metabolic disorders of childhood, like progressive encephalomyopathy, leukodystrophy or 
Leigh syndrome. Patients show a wide spectrum of clinical presentations and many die very 
young because of a fatal dysfunction of tissues with high metabolic energy rates[1]. 
Mammalian complex I is a ~980-kDa holoenzyme that consists of two functional parts: a 
catalytic peripheral arm that protrudes into the matrix, and a membrane arm for proton 
translocation, which is embedded in the mitochondrial inner membrane (Fig 1). Complex I is 
made up of at least 39 different structural proteins encoded by the nuclear genome and 
seven subunits encoded by the mitochondrial DNA[2]. By using mildly chaotropic detergents 
the complex has been resolved into various subcomplexes, each containing a different 
subunit composition[2]. Although in some cases mitochondrial DNA mutations have been 
described as causing a complex I deficiency, they only account for a small percentage of the 
total number of complex I-deficient patients. In the majority of these patients mutations in 
nuclear genes are expected. The identification and genetic characterization of 45 human 
complex I nuclear structural genes has been completed[1,2]. As a result of an extensive 
mutation detection program at our center in a research cohort of 24 patients presenting with 
an isolated complex I deficiency, pathogenic mutations were found in five complex I nuclear 
genes: NDUFS2[3], NDUFS4[4,5], NDUFS7[6], NDUFS8[7] and NDUFV1[8]. Later, other groups 
detected new mutations in NDUFS4[9,10], NDUFS1[11], NDUFV1[11] and NDUFV2[12,13]. Except 
for NDUFS4, all the pathogenic mutations are located in the structural core subunits that are 
highly conserved from bacteria to mammals[14]. In the remaining patients no mutations have 
been identified after screening all complex I structural genes, thus the genetic defect leading 
to an isolated complex I deficiency must be found in nuclear genes encoding regulatory 
proteins of complex I biogenesis or activity. The exact mechanisms by which these mutations 
affect the function of mitochondrial complex I remain unclear. Studies in Yarrowia 
lipolytica have shown that mutations in the genes encoding subunits PSST and TYKY 
(NDUFS7 and NDUFS8 homologues, respectively) affected electron transport by altering 
complex I in vitro kinetics, resulting in a catalytically impaired complex I[15]. Similarly, 
mutational analyses of the yeast NDUFS2 homologue revealed its central role (together with 
PSST and TYKY) in the catalytic core for ubiquinone reduction[16]. A 5-bp duplication in the 
NDUFS4 gene destroys a cAMP-dependent consensus phosphorylation site, abolishing 
complex I activity in a Leigh syndrome patient[17]. It has been recently demonstrated that 
patients with genetic alterations in NDUFS4 show low levels of mitochondrial complex I 
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together with an accumulation of an intermediate subcomplex[18], suggesting defects in 
complex I assembly or stability. To better characterize complex I deficiencies, we used 
western blotting in combination with sucrose gradient centrifugation in our patient 
cohort[19]. Differences found in the relative subunit composition of complex I in these 
patients seemed to depend on the gene mutated, suggesting that distinct pathogenic 
mutations within the same gene could lead to a similar assembly defect. Furthermore, a 
severe disturbance in complex I assembly was confirmed in one patient harboring an 
unknown nuclear mutation[19]. 
 
 
 
Figure 1. Approximate position of mitochondrial 
complex I nuclear-encoded core subunits plus 
others participating in the present study. 
Highlighted are the subunits in which mutations have 
been analyzed. Subcomplexes Iλ, Iβ and Iγ are indicated. 
 
 
In order to study how these mutations affect the integrity of mitochondrial OXPHOS 
complexes, we have now extended the biochemical studies by using blue native 
polyacrylamide gel electrophoresis (BN-PAGE)[20]. Here we report our results in cultured 
skin fibroblasts from 15 complex I-deficient patients harboring mutations in complex I-
related nuclear genes (Tab 1). Six patients with known mutations in complex I subunits show 
low relative amounts of fully assembled complex I that correlate with low levels of complex I 
activity detected in-gel, suggesting that complex I assembly or stability is compromised. By 
two-dimensional BN-PAGE, different patterns of complex I sub-products are detected in 
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Table 1. Clinical, biochemical and genetic characteristics of the investigated complex I-deficient patients 
Patient Gene Fraction Mutation Biochemistry CI act. (%) Other act. (%) Phenotype Ref. 
P1 NDUFS8 Iλ P79L/R102H 2x4Fe-4S clusters 69a All normal Leigh syndrome [7] 
P2 NDUFS7 Iλ V122M 4Fe-4S cluster (N2) 68a All normal Leigh syndrome [6] 
P3 NDUFS2 Iλ P229Q H+ translocation/Q-binding 36a All normal HCEM [3] 
P4 NDUFS2 Iλ R228Q H+ translocation/Q-binding 39a All normal HCEM [3] 
P5 NDUFS4 Iλ W97X cAMP dep. phosphorylation 59a/47b CIII 98a/87b Leigh-like syndrome [5] 
P6 NDUFS4  Iλ R106X cAMP dep. phosphorylation 36a/30b CIII 100a/88b Leigh syndrome [21] 
P7 unknown  unknown  45a All normal FILA  
P8 unknown  unknown  39a All normal UEM  
P9 unknown  unknown  60a All normal FILA  
P10 unknown  unknown  85a All normal Leigh syndrome  
P11 unknown  unknown  36a All normal Leigh-like syndrome  
P12 unknown  unknown  63a All normal FILA [47] 
P13 unknown  unknown  73a All normal PCA  
P14 unknown  unknown  42a All normal Leigh syndrome  
P15 unknown  unknown  27a All normal Leigh syndrome  
Enzymatic activities (act.) were measured in triplicate in at least two independent patient-derived samples. The values for the residual complex I (CI) and complex III 
(CIII) activities are given as a percentage of the lowest control value (set as 100%) after a) normalization by COX or b) normalization by the matrix enzyme citrate 
synthase. Q, ubiquinone; HCEM, hypertrophic cardiomyopathy and encephalomyopathy; FILA, fatal infantile lactic acidosis; UEM, unspecified encephalomyopathy; 
PCA, progressive cerebellar ataxia. 
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patients with different mutated genes. Two patients harboring unknown nuclear mutations 
present such low complex I activity/assembly levels, suggesting that the genetic defect 
should be found in a new complex I subunit or assembly factor. The remainder seven 
patients show almost normal levels of the fully assembled holoenzyme with low complex I 
activities, compatible with a catalytic defect in which a mutation could be found in a factor 
participating in the activation of complex I. Finally, we have analyzed how the different 
mutations in complex I genes affect the stability of other OXPHOS complexes, 
demonstrating a specific decrease of intact mitochondrial complex III in patients with 
mutations in NDUFS2 and NDUFS4. 
 
 
Patients, materials and methods 
Patients 
Table 1 summarizes the genetic, clinical and biochemical features of the patients‘ fibroblasts 
analyzed in this study. Patients and mutations were previously reported[3,5,6,7,21,24,47]. 
 
Cell cultures 
Fibroblasts were obtained from skin biopsies and cultured in M199 medium (Life 
Technologies) supplemented with 10% fetal calf serum (FCS) and 100 IU/ml penicillin and 
100 IU/ml streptomycin. 
 
Complex I assembly and in-gel activity studies 
One- and two-dimensional BN-PAGE and mitochondrial complex I in-gel activity assays 
were performed with digitonin-isolated mitochondria from patients‘ fibroblasts as previously 
described[48]. Proteins were transferred to a PROTRAN® nitrocellulose membrane 
(Schleicher and Schuell). Western blotting was performed using primary antibodies raised 
against complex I subunits NDUFA9, NDUFS3 and NDUFS5, against core protein 2 and 
COXI subunits from mitochondrial complexes III and IV, respectively, and against the α-
subunit of F0F1-ATPase (Molecular Probes). Peroxidase-conjugated anti-mouse 
immunoglobulins (Molecular Probes) were used as secondary antibodies. The signal was 
detected by using ECL® plus reagents (Amersham Biosciences) and the quantification of the 
blots was performed using ImagePro-Plus 4.1 image analysis software (Media Cybernetics, 
Silver Spring, MD, USA). 
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Results 
The integrity of human mitochondrial complex I is altered by mutations in nuclear-
encoded subunits 
Mitochondria isolated from cultured skin fibroblasts of complex I-deficient patients (Tab 1) 
in which mutations have been described in subunits NDUFS2[3], NDUFS4[5,21], NDUFS7[6] 
and NDUFS8[7] were run under native conditions in a BN-PAGE system and subjected to a 
complex I in-gel activity assay (Fig 2A). As expected, low complex I activities were confirmed 
in all the patient samples when compared with control levels. A second activity below 440 
kDa is normally observed in all samples tested, which include rho zero cells (unpublished 
data), and it could correspond to other NADH dehydrogenases present in mitochondria. A 
duplicate gel was blotted and incubated with antibodies raised against the complex I 
subunits NDUFA9 and NDUFS3 (Fig 2B and C, respectively). Decreased levels of fully 
assembled complex I were observed in all cases, which correlate with the low complex I 
activities found in the patients. These results suggest that disturbances in the assembly 
pathway or in the stability of mitochondrial complex I are the direct cause of the decreased 
activity levels. This effect seemed to be more pronounced in two patients with mutations in 
NDUFS8 (patient 1) and NDUFS2 (patient 3). Moreover, patients 5 and 6 carrying mutations 
in the NDUFS4 gene accumulated high levels of a lower-molecular weight subcomplex 
(~800 kDa, gray arrow) that showed no complex I activity in Figure 2A, as has been recently 
described[18]. The same product was observed in three additional patients with different 
mutations in NDUFS4 (data not shown). Other subcomplexes containing subunit NDUFS3 
were commonly present in patients and control samples (Fig 2C, small black arrows). 
Surprisingly, patient 3 (P229Q mutation in NDUFS2) repeatedly showed a band at a position 
higher than complex I (Fig 2C, dashed arrow). It also appeared in the NDUFS4 patients 5 
and 6 under different electrophoretic conditions (data not shown). In patient 3, this band 
was more intense than the one corresponding to the fully assembled complex (estimated 
ratio 2:1) and it could correspond to the presence of mitochondrial supercomplexes I1III2 or 
I1III2IV1[22]. To check this possibility and, at the same time, analyze the expression levels of 
native complexes III and IV in the different patients, the same blot was incubated with 
antibodies against core protein 2 (complex III) and COXI (complex IV) subunits (Fig 2E and 
D, respectively). Presence of complexes III or IV was not detected at the high-molecular 
weight range, suggesting that the upper band would contain only complex I, maybe 
representing an inactive conformation of this complex (it does not show NADH 
dehydrogenase activity in the in-gel activity assay). Further studies are necessary to fully 
confirm this hypothesis. 
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Figure 2. BN-PAGE analysis of mitochondrial complexes I, III and IV in fibroblasts 
from patients with characterized mutations in nuclear-encoded complex I subunits. 
Mitochondrial particles were isolated as described in ‘Patients, materials and methods’ and 30 µg 
protein was analyzed on a blue native 5-15% gradient gel for the separation of multisubunit 
complexes. A. In-gel activity assay (IGA) of mitochondrial complex I confirming a decrease in all 
the activities of patients compared to control samples. A non-specific NADH dehydrogenase 
activity below 440 kDa is indicated on the left with an arrowhead. B. A second gel was run in 
duplicate and western blot analysis was performed using antibodies against complex I subunits 
NDUFA9 and (C) NDUFS3, or (D) against complex IV subunit COXI and NDUFA9 or (E) complex 
III core protein 2. A high-molecular weight band containing NDUFS3 in patient 3 is indicated by a 
dashed arrow. The accumulation of the typical 800-kDa subcomplex observed in NDUFS4 patients 
(patients 5 and 6) is indicated by a gray arrow. Lower subcomplexes that are common to control 
and patient samples are indicated by small black arrows. CI, fully assembled complex I (~980 
kDa). CIII, mitochondrial complex III dimer (~600 kDa). CIV, mitochondrial complex IV (~200 
kDa). CIII+CIV indicates the presence of a supercomplex containing both complexes that is 
frequently observed in BN-PAGE analysis. The positions in the gel of the ferritin monomer (440 
kDa) and dimer (880 kDa) used as molecular mass standards are indicated on the left. 
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Mutations in NDUFS2 and NDUFS4 subunits affect the stability of mitochondrial complex 
III 
When we compared the ratios between native mitochondrial complexes, it appeared that the 
levels of the fully assembled complex III dimer (~600 kDa) were clearly decreased in the 
patients harboring different mutations in NDUFS2 (patients 3 and 4) and NDUFS4 (patients 
5 and 6), were slightly decreased by the mutation in NDUFS7 (patient 2), but not affected by 
the mutation in NDUFS8 (Fig 2E). This result supports the idea of a physical interaction 
between both complexes. In agreement with this, a combined complex I+III deficiency has 
been described for three patients carrying mutations in the NDUFS4 gene[5,21]. A similar 
reduction in the levels of complex III was observed in two out of three additional patients 
harboring different mutations in NDUFS4, making it a total of four patients. All these 
patients harbor missense mutations leading to premature stop codons in the central part of 
the protein. In the remainder patient with normal assembled complex III[4], the mutation is 
located very near to the carboxy terminus of the protein, suggesting that this region is 
important for the activity of complex I but not relevant for the stability of mitochondrial 
complex III (Ugalde et al., manuscript in preparation). Because all the patients showed 
normal cytochrome c oxidase (COX) enzymatic activities and the enzymatic values for 
complex I were calculated relative to COX (Tab 1), the antibody against COXI subunit was 
also used to normalize for the expression levels of mitochondrial complex IV (Fig 2D). Fully 
assembled COX levels were slightly increased in patients 4, 5 and 6 when compared with the 
control, but this is probably due to differences in sample loading in this particular 
experiment. 
The signals from the blots were quantified and the complex I/complex IV and complex 
III/complex IV ratios were used as numerical values for the expression levels of fully 
assembled complex I and III, respectively (Tab 2). An apparent lack of correlation between 
the residual complex I enzymatic activities shown in Table 1 and the amount of fully 
assembled complex I quantified in Table 2 occurred in some patients. For instance, patients 
1 and 2 presented a similar complex I activity but the differences in the amount of complex I 
calculated in Table 2 were bigger (7 and 50%, respectively). These differences might come 
from the mitochondrial extraction method used in each assay. For the biochemical activity 
measurements, differential centrifugation in glucose gradient was used, whereas for the BN-
PAGE assay, digitonin extraction was used. Although digitonin is considered a mild 
detergent, it could enhance the disruption of the complex and the loss of complex I activity 
under circumstances that would promote the loss of stability of the complex (such as certain 
mutations in complex I subunits). If this is the case, this treatment does not seem to affect 
the levels of fully assembled complex I in control fibroblasts. 
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Reversibly, patients with mutations in NDUFS2 and NDUFS4 showed a relatively important 
decrease of assembled complex III levels with very limited or no complex III enzymatic 
defect. Possibly the reduction in the levels of fully assembled complex III is not sufficient to 
reach the threshold necessary to provoke a marked decrease on complex III activity, as it has 
been shown in a parkinsonism-related complex III deficiency[23]. 
 
 
Table 2. Numerical values for the expression levels of mitochondrial complexes I, III 
and IV in patients with known mutations in nuclear DNA-encoded subunits 
Patient CI CIII CIV CI/CIV CIII/CIV 
C 100 100 100 1.00 1.00 
P1 7 ± 1 100 ± 4 95 ± 4 0.07 1.05 
P2 50 ± 2 87 ± 3 105 ± 7 0.48 0.83 
P3 10 ± 0 59 ± 3 103 ± 5 0.10 0.57 
P4 24 ± 2 55 ± 6 136 ± 8 0.18 0.40 
P5 24 ± 4 64 ± 5 125 ± 7 0.19 0.51 
P6 38 ± 4 73 ± 6 121 ± 5 0.31 0.60 
To calculate the expression levels of complexes I and III, three independent blue native blots were 
quantified and the values normalized to those obtained from complex IV. Values below the 
normal expression range are highlighted in bold. 
 
 
Distinct patterns of low-molecular weight subcomplexes in patients with mutations in 
nuclear structural genes 
To study in more detail how mutations in nuclear genes affected complex I assembly or 
stability, mitochondrial native (sub)complexes were separated in a second dimension SDS-
PAGE system, blotted and incubated with antibodies against three complex I subunits: 
NDUFS3, localized in the peripheral arm, and NDUFS5 and NDUFA9, localized in the 
peripheral and membrane arm boundary (Fig 3). Three different effects were observed: (i) 
the repeated presence of lower amounts of fully assembled complex I in patients‘ fibroblasts 
relative to controls; (ii) different patterns of low-molecular weight subcomplexes that 
contain the NDUFS3 subunit; and (iii) similar accumulation of an ~800-kDa subcomplex in 
patients with different mutated genes. These results confirm that the assembly and/or 
stability of mitochondrial complex I is severely affected by these mutations. The most 
dramatic effects were observed in the two patients with a heterozygous P79L/R102H 
mutation in the NDUFS8 subunit and with a homozygous P229Q mutation in NDUFS2 (data 
not shown), where the signals for complex I subunits were almost undetectable. In all the 
patients NDUFS3-containing subcomplexes below 450 kDa accumulated, probably  
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Figure 3. Different patterns of complex I subcomplexes are observed in fibroblasts 
from patients with known mutations by two-dimensional BN/SDS-PAGE. 
Mitoplasts were extracted and 40 µg protein separated on a blue native 5-15% gradient gel. For 
the separation of individual subunits a SDS-PAGE (10%) gel was run in the second dimension. 
Gels were blotted. For the positioning of complex I (~980 kDa) primary antibodies against 
complex I subunits NDUFA9 (39 kDa), NDUFS3 (30 kDa) and NDUFS5 (15 kDa) were used in 
control and patients’ fibroblasts. An antibody against the α-subunit of F0F1-ATPase was used as 
a reference molecular weight marker for the relative position of complex V (~750 kDa) and F1-
ATPase subcomplex (~450 kDa), depicted as V and F1 respectively. CI indicates the relative 
position of fully assembled complex I. Lower-molecular weight subcomplexes are indicated by 
vertical arrows. The directions of the first (1D) and second (2D) dimension are shown. 
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indicating that the formation of the peripheral arm is interrupted at very early stages of the 
assembly process. Subunits NDUFS5 and NDUFA9 were mostly present in the ~800-kDa 
subcomplex, suggesting their incorporation at a later stage of complex I assembly. According 
to the results obtained in the first dimension, the accumulation of this late subcomplex is 
especially abundant in patients harboring mutations in the NDUFS4 gene (Fig 3, lower 
panel). 
 
Differences in catalytic versus assembly defects in patients harboring unknown mutations 
in nuclear genes 
The same analysis was extended to nine fibroblast cell lines from patients in which 
mutations have been discarded in nuclear and mitochondrial complex I structural genes[24]. 
Again, a complex I deficiency was confirmed in all the patients by a complex I in-gel activity 
assay (Fig 4A). A complex I assembly/activity correlation was only found in patients 11 and 
15 (Fig 4B). In these cases the levels of fully assembled complex I were very low and the 
levels of complex I activity were almost undetectable, suggesting an assembly defect as the 
primary cause of the decreased complex I activity. A lower-molecular weight subcomplex 
also accumulated in patient 15 (Fig 4B, gray arrow). Remarkably, patient 11 is the same in 
which an assembly defect was previously described by other means[19]. These data indicate 
that these two patients are good candidates for carrying mutations in a yet unknown 
complex I subunit or assembly factor. In the rest of this second group of patients complex I 
activities were low but the levels of fully assembled complex I were normal, so the 
impairment of complex I activity is most probably due to a catalytic defect. The pattern and 
expression levels of native complexes III (Fig 4C) and IV (data not shown) were also 
analyzed, but no significant differences were detected between patients and controls. 
 
 
Discussion 
Complex I deficiency comprises a number of clinically heterogeneous disorders of energy 
metabolism of which Leigh (or Leigh-like) syndrome is the most commonly diagnosed. 
Unlike complex IV-deficient Leigh syndrome patients, in whom mutations have been mostly 
found in complex IV assembly factors such as SURF1 or SCO2, all mutations responsible for 
complex I deficiencies detected so far are located in complex I structural genes[25,26]. Patients 
with mutations in the complex I nuclear-encoded subunits NDUFS4, NDUFS7 and NDUFS8 
plus, in our hands, 50% of the patients in whom no mutations have been found yet, present 
with this devastating disorder (Tab 1). Mutations found in the NDUFS2 gene have been 
specifically associated with hypertrophic cardiomyopathy and encephalomyopathy[3].  
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Figure 4. Mitochondrial complex I catalytic versus assembly defects can be 
distinguished in fibroblasts from isolated complex I-deficient patients by BN-
PAGE analysis. 
Mitochondria were isolated and analyzed as described in Figure 2. A. Complex I in-gel activity 
assay of mitochondrial complex I. The unspecific NADH dehydrogenase activity below 
440 kDa is indicated with arrowheads. B. Western blotting analysis of native complex I with 
antibodies against complex I subunit NDUFA9. The presence of a lower-molecular weight 
subcomplex is indicated with a gray arrow. C. Same analysis with an antibody against 
mitochondrial complex III core protein 2. The top band indicated as CI is a residual band from 
incomplete stripping of the membrane after probing for complex I. CI, CIII and CIV are 
mitochondrial complexes I, III and IV, respectively. The positions of the ferritin monomer 
(440 kDa) and dimer (880 kDa) used as molecular mass standards are indicated on the left. 
 
 
Despite genetic and clinical differences, in these patients there seems to be a common 
pathogenic mechanism leading to complex I or IV deficiencies that would involve a problem 
in the proper assembly or stabilization of the mitochondrial OXPHOS complexes. This in 
turn would lead to a decrease of OXPHOS activities and to structural changes in the 
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mitochondrial inner membrane that subsequently could induce proton leakage, 
accumulation of toxic reactive oxygen species and release of apoptosis-inducing factors. 
According to this hypothesis, it has been recently demonstrated that complex I-deficient 
Leigh syndrome patients with genetic alterations in NDUFS4 or in the mitochondrial ND6 
gene show low levels of native mitochondrial complex I together with an accumulation of 
lower intermediate assemblies[18,27]. In rodent cells, complex I assembly and activity are 
affected by the lack of the NDUFA1-homologue subunit, MWFE[28]. In Neurospora crassa, 
complex I nuclear-encoded subunits play a central role of in the assembly and function of the 
holoenzyme[29]. In this paper we show that, in six complex I-deficient patients where 
mutations in nuclear subunits have been found, complex I assembly and/or stability are 
severely compromised. Decreased levels of fully assembled complex I correlate with the low 
complex I activities found in the patients, suggesting an assembly/stability defect as the 
primary pathogenic mechanism. To explain the causes we must take into account different 
factors, like the position and conservation of the mutations, the localization of the mutated 
subunits within the complex and the individual role of each subunit within the overall 
function of complex I. All the mutations are found in highly conserved amino acid positions 
during evolution, but maybe some positions are functionally more relevant than others and 
provoke a more dramatic complex I defect. All the mutations analyzed are located in 
subunits forming the peripheral arm of the complex, therefore these mutations are expected 
to affect the formation and catalytic activity of this specific fragment. Little is known about 
the function of the so-called complex I accessory subunits, but studies mainly performed in 
N. crassa and Y. lipolytica have shed light on the precise role of the core subunits. The most 
evident complex I defect was found in patients with P79L/R102H amino acid changes in 
NDUFS8 and a P229Q substitution in NDUFS2, in whom native complex I was almost 
undetectable. The homologues of NDUFS7 and NDUFS2 have been described in Y. lipolytica 
to form the catalytic core for ubiquinone binding, a process in which NDUFS8 is also 
involved[16]. Reconstruction in Y. lipolytica of the human pathogenic mutations found in the 
NDUFS7 and NDUFS8 genes did not lead to an impaired complex I assembly but only to a 
complex I catalytic defect[15]. The same occurred with mutations in highly conserved residues 
of the NDUFS7 and NDUFS2 homologues[30,31]. However, disruption of any of these three 
subunits in N. crassa showed impaired assembly of the peripheral arm, accumulation of the 
membrane arm and a consequent catalytic defect[32-34]. The differences found in complex I 
defects between our complex I-deficient patients and the yeast model give evidence of the 
necessary precaution that must be taken when mimicking human physiological conditions in 
lower species. All our patients with mutations in NDUFS4 also showed a marked decrease in 
the levels of fully assembled complex I together with high levels of a defective subcomplex of 
~800 kDa not present in controls, as already described[18]. Additionally, the presence of 
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lower bands between ~100-450 kDa containing complex I NDUFS3 subunit was detected 
both in control and all patient samples. These subcomplexes possibly correspond to 
assembly intermediates from the pathway recently proposed for complex I assembly[35]. In a 
second dimension, distinct patterns of lower-molecular weight subcomplexes were clearly 
observed in patients carrying mutations in different complex I subunits. The low amounts of 
fully assembled complex I and the relative accumulation of NDUFS3-containing 
subcomplexes below 450 kDa suggest that the formation of the peripheral arm is interrupted 
at very early stages of the assembly process. This result is in agreement with the complex I 
assembly model in which the NDUFS3 subunit would form part of assembly intermediates 
since the beginning of the process[35]. Because of the malformation of the peripheral arm, the 
membrane arm might have problems getting incorporated and form the final assembled 
holoenzyme. Then subunits NDUFS5 and NDUFA9, present in the peripheral and 
membrane arm boundary region, would get accumulated at a later stage of assembly 
forming, together with the peripheral arm, an incomplete intermediate of ~800 kDa. This is 
especially noticeable in patients with mutations in the NDUFS4 gene. The two mutations 
analyzed here lead to a truncated version of NDUFS4. It has been previously reported in 
other NDUFS4 patients that this intermediate contains a number of complex I subunits 
including NDUFS3, NDUFS5 and NDUFA9, but not NDUFS4 itself[18]. These results suggest 
that NDUFS4 would be incorporated at this late stage in the assembly process, as has been 
reported[35], and that the lack of NDUFS4 would hamper the next step in the formation of 
fully assembled complex I. The possibility also exists that the accumulation of lower-
molecular weight subcomplexes in these patients could not be only due to an assembly defect 
or to a lower rate of incorporation of the different subunits into the complex, but also to a 
lower complex I stability and its consequent disruption. Additional experiments must be 
performed in order to reach definitive conclusions. 
In the remainder complex I-deficient patients harboring unknown mutations, catalytic 
versus assembly (or stability) defects have been easily distinguished by BN-PAGE. Two 
patients show a similar complex I assembly defect as established in the patients carrying 
mutations in nuclear-encoded subunits. Mutations in complex I subunits have been 
discarded in all 45 complex I subunits. These two patients are candidates to carry mutations 
in a complex I assembly factor. Our identification of the human homologue of a N. crassa 
complex I assembly protein, CIA30, proves the existence of such factors[36]. Unfortunately, 
no disease-causing mutations have been found in any of these genes yet. In the rest of this 
second group of patients the levels of fully assembled complex I are normal. The impairment 
in complex I activity cannot be explained by a defect in complex I assembly but to a pure 
catalytic defect, suggesting a different pathogenic mechanism leading to an isolated complex 
I deficiency. In these cases, mutations should be found in nuclear genes that regulate crucial 
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steps in the activation of mitochondrial complex I. Examples of such candidate genes could 
be found in proteins involved in the phosphorylation of complex I subunits that could 
participate in the complex I activation/inactivation transition process, like mitochondrial-
specific isoforms of cAMP dependent kinases or phosphatases[37,38]. In support of this, it has 
been shown in different species that mitochondrial complex I reversibly alternates between 
an active and a de-activated conformation that probably depends on the cell respiratory 
status[39-41]. 
Finally, how these mutations affect the stability of native mitochondrial complexes III and IV 
in our patient group has been analyzed. In different experiments, the steady-state levels of 
fully assembled complex IV did not vary substantially in these patients when compared with 
controls. However, the levels of the native complex III dimer were clearly decreased in the 
patients harboring mutations in NDUFS2 and NDUFS4, but not significantly altered by the 
mutations in the NDUFS7 or NDUFS8 genes, or in any patient with unknown mutations in 
nuclear genes. This finding is in agreement with the combined complex I+III deficiency 
described for three patients carrying mutations in the NDUFS4 gene[5,21]. Reversibly, a 
specific mutation in cytochrome b has been found to lead to a combined complex III+I 
deficiency in a patient with progressive exercise intolerance[42]. These results suggest a 
physical interaction between complexes I and III that could be mediated through these 
subunits. Experimental evidence supports this idea. The association of the mitochondrial 
respiratory chain complexes into higher supramolecular structures called supercomplexes 
seems to be well established in different organisms, including mammals[43]. In Y. lipolytica, 
the ubiquinone-binding 49-kDa subunit (homologue of NDUFS2) seems to be located in an 
external position near the tip of the peripheral arm[44]. By cross-linking studies, a direct 
interaction between the homologues of NDUFS2 and NDUFS4 (49- and 18-kDa subunits, 
respectively) has been observed in bovine[45]. It would explain the similar phenotypes found 
in patients with mutations in these two genes. In these patients carrying mutations in 
NDUFS2 or NDUFS4, the decreased stability of mitochondrial complex III is accompanied 
by a slight or no reduction of complex III activity. This could be explained by internal 
compensatory activation mechanisms or by the fact that a loss of bigger amounts of 
assembled complex III could be necessary before getting a considerable decrease of complex 
III activity, as has been suggested in cybrid clones harboring increasing amounts of mutant 
cytochrome b[23]. Finally, the first report demonstrating that complex I mutations interfere 
with the function or assembly of other OXPHOS complexes has been recently described in a 
Caenorhabditis elegans model[46]. Summarizing, by BN-PAGE we have been able to 
differentiate catalytic versus assembly/stability defects in complex I-deficient patients and to 
study the effects of these mutations on the stability of other mitochondrial OXPHOS 
complexes. Using this technique will not only expand the cell biological knowledge of the 
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mitochondrial energy metabolism, but it will also be useful as an additional tool to improve 
the pre- and postnatal diagnostic possibilities in patients with a mitochondrial complex I 
deficiency. 
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Abstract 
Amongst mitochondrial disorders contiguous gene syndromes are rarely encountered. In 
this report, we describe a patient presenting with an apparently mitochondrial 
encephalomyopathy accompanied by several abnormal dysmorphic features, which is caused 
by a homozygous triple gene deletion on chromosome 5. The deletion encompasses the 
NDUFAF2, ERCC8, and ELOVL7 genes, encoding complex I assembly factor 2 (also known 
as human B17.2L), a protein of the transcription-coupled nucleotide excision repair (TC-
NER) machinery, and a putative elongase of very long-chain fatty acid synthesis, 
respectively. This is the first chromosomal microdeletion associated with a mitochondrial 
phenotype and isolated complex I deficiency. Besides, mutations of the ELOVL7 gene have 
not been implicated in human disease before. Patient fibroblasts demonstrated disturbance 
of complex I assembly and defective TC-NER. Due to the low expression level of ELOVL7 in 
human fibroblasts, changes in fatty acid synthesis could not be assessed in the patient‘s 
fibroblasts. Furthermore, downstream alterations in mitochondrial physiology have been 
established, e.g., depolarization of mitochondrial membrane potential, increased 
mitochondrial NAD(P)H levels and increased intracellular superoxide production. By means 
of a complementation assay, wild-type NDUFAF2 has been demonstrated to not only fully 
restore complex I activity and protein amount in our patient‘s fibroblasts, but also to 
reinstate normal mitochondrial physiology. 
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Introduction 
Contiguous gene syndromes are rare disorders characterized by apparently unrelated clinical 
signs and symptoms, which are caused by deletion of two or more genes that are adjacent to 
one another on a chromosome. Each of the individual genes involved may give rise to 
distinct clinical and biochemical features. Numerous examples of such syndromes have been 
described in literature, e.g., Prader-Willi/Angelman syndrome[1,2] (MIM 176270, 105830), 
Williams-Beuren syndrome[3] (MIM 194050), Miller-Dieker lissencephaly syndrome[4] (MIM 
247200), DiGeorge syndrome[5] (MIM 188400), and Smith-Magenis syndrome[6] (MIM 
182290). Because of certain characteristic signs and symptoms, some of these syndromes 
have been described as clinical entities prior to establishment of their chromosomal etiology. 
Investigation of these disorders on the molecular level offers unique insights into the 
function of affected genes and their relation to the disease phenotype. 
Disturbances of the oxidative phosphorylation (OXPHOS) system are the cause of a broad 
spectrum of multisystem disorders that are often referred to as mitochondrial 
encephalomyopathies because of the prominent involvement of the nervous system and 
striated muscle. With an incidence of 1 in 5,000 live births, OXPHOS disorders are amongst 
the most frequent inborn errors of metabolism[7,8]. The OXPHOS system comprises five 
membrane-bound multi-protein complexes and two mobile electron carriers that transfer 
electrons from NADH and succinate to molecular oxygen. Simultaneously, protons are 
translocated across the mitochondrial inner membrane; thereby creating a membrane 
potential, which is the driving force of ATP production. Isolated complex I deficiency is the 
most common cause of OXPHOS disorders. Complex I, or NADH:ubiquinone 
oxidoreductase, represents the main entry point of the OXPHOS system, as it initiates 
electron transfer by oxidizing NADH. Mammalian complex I consists of 45 subunits of which 
seven are encoded by the mitochondrial DNA (mtDNA) and 38 by the nuclear genome[9]. 
Being accountable for a heterogeneous group of clinical phenotypes, the primary defects 
underlying complex I deficiency are genetically heterogeneous as well. Mutations have been 
found in each of the seven mtDNA-encoded subunits, resulting in either single-organ 
phenotypes, as Leber hereditary optic neuropathy (LHON; MIM 535000), or multisystemic 
syndromes, e.g., mitochondrial encephalomyopathy with lactic acidosis and stroke-like 
episodes (MELAS; MIM 540000). Furthermore, mutations have been found in twelve of the 
nuclear genes encoding structural components of complex I. Nine of those genes are mainly 
associated with brain and brainstem disorders, mostly Leigh(-like) syndrome or 
leukoencephalopathy, while three others are exclusively associated with hypertrophic 
cardiomyopathy and encephalomyopathy[10-12]. 
In addition to 45 structural components, probably numerous, yet unknown, nuclear factors 
are needed for proper assembly and functioning of complex I, as has been reported 
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extensively for complex IV. The intricate assembly process of mitochondrial complex I is 
starting to unravel with the characterization of the first few known complex I assembly 
factors, supported by the recent identification of patients with corresponding disease causing 
genotypes. Identification of these assembly factors will open a new field of possible 
candidates for complex I deficiency. To date, two characterized human complex I assembly 
chaperones have been proved responsible for complex I deficiency. Ogilvie et al. reported the 
first mutation in an assembly chaperone: a patient presenting with an early-onset 
progressive encephalopathy resembling vanishing white matter disease carried a null 
mutation in the NDUFAF2 gene (GenBank, NM_174889), encoding complex I assembly 
factor 2 (also known as chaperone B17.2L for B17.2-like protein) [13]. Dunning et al. described 
a complex I-deficient patient with cardioencephalomyopathy caused by two compound 
heterozygous missense mutations in the gene encoding complex I assembly factor 1, 
NDUFAF1 (also known as CIA30; GenBank, NM_016013) [14]. More recently, a mutation in a 
putative third assembly chaperone, a mitochondrial protein encoded by the C6ORF66 gene 
(GenBank, NM_014165), has been detected in a consanguineous family of complex I-
deficient patients presenting with infantile mitochondrial encephalomyopathy[15]. 
Contiguous gene syndromes characterized by a ‗mitochondrial phenotype‘ have been rarely 
reported[16]. A possible explanation is that disturbances of the integrity of the OXPHOS 
system result in a broad range of clinical manifestations presenting from infancy to late 
adulthood and affecting many different organs and tissues and therefore, characteristic 
constellations of symptoms and anomalies may be under-recognized. In addition, mutations 
in nuclear structural genes of complex I are usually associated with very severe clinical 
phenotypes (e.g. Leigh syndrome or fatal infantile lactic acidosis), resulting in early death, 
mostly within the first five years of life, and accordingly, the involvement of other genes with 
less severe clinical manifestations may be overshadowed[17]. To date, no contiguous gene 
syndromes associated with isolated complex I deficiency are known. In this report, we 
describe a patient presenting with an apparently mitochondrial encephalomyopathy 
accompanied by several abnormal dysmorphic features, which is caused by a homozygous 
triple gene deletion on chromosome 5. The deletion encompasses the NDUFAF2 gene 
encoding complex I assembly factor 2, the ERCC8 gene (GenBank, NM_000082), involved 
in the transcription-coupled nucleotide excision repair (TC-NER) pathway, and ELOVL7 
(GenBank, NM_024930), a member of the elongase (ELOVL: elongation of very long-chain 
fatty acids) gene family. We investigated the consequences of the lack of chaperone 
NDUFAF2 for the biogenesis and functioning of the OXPHOS system and established 
downstream alterations in mitochondrial physiology. Moreover, we confirmed Cockayne 
syndrome type A (CSA; MIM 216400) deficiency, as a result of the ERCC8 deletion, by 
analysis of the NER system. Unfortunately, due to the low expression level of ELOVL7 in 
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human fibroblasts, specific changes in endogenous fatty acid levels as a consequence of the 
ELOVL7 deletion could not be assessed in the patient‘s fibroblasts. 
 
 
Patients, materials and methods 
Case report 
The girl was the second child of healthy consanguineous parents (first cousins). Family 
history was unremarkable (one older sister and two younger brothers not affected). Prenatal 
ultrasound screening revealed intrauterine growth retardation. The patient was born at 38 
weeks of gestation by caesarean section. Birth weight was 1.815 kg (~0.5 kg <3rd percentile), 
length 45 cm (~1 cm <3rd percentile) and head circumference 31 cm (~0.5 cm <3rd 
percentile). APGAR scores were 6/8/10. Postpartally, the girl appeared dysmature and 
developed respiratory distress. Apart from microcephaly, several abnormal features 
including long philtrum, micrognathia, low-set ears, and unusually dry skin were noted. 
Laboratory investigations revealed elevated levels of lactate (2.5-3.4 mmol/L; normal range 
0.6-1.8) and alanine in blood (1046 µmol/L; normal range <350). Urine screening was, apart 
from increased alanine excretion, normal. Cranial ultrasound and a computed tomography 
scan of the brain revealed no obvious pathology. Abdominal ultrasound demonstrated 
hepatomegaly. The further clinical course of the patient was characterized by severe 
developmental delay, failure to thrive, progressive microcephaly, myoclonic epilepsy, 
pyramidal signs, and spasticity. The girl repeatedly developed aspiration pneumonias and 
finally died at the age of 14 months due to cardiorespiratory failure. Electron microscopy 
(EM) studies of liver tissue revealed abnormally swollen mitochondria and inclusions of 
granula in the endoplasmic reticulum, possibly accumulations of lipids. Histological 
evaluation of muscle tissue showed few small atrophic fibers, but was otherwise normal. No 
ragged-red fibers or cytochrome c oxidase-negative fibers were seen. However, also in this 
tissue, ultrastructural studies by EM demonstrated swollen mitochondria. 
 
Cell culture and sample preparation 
Patient and healthy control fibroblasts were obtained from skin biopsies and cultured to 
confluence in medium 199 with Earle's salt (M199; Invitrogen) supplemented with 10% (v/v) 
fetal bovine serum (Greiner Bio-One) and 100 IU/mL penicillin and 100 µg/mL 
streptomycin (Invitrogen) in a humidified atmosphere of 95% air and 5% CO2 at 37 C. For 
microscopy analysis, cells were seeded on glass coverslips (Ø 24 mm) and cultured to ~70% 
confluence[3] in a humidified atmosphere (95% air, 5% CO2) at 37 C. Cells were harvested 
with 0.25% (w/v) trypsine (Becton Dickinson), resuspended in PBS (Invitrogen) and 
mitochondria-enriched fractions were obtained by incubation with 2% (w/v) digitonin 
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(Calbiochem) on ice for 10 min, followed by centrifugation at 10,000 g and 4 °C for 10 min 
and washing with PBS, twice. Mitochondrial fractions were resuspended in 1.75 M 
aminocaproic acid (Fluka) and 75 mM bis-tris (Fluka) at pH 7.0, and (OXPHOS) protein 
complexes were solubilized using 2% (w/v) of n-dodecyl- -D-maltoside (DDM; Sigma-
Aldrich) during incubation on ice for 10 min, followed by centrifugation and washing at the 
same conditions described above. The protein concentration was determined using the 
Micro BCA protein assay kit (Pierce Biotechnology). 
 
SDS and blue native polyacrylamide gel electrophoresis and western blotting 
SDS and blue native polyacrylamide gel electrophoresis (BN-PAGE) was performed as 
described previously[18]. Twenty micrograms of mitochondrial protein fractions were loaded 
on 10% polyacrylamide gels for SDS-PAGE and 40 µg of mitochondrial protein fractions on 
5-15% polyacrylamide gradient gels for BN-PAGE. For second dimension SDS-PAGE, first 
dimension BN-PAGE lanes were excised and placed on top of a 10% polyacrylamide SDS gel 
and run as described previously[18]. 
SDS and BN gels were subjected to western blotting using nitrocellulose membranes 
(Schleicher and Schuell). Subsequently, immunodetection was performed using monoclonal 
or polyclonal antibodies directed against complex I subunits NDUFA9 (Invitrogen), 
NDUFB6 (MitoSciences), NDUFS2 (Prof B. Robinson, Toronto), NDUFS3 (Invitrogen), and 
ND1 (Dr A. Lombes, Paris), complex II subunit SDHA (Invitrogen), complex III subunit 
Core2 (Invitrogen), complex IV subunit COXII (Invitrogen), and complex I assembly 
chaperones NDUFAF1 (our laboratory)[19] and NDUFAF2 (Prof M. Tsuneoka, Kurume). 
Peroxidase-conjugated anti-mouse and anti-rabbit IgGs (Invitrogen) were used as secondary 
antibodies. Signals were generated by means of ECL plus (Amersham Biosciences) and 
autoradiography. 
 
Complex I in-gel activity assay 
Complex I in-gel activity was detected as NADH:nitrotetrazolium blue oxidoreductase 
activity by incubation of BN gels in the presence of 0.15 mM NADH (Roche), 3 mM 
nitrotetrazolium blue chloride (NTB; Sigma-Aldrich) and 2 mM (2.5 mg/mL) Tris-HCl 
(Sigma-Aldrich) at pH 7.4, for 1 h protected from light. 
 
RNA isolation, PCR amplification and DNA sequencing 
Patient and control total DNA and mRNA was isolated from fibroblasts and blood samples 
according to standard procedures. cDNA was obtained by reverse transcriptase-polymerase 
chain reaction (RT-PCR) of mRNA according to manufacturer‘s protocol (Promega) and was 
subjected to PCR amplification using a primer set encompassing the total NDUFAF2 mRNA 
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sequence (GenBank, NM_174889; forward (5‘ 3‘) CTGGAGCATTACCCCTACTGCG, reverse 
(5‘ 3‘) TAGTCACATCCATATACATGAAAAG). PCR products were cycle-sequenced using 
the ABI Prism BigDye Terminator v3.1 Cycle Sequencing Ready Reaction Kit (Applied 
Biosystems) and analyzed by a 3130xl Genetic Analyzer (Applied Biosystems), according to 
the manufacturer‘s protocol.   
 
Cloning of baculoviral constructs and generation of recombinant baculoviruses 
The cDNA sequences of the coding region of the NDUFAF2 gene and of the mitochondrial 
targeting sequence of the gene encoding subunit VIII of cytochrome c oxidase (COX8) were 
cloned into a baculovirus vector (pFastBacTMDual vector (Invitrogen) modified for protein 
expression in mammalian cells by Visch et al.[20]) behind the cytomegalovirus (CMV) 
promoter and adjacent to a C-terminal GFP-tag sequence. The obtained baculoviral vector 
constructs were used to generate infectious recombinant baculoviruses by site-specific 
transposon-mediated insertion into a baculovirus genome (bacmid) propagated in 
Escherichia coli cells, as described by Luckow et al.[21]. Isolated recombinant bacmids were 
used to infect Spodoptera frugiperda 9 (Sf9) insect cells for amplification of viruses. 
 
Transduction of complex I-deficient fibroblasts with baculoviral constructs 
Fibroblasts were grown to ~70% confluence in 25-cm2 tissue culture flasks (NUNC) before 
they were transduced with the appropriate baculovirus (virus titer: 3 * 107) at a multiplicity 
of infection of ~10 by incubating in a total volume of 1.6 mL M199 medium for 3 h at 37 °C. 
After incubation, the virus-containing medium was discarded and replaced by normal 
growth medium (M199). The next day 5 mM sodium butyrate (Sigma-Aldrich) was added to 
the medium to enhance protein expression and 3 days after transduction, cells were 
harvested. 
 
Fluorescence microscopy of TMRM, NAD(P)H and HEt oxidation products 
For quantitative analysis of tetramethyl rhodamine methyl ester (TMRM; Invitrogen), 
NAD(P)H and hydroethidine (HEt; Molecular Probes) oxidation product fluorescence, 
coverslips were mounted in an incubation chamber and placed on the stage of an inverted 
microscope (Axiovert 200M, Carl Zeiss) equipped with a 40×/1.3 NA (used for HEt and 
NAD(P)H measurements) and a 63×/1.25 NA (for TMRM measurements) Plan NeoFluar 
objective (Carl Zeiss). All experiments were performed at 37 C during which cells were 
maintained in HEPES-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 
5.5 mM D-glucose and 10 mM HEPES at pH 7.4). Fluorescence of TMRM, NAD(P)H and 
HEt oxidation products was exited using a monochromator (Polychrome IV, TILL 
Photonics) and images were obtained using a CoolSNAP HQ monochrome CCD-camera 
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(Roper Scientific Photometrics). Hardware was controlled with Metafluor 6.0 software 
(Universal Imaging Corporation). 
Quantification of TMRM fluorescence Mitochondrial TMRM fluorescence was analyzed 
according to a novel protocol[22,23]. In brief, fibroblasts were incubated in medium 199 
containing 100 nM TMRM for 25 min at 37 C. After loading, cells were washed with PBS. 
Fibroblasts were imaged using 63×/1.25 NA Plan NeoFluar objective (Carl Zeiss) and TMRM 
was excited at 540 nm with an exposure time of 100 ms. Fluorescence light was directed by a 
560DRLP dichroic mirror (Omega Optical Inc) through a 565ALP emission filter (Omega 
Optical Inc). The acquired images were processed to generate a mitochondria-specific mask. 
The latter was superimposed on the original image to allow quantification of TMRM 
fluorescence exclusively in the mitochondrial structures.  
Quantification of intracellular NAD(P)H autofluorescence Measurement of intracellular 
NAD(P)H autofluorescence was carried out according to a protocol described 
previously[23,24]. Briefly, fibroblasts were imaged using a 40×/1.3 NA Plan NeoFluar objective 
(Carl Zeiss). The cells were excited at 360 nm and fluorescence emission light was directed 
by a 415DCLP dichroic mirror (Omega Optical Inc) through a 510WB40 emission filter 
(Omega Optical Inc). Routinely, 10 fields of view were analyzed per coverslip using an image 
capturing time of 1s. 
Quantification of superoxide production Fluorescence of HEt oxidation products was 
analyzed as described previously[25]. In brief, fibroblasts were incubated in HEPES-Tris 
medium containing 10 μM HEt for 10 min at 37 C. The reaction was stopped by washing of 
the cells with PBS. Cells were excited at 490 nm, using a 40×/1.3 NA Plan NeoFluar 
objective (Carl Zeiss), and fluorescence emission light was directed by a 525DRLP dichroic 
mirror (Omega Optical Inc) through a 565ALP emission filter (Omega Optical Inc). 
Routinely, 10 fields of view were analyzed per coverslip using an acquisition time of 100 ms. 
Quantitative image analysis of TMRM, NAD(P)H and HEt measurements was performed 
with Metamorph 6.0 (Universal Imaging Corporation) and Image Pro Plus 5.1 (Media 
Cybernetics). In each experiment, the average value obtained with the corresponding control 
cell line was set at 100%, to which all other values were related. Numerical results were 
visualized using Origin Pro 7.5 software (Originlabs) and values from multiple experiments 
were expressed as means ± SEM (standard error of the mean). Statistical significance 
(Bonferroni corrected) was assessed using Student‘s t-test. 
 
Nucleotide excision repair assays 
Transcription-coupled NER (TC-NER) and global genome NER (GG-NER) activities of 
cultured fibroblasts after exposure to germicidal UV-C rays were assayed using standard 
autoradiographic methods described elsewhere[26] and expressed as a percentage of the 
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activities of UV-exposed normal control cells. Overall cell survival was routinely assayed by 
global incorporation of tritiated thymidine 4 days after exposure to graded UV doses[27]. 
 
Measurement of very long-chain fatty acid levels 
Total cellular fatty acids were analyzed using the electrospray ionization mass spectrometry 
(ESI-MS) method described previously[28]. 
 
 
Results 
Enzyme activity measurements of OXPHOS complexes 
The enzyme activities of all five OXPHOS complexes were determined by spectroscopy 
measurements in patient fibroblasts and frozen muscle tissue. Complex I activity was 
significantly impaired in fibroblasts as well as frozen muscle tissue (data not shown), 
whereas all other complexes (CII, CIII, CIV, and CV) showed normal values. The residual 
complex I activity in the patient‘s fibroblasts is 45% of the lowest control value (Tab 1). 
Enzyme activities of all other complexes are within the reference ranges. Additional complex 
I activity measurements in liver demonstrated a severe complex I deficiency (data not 
shown). 
 
 
Table 1. OXPHOS enzyme activities in fibroblasts 
Enzyme activitiesa Activity (Reference range) 
Complex I 49 (110-260) 
Complex II 871 (536-1027) 
Complex III 2170 (1270-2620) 
Complex II+III (Succ:cyt c oxidoreductase; SCC) 189 (160-440) 
Complex IV (Cytochrome c oxidase) 801 (680-1190) 
Complex V (ATP synthase) 421 (209-935) 
Citrate synthase 250 (144-257) 
a Enzyme activities are expressed in mU/mU COX except for complex IV, which is expressed in 
mU/mU CS, and citrate synthase (CS), which is expressed in mU/mg protein. COX and CS levels 
were normal in the patient. Enzymatic activities were measured in triplicate in at least two 
independent patient-derived samples. 
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Complex I deficiency confirmed by decreased amounts of fully assembled complex I 
To investigate the complex I deficiency on protein level mitoplast fractions of the patient‘s 
fibroblasts were subjected to blue native polyacrylamide gel electrophoresis (BN-PAGE) 
followed by either an in-gel activity assay (IGA), or western blotting and immunodetection 
using antibodies directed against complexes I, II, and III (Fig 1A). The patient‘s fibroblasts 
showed a severe decrease in both complex I activity and protein amount compared to two 
control fibroblasts cell lines, whereas normal control levels were shown for complexes II and 
III. Subsequently, SDS-PAGE analysis of the mitoplast fractions was performed to examine 
the protein levels of several complex I subunits and assembly chaperones using monoclonal 
and polyclonal antibodies directed against several OXPHOS proteins (Fig 1B). A significant 
decrease in the protein levels of complex I subunits NDUFS3, NDUFA9, and NDUFB6, as 
well as complex I assembly factor NDUFAF1, was shown for the patient compared to normal 
control fibroblasts, whereas subunit NDUFS2 showed a milder decrease. Remarkably, no 
protein at all was detected for the complex I assembly factor NDUFAF2 in the patient 
fibroblasts. In contrast, normal NDUFAF2 protein levels were observed for two complex I-
deficient patients with unknown mutations. In addition, all patients showed normal levels of 
subunit SDHA of complex II.  
 
 
 
 
 
 
 
Figure 1. BN- and SDS-PAGE analysis of patient and control fibroblasts. 
A. 1D BN-PAGE shows a decrease in fully assembled complex I activity and protein amount for the 
patient (P(del)) in duplicate, compared to control fibroblasts (C1 and C2). Subunits against which the 
antibodies are used are depicted in between brackets. B. SDS-PAGE shows decreased levels of 
complex I subunits in the patient and a total lack of assembly chaperone NDUFAF2. Two complex I-
deficient patients with unknown mutations are also shown (lanes 2 and 3). CI, II, III: complexes I, II, 
III; IGA: in-gel activity assay 
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Mutational analysis 
In the past, extensive mutational analysis performed on the patient i.e., screening for 
mtDNA rearrangements (deletions, insertions or duplications) and common mtDNA point 
mutations and screening of all 38 nuclear genes and seven mitochondrial ND genes encoding 
the 45 complex I subunits for mutations did not reveal the molecular defect. Because of 
lack of detection of NDUFAF2 protein, we investigated the corresponding NDUFAF2 mRNA 
sequence. Noticeably, analysis of PCR amplification of cDNA derived from the patient‘s 
fibroblasts, did not reveal a PCR-product for the NDUFAF2 sequence, suggesting a 
destabilized mRNA, a promoter mutation, or a gene deletion. Subsequently, PCR 
amplification of the patient‘s genomic DNA failed to retrieve the NDUFAF2 gene, indicating 
a (total) gene deletion. Further genomic analysis of the region surrounding the NDUFAF2 
gene led to detection of a homozygous deletion of ~450 kb on chromosome 5. The location 
was refined using chromosome map markers at 5q12.1 ranging from nucleotide 60,082,769 
to 60,530,221 (UCSC Genome Browser, March 2006 assembly). The deletion encompasses 
three known genes, i.e., ELOVL7 (GenBank, NM_024930), ERCC8 (GenBank, 
NM_000082), and NDUFAF2 (GenBank, NM_174889). Screening of genomic DNA isolated 
from blood samples of the patient‘s relatives revealed that both parents, two brothers and a 
sister are heterozygous for the deletion. 
 
Complementation of the complex I defect with wild-type NDUFAF2 
To prove the pathogenicity of the NDUFAF2 deletion, functional complementation of the 
complex I defect was carried out by means of baculoviral transduction of patient and healthy 
control fibroblasts with constructs expressing either GFP-tagged NDUFAF2 protein or COX8 
leader peptide fused to GFP. Three days after transduction mitoplast fractions were 
subjected to BN-PAGE followed by an in-gel activity assay or western blotting and 
immunodetection (Fig 2A). NDUFAF2-GFP transduced patient cells showed a marked 
increase in complex I activity and protein amount when compared to untransduced and 
COX8-GFP transduced patient cells. Complex I activity as well as protein amount was 
restored to normal control levels, whereas control cells themselves showed no changes upon 
NDUFAF2-GFP or COX8-GFP transduction. In addition, protein levels of complexes II and 
III remained unaffected in both patient and healthy control cells. 
To examine the specificity of complementation, two other complex I-deficient patient cell 
lines, bearing mutations in the NDUFS4 and NDUFS7 subunits, were subjected to the 
complementation assay (Fig 2A). The NDUFS4 patient, who totally lacks fully assembled 
complex I—detectable by BN-PAGE analysis—in fibroblasts, did not show any changes in 
holocomplex I levels and activity after NDUFAF2-GFP transduction. Also the level of the 
830-kDa subcomplex of complex I, which is normally observed in patients with mutations in 
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Figure 2. Complementation of the complex I defect with wild-type NDUFAF2. 
A. BN-PAGE analysis of transduction of patient and control fibroblasts with baculoviral constructs encoding either wild-type GFP-tagged 
NDUFAF2, or GFP targeted to mitochondria by the COX8 leader peptide. Complex I activity as well as protein amount have specifically been 
restored to normal control levels for our patient (P(del)) upon NDUFAF2 transduction, when compared to transduction with COX8-GFP. 
Control fibroblasts (C1 and C2) show no changes in complex I activity and protein amount after transduction with wild-type NDUFAF2. The 
complex I defect in patients with mutations in the NDUFS4 (P(S4)) and NDUFS7 (P(S7)) subunits cannot be complemented by wild-type 
NDUFAF2. Levels of complexes II and III remain unaffected upon transduction in each cell line. Subunits against which the antibodies are used 
are depicted in between brackets. B. SDS-PAGE analysis of expression of NDUFAF2-GFP and COX8-GFP constructs in patient and control 
fibroblasts using polyclonal anti-EGFP antibody. untr: untransduced; AF2: NDUFAF2-GFP transduced; COX8: COX8-GFP transduced; CI, II, 
III: complexes I, II, III; 830kD: 830-kDa subcomplex of complex I; IGA: in-gel activity assay 
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the NDUFS4 subunit, did not change upon NDUFAF2-GFP transduction. The NDUFS7 
patient, who bears very low amounts of holocomplex I in fibroblasts and likewise activity, 
remained also unaffected by NDUFAF2-GFP transduction. The inability to complement 
complex I deficiency caused by other mutations confirms the specificity of NDUFAF2 
complementation for our patient. 
 
Complex I assembly profile 
More insight in the patient‘s complex I assembly profile can be achieved by subjecting first 
dimension BN-PAGE-separated complexes to second dimension SDS-PAGE (2D BN/SDS-
PAGE) followed by western blotting and immunodetection with antibodies against several 
complex I subunits and assembly chaperone NDUFAF1 (Fig 3). Disturbance of complex I 
assembly in the patient was demonstrated by accumulation of low-molecular weight complex 
I subcomplexes, containing complex I subunits NDUFS2, NDUFS3 (sub 2-5), and ND1 (sub 
4,5), which correspond to complex I assembly intermediates 2, 3, 4, and 5 of the model for 
human mitochondrial complex I assembly proposed by Vogel et al.[29]. The accumulation of a 
high-molecular weight subcomplex containing subunits NDUFB6 and ND1 was also more 
pronounced in the patient when compared to control fibroblasts. This subcomplex 
corresponds to the ‗appearing subcomplex‘ a1 of the model. In addition, there was a decrease 
in NDUFAF1 associated with the ~500-kDa complex, which was described before by Vogel et 
al. in complex I-deficient patients with mutations in structural complex I subunits[30]. As 
expected, no changes in complex IV levels were observed after incubation with anti-COXII 
antibody. 
 
Lack of NDUFAF2 alters mitochondrial physiology and function 
To investigate the effects of the complex I deficiency on mitochondrial physiology, several 
intracellular and mitochondrial parameters were measured in control and patient 
fibroblasts. Subsequently, we investigated whether these alterations could be restored by 
transduction with NDUFAF2-GFP. 
As an estimate of mitochondrial membrane potential, TMRM fluorescence intensity was 
measured in living cells using a recently developed method[22,23] (Fig 4A). The accumulation 
of the lipophilic fluorescent cation TMRM in the mitochondrial matrix follows the Nernst 
equation and, therefore, its fluorescence intensity is a sensitive readout of mitochondrial 
membrane potential[23]. Membrane potential was reduced in our patient‘s fibroblasts by 9% 
(± 1% SEM) compared to control fibroblasts. This reduction in fluorescence corresponds to 
an estimated depolarization of 17.5 mV. A 7% (± 1.2% SEM) reduction was measured for the 
NDUFS7 patient cells. Transduction with NDUFAF2-GFP almost completely restored 
membrane potential in our patient, whereas no significant effect could be observed for the  
Contiguous gene deletion of ELOVL7, ERCC8, and NDUFAF2 
163 
 
 
 
 
 
Figure 3. Complex I assembly profile of patient and control fibroblasts. 
2D BN/SDS-PAGE shows accumulation of low-molecular weight subcomplexes 1-5 in the 
patient’s fibroblasts (P(del)) and a decrease in the NDUFAF1-containing complex, compared to 
control fibroblasts (C2)). Subcomplexes have been numbered according to the human complex 
I assembly pathway model described by Vogel et al.[29]. Accumulation of ‘appearing 
subcomplex 1’ (a1) is also more pronounced for the patient. Normal levels of COXII 
demonstrate undisturbed complex IV assembly. 
 
 
complex I-deficient NDUFS7 patient. 
Besides depolarization of mitochondrial membrane potential, increase in NAD(P)H levels is 
another hallmark of complex I dysfunction, as a consequence of decreased NADH oxidation 
by complex I. Mitochondrial NAD(P)H levels of patient and control fibroblasts were 
measured as NAD(P)H autofluorescence intensity[24] (Fig 4B). Mitochondrial NAD(P)H 
levels were significantly increased in the patient, to an average of 180% (± 11.7% SEM) of 
normal control levels, and dropped to an average of 118% (± 4.2% SEM) after transduction 
with NDUFAF2-GFP. Since the NDUFS7 patient did not present with elevated mitochondrial 
NAD(P)H levels, fibroblasts of a complex I-deficient patient with a mutation in the NDUFS2 
subunit were used for comparison. The average NAD(P)H level of 125% (± 3.6% SEM) in this 
NDUFS2 patient did not change upon NDUFAF2-GFP transduction.  
Chapter VII 
164 
 
 
 
 
 
 
Figure 4. Measurement of mitochondrial membrane potential, mitochondrial NAD(P)H levels and intracellular superoxide 
levels. 
Measurements were performed on patient and control fibroblasts that remained untransduced or had been transduced with the NDUFAF2-GFP 
baculoviral construct. Measurements of all transduced and untransduced patient cells have been normalized to the average values of the 
corresponding transduced and untransduced control cells, respectively. A. Mitochondrial membrane potential of patient (P(del), n=68; P(S7), n=31) 
and control (C1, n=58) fibroblasts was estimated from the average measured TMRM fluorescence pixel intensity. Wild-type NDUFAF2 almost 
completely restores membrane potential to normal control levels (C1, n=55) in our patient (P(del), n=87), whereas no significant effect can be 
observed for the complex I-deficient NDUFS7 patient (P(S7), n=82). B. Mitochondrial NAD(P)H levels of patient (P(del), n=34; P(S2), n=57) and 
control (C1, n=57) fibroblasts were measured as average NAD(P)H autofluorescence intensity. Mitochondrial NAD(P)H levels have significantly been 
reduced in our patient (P(del), n=84) upon NDUFAF2-GFP transduction, but have not been changed for an NDUFS2 patient (P(S2), n=59). Control: 
C1, n=44. C. Intracellular superoxide levels of patient (P(del), n=130; P(S7), n=89) and control fibroblasts (C1, n=388) were measured as rates of 
hydroethidine (HEt) oxidation. The level of superoxide production has significantly been reduced in our patient (P(del), n=145) upon NDUFAF2-GFP 
transduction, but has not been changed for the NDUFS7 patient (P(S7), n=157). Control: C1, n=215. P values < 0.01 (**) and < 0.001 (***) were 
considered significantly different from corresponding control. 
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A third common feature of fibroblasts harboring complex I deficiency is superoxide 
production. To investigate intracellular superoxide levels, oxidation rates of hydroethidine 
(HEt) were determined by quantification of its fluorescent oxidation products[25] (Fig 4C). 
The patient‘s fibroblasts demonstrated remarkably high superoxide levels, i.e., an average of 
354% (± 11.5% SEM) of control levels, compared to 167% (± 6.6% SEM) for the NDUFS7 
patient. After transduction with NDUFAF2-GFP, superoxide levels reduced significantly to 
an average of 127% (± 4.3% SEM) in our patient, whereas no changes could be observed for 
the NDUFS7 patient.  
Taken together, complementation of the observed cell physiological consequences with wild-
type NDUFAF2 is specific for our complex I-deficient patient with deletion of the NDUFAF2 
gene, since no recovery is observed for the complex I-deficient patients with mutations in the 
NDUFS7 and NDUFS2 subunits. Thus, these data underscore the view that NDUFAF2 is 
required for normal complex I functioning and mitochondrial physiology. 
 
Investigation of the nucleotide excision repair mechanism 
The ERCC8 gene is essential for transcription-coupled nucleotide excision repair (TC-NER) 
of UV-induced DNA damage and is typically defective in patients with Cockayne syndrome 
belonging to complementation group A[31,32] (CSA; MIM 216400). Since the ERCC8 gene is 
located in the deleted area, the patient‘s fibroblasts were subjected to NER analysis. Patient 
fibroblasts displayed lowered TC-NER and normal global genome (GG) NER activities 
compared to normal controls fibroblasts after exposure to UV radiation (Fig 5A), indicating 
defective TC-NER but proficient GG-NER. Analysis of cellular survival after exposure to 
increasing UV doses revealed a UV sensitivity of our patient´s cells that is characteristic of 
CSA patients (Fig 5B). Moreover, the TC-NER defect could be fully restored by cell fusion 
with Cockayne syndrome type B (CSB) patient fibroblasts (defective in the ERCC6 gene), but 
not with cells from a CSA patient (data not shown). These repair parameters in combination 
with the genetic complementation analysis unequivocally demonstrate an ERCC8/CSA 
defect in our patient‘s fibroblasts. 
 
Analysis of fatty acid levels 
Proteins belonging to the ELOVL (elongation of very long-chain fatty acids) family are 
required for the first reaction in the elongation cycle of very long-chain fatty acid (VLCFA) 
synthesis[33,34]. To examine the effect of the deletion of the ELOVL7 gene on fatty acid 
biosynthesis, endogenous levels of saturated (C14:0–C28:0), mono-unsaturated (C18:1–
C28:1) and poly-unsaturated (omega-3 and omega-6 series) fatty acids were determined in 
fibroblasts of our patient, of two healthy control cell lines, and of four complex I-deficient 
patient cell lines with mutations in the NDUFAF2, NDUFS4 (two cell lines) and NDUFS7 
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genes. Unfortunately, no differences could be observed in fatty acid levels between patient 
and control fibroblasts. To establish whether this could be due to a low expression level of 
ELOVL7 in human fibroblasts, we performed PCR analysis using mRNA derived from a 
neuroblastoma cell line (SK-N-BE(2)c) as a positive control. This revealed that ELOVL7 is 
highly expressed in SK-N-BE(2)c cells, but not in human primary fibroblasts (unpublished 
data S. Kemp).  
 
 
 
 
 
 
Figure 5. NER analysis of patient and control fibroblasts after exposure to UV 
radiation. 
A. NER activities of our patient have been expressed as percentages of UV-exposed normal 
control cells tested in the same experiment. Global genome NER (GG) was measured 
autoradiographically as ‘unscheduled DNA synthesis’ and transcription-coupled NER (TC) 
by recovery of overall RNA synthesis after UV exposure as described elsewhere[31]. B. Overall 
cell survival after exposure to graded UV doses[32]. Proliferative activity of patient and 
control fibroblasts after UV exposure has been expressed as a percentage of unirradiated 
cells. The UV-survival curve of our patient matches the curve of a known CSA patient. NER: 
nucleotide excision repair 
 
Contiguous gene deletion of ELOVL7, ERCC8, and NDUFAF2 
167 
 
Discussion 
We describe a patient, presenting with an apparently mitochondrial encephalomyopathy 
that is caused by a homozygous triple gene deletion encompassing the genes NDUFAF2, 
ERCC8, and ELOVL7. This is the first homozygous chromosomal microdeletion associated 
with a mitochondrial phenotype and isolated complex I deficiency, and the fourth patient 
found lacking the complex I assembly factor NDUFAF2[13,35]. The ERCC8 gene encodes a 
protein involved in DNA repair and mutations of the gene cause Cockayne syndrome type A. 
The ELOVL7 gene encodes a putative elongase of VLCFA synthesis and has not been linked 
with pathogenic mutations and/or deletions before. We investigated the consequences of 
deletion of each gene for the molecular mechanisms of cellular metabolism in which they 
exert their functions. 
 
NDUFAF2 
Considering the alleged mitochondria-involved clinical manifestation, disturbance of the 
OXPHOS system substantiated by enzyme activity measurements revealing an isolated 
complex I deficiency is believed to play a major role in the pathology of our patient. We 
investigated the effects of the null mutation of chaperone NDUFAF2 in our patient on the 
assembly of the OXPHOS system and especially complex I assembly. The total lack of 
NDUFAF2 protein in our patient leads to the accumulation of assembly intermediates 2 to 5 
of our human complex I assembly pathway model[29]. The assembly intermediates contain 
both peripheral arm and membrane arm subunits, i.e., NDUFS2 and NDUFS3 in 2-5 and 
ND1 in 4 and 5, respectively. 
To prove that the disturbance of complex I assembly is due to the lack of chaperone 
NDUFAF2 and not to the lack of the other two proteins (ERCC8 and ELOVL7), 
complementation of the complex I defect by wild-type NDUFAF2 has been established. 
NDUFAF2-GFP recombinant protein fully complemented the complex I deficiency in our 
patient by restoring fully assembled complex I protein amount and complex I in-gel activity 
to normal control levels. Contrarily, two complex I-deficient patient cell lines with mutations 
in the NDUFS4 and NDUFS7 subunits could not be complemented by NDUFAF2-GFP, 
underlining its specificity for our NDUFAF2 mutated patient.  
Furthermore, we investigated the cell physiological consequences of complex I dysfunction 
due to lack of NDUFAF2 in our patient. Several intracellular and mitochondrial parameters 
indicated impaired mitochondrial function and disturbed mitochondrial physiology, e.g., 
increased intracellular superoxide and mitochondrial NAD(P)H levels, and decreased 
mitochondrial membrane potential. Interestingly, all observed physiological alterations 
could be restored (in our patient) upon complementation with wild-type NDUFAF2, while 
no recovery was observed for the complex I-deficient patients with mutations in the 
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NDUFS7 and NDUFS2 subunits. Hereby, the complementation assay proves the 
pathogenicity of the NDUFAF2 deletion for normal complex I functioning and mitochondrial 
physiology in our patient. 
Since there is still a small amount of fully assembled active complex I present in the patient‘s 
fibroblasts, complex I assembly is not entirely prevented by the total lack of NDUFAF2 
protein. This means that chaperone NDUFAF2 probably facilitates efficient assembly, 
possibly by catalyzing a step in the process or by stabilizing an assembly intermediate, as has 
been argued before by Ogilvie et al.[13]. To elucidate the function of NDUFAF2 in complex I 
assembly we have to focus on its association with an 830-kDa subcomplex of complex I, 
which is accumulating in patient fibroblasts harboring mutations in the NDUFS4, NDUFS6 
and NDUFV1 subunits[13,36,37] and possibly also the NDUFS1 subunit[38]. 
Transduction experiments of fibroblasts with the NDUFAF2-GFP construct revealed the 
presence of NDUFAF2 associated with the 830-kDa subcomplex not only in a disturbed state 
of complex I assembly (i.e., in patient cells with a mutation in of one of the above mentioned 
subunits), but also in a healthy state of complex I assembly (unpublished data R. Janssen). 
Besides, NDUFAF2 does not associate with smaller (<830 kDa) subcomplexes (low-
molecular weight assembly intermediates) in patient and control fibroblasts under normal 
conditions, nor under inhibition of mitochondrial protein synthesis (by chloramphenicol), 
i.e., when small, nuclear encoded subunit-containing subcomplexes accumulate[29] 
(unpublished data R. Janssen). This confirms the observations of the in vitro import and 
assembly assays performed by Lazarou et al.[39], with radiolabeled NDUFAF2 strictly 
associating with the 830-kDa subcomplex (named ‗~800-kDa subassembly‘). Together, 
these findings strongly suggest a role for NDUFAF2 restricted to the late stages of complex I 
assembly, while absence of NDUFAF2 results in stalling of the process at the stage of 
assembly intermediate 5 of the assembly model as is demonstrated by the accumulation of 
intermediates 4 and 5 in our patient‘s fibroblasts. It can be argued that NDUFAF2 associates 
with the 830-kDa subcomplex, facilitates the incorporation of the NADH dehydrogenase 
module of complex I, i.e., the flavoprotein part (subunits NDUFV1-3) and some additional 
subunits of the peripheral arm of the complex (e.g., NDUFS4, NDUFS6, and possibly 
NDUFS1)[13,39], and releases the complex when its fully assembled state is reached. 
 
ERCC8  
In mammalian cells, various DNA repair systems exist in order to cope with attacks of 
endogenous and environmental genotoxic agents on their genomes. One of them is the 
nucleotide excision repair (NER) pathway, a complex system that removes chemically and 
UV-induced helix-distorting lesions. The transcription-coupled repair subpathway of the 
NER (TC-NER) is a mechanism that specifically removes transcription-blocking lesions from 
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the transcribed strands of actively transcribed genes[31,32]. In contrast, global genome NER 
(GG-NER) removes lesions in the entire genome. Cockayne syndrome type A, a rare 
autosomal recessive disorder characterized by UV sensitivity, severe neurological 
abnormalities, and progeriod symptoms, is caused by mutations in the ERCC8 gene, which 
encodes the Cockayne syndrome type A protein (CSA) that is part of the core of the TC-NER 
machinery[40]. 
Cockayne syndrome (CS) is primarily characterized by mild cutaneous photosensitivity, 
postnatal growth failure, progressive neurological dysfunction, and symptoms reminiscent of 
segmental accelerated ageing. This progressive disorder generally manifests at 1-2 years of 
age and results in death at puberty or early adulthood[40,41]. In addition to this classic CS, 
called type I, there is a less common early-onset form of CS, called type II, with more severe 
symptoms that already present at birth, with a concomitant shortened life expectancy 
(average 2 years). The genetic basis underlying the type I and II differences has not been 
elucidated and is independent of the severity of the TC-NER deficiency. In CS patients, a 
wide range of additional severe physical and mental manifestations develop, including 
microcephaly, retinal degeneration, deafness, and skeletal abnormalities such as 
osteoporosis and a bird-like face[40,41]. In our patient‘s fibroblasts we unequivocally 
demonstrated the presence of the distinct repair defect of CSA patients. Indeed, some of her 
symptoms, such as microcephaly, reduced birth weight, facial dysmorphology, and dry skin, 
may well be compatible with CS type II. However, we cannot dismiss the possibility that the 
patient‘s early demise at 14 months prevented any clear typical signs associated with the 
more common CS type I to become manifest. Finally, the option of an interaction between 
CS and the phenotypes associated with the other gene defects remains fully open. 
 
ELOVL7 
In mammals, fatty acids consisting of up to 16 carbons in length, which are synthesized by 
the cytosolic fatty acid synthase (FAS) complex, as well as fatty acids taken up from the diet, 
are further elongated into long-chain fatty acids containing up to 20 carbon atoms, and/or 
into very long-chain fatty acids (VLCFAs) with over 20 carbon atoms[34]. Synthesis of 
VLCFAs takes place at the cytoplasmic side of the endoplasmic reticulum (ER) and involves 
four successive enzymatic steps, which are carried out by individual membrane-bound 
proteins. The first regulatory reaction step in the elongation cycle, the condensation of a fatty 
acyl-CoA and malonyl-CoA, is the rate-limiting step, and is performed by members of the 
ELOVL protein family. To date, seven enzymes, elongases termed ELOVL1-7, have been 
identified in mammals and are suggested to perform the condensation reaction in the 
elongation cycle[34]. Noteworthily, the substrate specificity for all of the seven ELOVL 
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proteins has not been determined yet, and mutations of the ELOVL7 gene have not been 
reported before. 
To examine its involvement in VLCFA elongation, and to examine the consequences of lack 
of ELOVL7 for fatty acid metabolism, we performed analysis of fatty acid biosynthesis in our 
patient. Unfortunately, no significant differences in endogenous fatty acid levels could be 
observed when compared to the levels of controls and other complex I-deficient patients 
(with single mutations in NDUFAF2 or subunits NDUFS4 and NDUFS7). The low expression 
level of the ELOVL7 gene in fibroblasts, compared to the other elongases, can be an 
explanation for these results. Reminding the tissue specificity of the ELOVL family 
members, it might also be possible that ELOVL7 does not have a function in skin fibroblasts, 
and exerts its function and consequently displays its defect in other tissues. Therefore, 
investigation of other tissues will be needed to assign a function in fatty acid synthesis to 
ELOVL7. For instance, the apparent lipid inclusions observed in the ER of a liver biopsy of 
the patient could be indicative of disturbance of fatty acid metabolism, and thus of 
involvement of the ELOVL7 deletion in the pathology. This hypothesis is supported by the 
observation of Ikeda et al., that ELOVL7 has a preference for interaction with 3-hydroxyacyl-
CoA dehydratase 3 (HACD3), another enzyme of the elongation cycle, which exhibits a 
remarkably high expression in liver[42]. Additionally, the hepatomegaly established in our 
patient was not observed in the NDUFAF2 patients reported before, who all are assumed to 
have wild-type ELOVL7 and had normal liver function[13,35]. 
 
In conclusion, we present here a unique case of deletion of three genes with distinct 
functions, in which all three possibly contribute to the pathology of the patient. Involvement 
on a cell pathological level has been proven for NDUFAF2 and ERCC8 by complementing the 
defects in their distinct biochemical pathways, whereas involvement of the ELOVL7 deletion 
can be presumed. Moreover, we argue that the mitochondrial defect is the severest of all in 
this constellation, which is nicely sustained by the reinstatement of normal mitochondrial 
physiology in living cells upon complementation of the genetic defect. From a clinical 
perspective, it is quite plausible that the most severe disease condition with the earliest onset 
and the fastest progression will overshadow the clinical phenotypes of less severity and with 
a later onset emerging from the other gene defects. On the other hand, having a clinical 
phenotype diverging reasonably from the phenotype presented by patients with solely 
NDUFAF2 mutations, argues for a contribution of the other deleted genes to the condition of 
the patient. Considering the broad clinical spectrum of mitochondrial disorders and the 
discrepancy in symptoms amongst patients with the same gene defects, it is plausible that 
additional gene defects may be present next to the main mitochondrial defect and influence 
the clinical outcome as is illustrated by this case of a contiguous gene deletion. 
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Defects underlying human complex I deficiency 
Cohort of patients with isolated complex I deficiency 
Isolated complex I deficiency is the most common cause among OXPHOS disorders. 
Although late-onset (late childhood or adolescence) diseases haven been encountered, 
clinical presentation of isolated complex I deficiency usually starts directly after birth or in 
early childhood and comprises a great variety of signs and symptoms in many different 
organs. Organs with a high energy demand, e.g., the brain, heart, skeletal muscles, kidneys 
and the liver, are the most affected ones. Complex I failure often leads to severe multisystem 
disorders that result in early death[1-4]. Unfortunately, besides a couple of positive 
therapeutic efforts in some individual patients, rational treatment strategies for complex I 
deficiency are hardly available. This emphasizes the importance of prenatal diagnosis of the 
disease and subsequent genetic counseling. The most commonly applied prenatal diagnostic 
test is biochemical analysis of enzymatic activities of the OXPHOS system in native chorionic 
villi. However, a negative test, i.e. measurement of normal complex I activity in chorionic 
villi, does not necessarily mean that a complex I deficiency in the neonate can be excluded 
for the full 100%. For prenatal diagnosis in the case of mtDNA mutations there are two 
concerns[5]. One, the mutation load in chorionic villi does not necessarily correspond to that 
of other fetal tissues, and two, the mutation load measured in prenatal samples may shift in 
utero or after birth due to mitotic segregation. If the nuclear genetic defect in the patient is 
known, more specific and accurate prenatal diagnosis can be established by means of 
mutational analysis at the nuclear DNA level. Therefore, characterization of the genetic 
defects causing complex I deficiency, will not only expand our understanding of the 
pathological mechanisms underlying OXPHOS disease, but will also improve the prenatal 
diagnostic possibilities. 
For this purpose, several years ago, within the Nijmegen Center for Mitochondrial Disorders 
(NCMD), we started investigating a defined cohort of 27 patients from 24 families with 
established isolated complex I deficiency (i.e. sustaining normal functioning of the other four 
OXPHOS complexes) in muscle tissue and in cultured skin fibroblasts. At first, mutational 
analysis of the genes expressing the structural components of complex I was started. After 
characterization of the genes corresponding to the 38 nuclear DNA-encoded subunits of 
complex I, mutational screening yielded 15 patients (from 13 families) with molecular 
defects in one of the 38 nuclear or seven mitochondrial ND genes: in NDUFS2 in three 
families[6], NDUFS4 in three families[7,8], NDUFS7 in one family[9], NDUFS8 in one family[10], 
NDUFV1 in three families[11], ND2 in one family[12] and in ND6 in one family[13]. Additional 
screening for common point mutations and large rearrangements (e.g., deletions, insertions, 
and duplications) of the mtDNA completed the screening of structural components of 
complex I. At this point, the patient cohort had been diminished to twelve complex I-
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deficient patients (from eleven families) with unidentified genetic defects. Numerous (yet 
unidentified) external factors involved in complex I biogenesis, maintenance or functioning 
were possible candidates for carrying the defects responsible for the complex I deficiencies 
in our remaining patient cohort. 
The characterization of the human genes encoding the nuclear subunits of complex I and the 
identification of the first mutations in these genes was the starting point for nuclear 
mutational screening of complex I-deficient patients in many research centers all over the 
world yielding molecular defects in NDUFA1[14], NDUFA2[15], NDUFA11[16], NDUFS1[17], 
NDUFS3[18], NDUFS6[19] and NDUFV2[20]. 
 
Chaperones of complex I assembly possible candidates for complex I deficiency 
One group of candidates comprises the assembly chaperones, proteins involved in the 
guidance of the build-up of a complex out of 45 individual subunits. Analogous to 
cytochrome c oxidase (COX), or complex IV, for which many assembly factors have been 
described, comparable factors could be expected for complex I assembly, too. Many of these 
factors are known to be involved in the etiology of COX deficiencies. However, at that time 
the only two complex I assembly chaperones that had been described, had been found in the 
fungus Neurospora crassa: the complex I intermediate associated proteins CIA30 and 
CIA84. We identified the first human complex I assembly factor, a homologue of the CIA30 
protein, NDUFAF1, and screened our patient cohort for mutations in its gene, which has 
been described in Chapter IV. Four new single nucleotide polymorphisms (SNPs) were 
detected but no pathogenic mutation was found, declining NDUFAF1 as a candidate gene for 
complex I deficiency in our original patient cohort. Recently, the first mutation in the 
NDUFAF1 gene causing complex I deficiency has been reported[21]. Two independent studies 
based on comparative genomics analysis brought to light a putative second human complex I 
assembly chaperone, NDUFAF2 (known before as B17.2L), which was consequently posed as 
a candidate for complex I deficiency[22,23]. The NDUFAF2 gene that has been arisen from a 
duplication event, encodes a paralogue of complex I subunit NDUFA12 (B17.2 in bovine 
nomenclature). Ogilvie et al.[23] reported the first mutation in this gene being responsible for 
complex I deficiency. Screening of our patient cohort resulted in one patient with isolated 
complex I deficiency lacking the NDUFAF2 gene, which has been described in Chapter VII. 
A homozygous (total) gene deletion of the NDUFAF2 gene appeared to cause the complex I 
deficiency in our patient, as has been proven with a baculoviral complementation assay 
using wild-type NDUFAF2 cDNA. A third putative complex I assembly factor with 
pathogenic mutations causing complex I deficiency has been reported recently[24]. 
Noteworthily, the gene, C6ORF66, encodes a calmodulin-binding protein (HRPAP20) that 
has previously been shown to increase breast cancer cell invasion[25]. Despite the many genes 
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that are currently known to cause complex I deficiency, mutations in these genes have not 
been found in the remainder of our patient cohort. Other genes encoding proteins that are 
associated with complex I functioning or biogenesis such as PTCD1 (CIA84 homologue), 
Ecsit, HtrA2/Omi and a couple of yet uncharacterized complex I-related proteins derived 
from the comparative genomics analysis studies mentioned earlier[22] have been subjected 
to mutational analysis without retrieving any pathogenic mutations (R. Janssen unpublished 
results). Thus, further exploring of candidate genes in the field of complex I biogenesis will 
be needed for this patient cohort. 
 
 
Survey of mitochondrial complex I assembly 
Differences in assembly profiles implications for the complex I assembly process 
Mitochondrial complex I assembly is an intricate process, which is currently believed to 
proceed through a series of distinct assembly intermediates by combining evolutionarily 
conserved functional modules. Disturbances of the process by, for instance, mutation of 
subunits can lead to accumulation and/or depletion of several intermediate subassemblies, 
providing so-called assembly profiles. 
To interpret these assembly profiles we must take into account the following factors: the 
nature of the mutation (missense, nonsense, neutral) and conservation of the mutated 
residues within the subunit, the localization of the mutated subunit within the complex and 
the direct interactions with other subunits. A model for the topology of the subunits of 
mammalian complex I based on the fractionation of bovine complex I using mildly 
chaotropic detergents[26] has been depicted in Figure 1. 
From investigation of assembly profiles of six complex I-deficient patients with mutations in 
nuclear DNA-encoded subunits (NDUFS2, NDUFS4, NDUFS7, NDUFS8) it appeared that 
complex I assembly and/or stability has severely been compromised (Chapter VI). 
Decreased levels of fully assembled complex I correlate with the low enzymatic complex I 
activities a finding that has later been confirmed by a follow-up study[27]. These results 
suggest that disturbances in the assembly pathway or the stability of complex I are the direct 
cause of the decreased complex I activity in these patients. Besides lower amounts of fully 
assembled complex I, different patterns of low-molecular weight subcomplexes containing 
the NDUFS3 subunit occur (Chapter VI). 
Regarding the relative accumulation of NDUFS3-containing subcomplexes in the low-
molecular weight range (~100–450 kDa), it seems that, when the NDUFS4 subunit is 
mutated, assembly is stalled at a certain point, but part of the peripheral arm can still be 
formed. In addition, absence of (most of) these subcomplexes would indicate that the  
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Figure 1. A model for the topology of the subunits of mammalian complex I. 
With mildly chaotropic detergents, intact bovine complex I has been resolved into various 
subcomplexes that have subsequently been subjected to extensive analysis[26]. Subcomplex 
I  represents the peripheral arm of the complex, subcomplex I  consists of subcomplex I  
plus part of the membrane arm and subcomplex I  forms the major part of the membrane 
arm. Subunits that do not associate with the I  or I  subcomplexes are grouped as the I  
‘subcomplex’, a fraction for which it is not clear whether it represents a true fragment of 
complex I. Some subunits associate with two subcomplexes (I /I ), for others it is not 
exactly clear which subcomplex they associate with (I /I ). The nuclear DNA-encoded 
subunits are named according to the human nomenclature and preceded by the prefix 
‘NDUF’. 
 
 
formation of the peripheral arm is interrupted at very early stages of the assembly process, 
when the NDUFS2, NDUFS7 and NDUFS8 subunits are mutated. 
In patients with mutations in the NDUFS4 subunit, an additional subcomplex of ~800 kDa, 
that shows no in-gel activity, accumulates instead of fully assembled complex I (Chapter 
VI). This indicates that NDUFS4 is incorporated at a late stage in the assembly process and 
that lack of NDUFS4 would hamper the final step in the assembly of complex I. Two 
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subunits located in the peripheral and membrane arm boundary region, NDUFA9 and 
NDUFS5, associate with the ~800-kDa subcomplex (Chapter VI). The NDUFS5 subunit is 
likely to be incorporated at a late stage of assembly since it is absent in low-molecular weight 
subcomplexes and it did not co-precipitate with NDUFAF1-containing assembly 
intermediates[21]. For the NDUFA9 subunit, however, it might as well still be possible to 
assemble at early stages in the assembly process, as has been proposed by Antonicka et al.[28] 
and Lazarou et al.[29]. Since NDUFA9 is located in the peripheral and membrane arm 
boundary region, lack of detection of NDUFA9 in low-molecular weight subcomplexes 
(Chapter VI) might be due to its loose association with assembly intermediates[26]. 
 
Elucidating the pathway of de novo complex I assembly 
The subcomplexes observed in the patients fit well within the recently published complex I 
assembly model[30] that described low-molecular weight assembly intermediate complexes, 
which the NDUFS3 subunit is part of. According to this model, six distinct assembly 
intermediate complexes containing the NDUFS3 subunit could be distinguished by means of 
an inducible NDUFS3-green fluorescent protein (GFP) expression system in human 
embryonic kidney (HEK293) cells. Assembly intermediates could be identified when they 
reappeared after the release of chloramphenicol inhibition of mitochondrial translation, i.e., 
when synthesis of the mtDNA-encoded ND subunits is resumed. A shift in NDUFS3-GFP 
signal from the smaller subcomplexes 2 and 3 towards the larger subcomplexes 4–6 and 
fully assembled complex I indicated that the smaller subcomplexes (2 and 3) rather 
represent products of assembly than of instability and/or degradation. Furthermore, it could 
be concluded that the presence of ND subunits is prerequisite to subsequent formation of the 
larger assembly intermediates (4–6) and fully assembled complex I. Analogously, the 
NDUFS3-containing subcomplexes accumulating in the patients (Chapter VI) likely 
represent true intermediates of assembly rather than instability or degradation products, as 
well. In conclusion, the observation of accumulated subcomplexes in complex I-deficient 
patients supports the hypothesis that de novo complex I assembly proceeds through a series 
of distinct assembly intermediates. 
The association of the NDUFS2 subunit with the same six NDUFS3-containing 
subcomplexes[30] implies that both subunits are assembled at an early stage in the process 
and that they occur in close contact of each other. Together with subunits NDUFS7 and 
NDUFS8 they are part of the hydrogenase module that is believed to be formed at the 
beginning of the assembly process[31] and to proceed up to subcomplex 3 of the assembly 
model[30]. The next step is the incorporation of preassembled membrane modules containing 
the mtDNA-encoded subunits, with ND1 being the first to be assembled, together with more 
nuclear DNA-encoded subunits first NDUFA13 and others, then NDUFA1, NDUFA2, 
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NDUFA6, NDUFA9, NDUFB6 and others[30,31]. Finally, the NADH dehydrogenase module, 
containing NDUFV1–3, NDUFS4 and NDUFS6 (and NDUFS1), is incorporated to complete 
complex I assembly (Chapter VII)[23,29,31]. Mentioned steps are illustrated in an adapted 
model of the pathway of de novo complex I assembly, which is depicted in Figure 2. 
 
 
 
 
 
Figure 2. A model of the human complex I assembly pathway. 
It is hypothesized that de novo complex I assembly proceeds through a series of distinct assembly 
intermediates by combining evolutionarily conserved functional modules. Several assembly 
chaperones (NDUFAF1, NDUFAF2, Ecsit) associate with the intermediate complexes while facilitating 
specific steps during the assembly process and dissociate from the complex when its fully assembled 
state is obtained. Adapted from Vogel et al.[30]. 
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An alternative route for nuclear DNA-encoded subunits to assemble 
Recently, Lazarou et al.[29] hypothesized a novel complementary mechanism of complex I 
biogenesis involving exchange of preexisting subunits with newly imported ones via a 
dynamic process to maintain complex I homeostasis. Besides following the route of de novo 
complex I assembly (which is the case after release of inhibition of mitochondrial 
translation) incorporation of newly synthesized nuclear DNA-encoded subunits directly into 
preexisting assembly intermediates or the fully assembled complex takes place. Since most 
mtDNA-encoded complex I subunits are highly hydrophobic they are cotranslationally 
inserted into the mitochondrial inner membrane, mediated by chaperones such as Oxa1l, 
Letm1 and Mrpl45[32,33], where they assemble via intermediate membrane modules[28,29,31]. 
In contrast, many nuclear DNA-encoded subunits are not hydrophobic and appear capable 
of direct incorporation into the holocomplex or assembly intermediate complexes. Lazarou 
et al.[29] investigated the assembly of newly imported (nuclear DNA-encoded) subunits in 
mitochondria by means of radioactive labeling and chase assays. Subunits NDUFV3, 
NDUFS4 and NDUFS6 all appeared to assemble directly into complex I and their absence in 
intermediate assemblies indicates that they are incorporated at a late stage of complex I 
assembly[29]. They are required for the assembly of NDUFV1 and NDUFV2, and therewith, 
for the stabilization of the NADH dehydrogenase part that is located at the tip of the 
peripheral arm. A number of subunits, such as NDUFB8, NDUFS1, NDUFS2, NDUFS7, and 
NDUFA9 also integrate into additional subcomplexes in the ~480-kDa and ~550-kDa 
ranges[29], which correspond with assembly intermediates of the complex I assembly models 
mentioned before[28,31]. 
Conclusively, the dynamic process of exchange of newly imported subunits with ones in 
preexisting complexes may enable a mechanism to aid in the turnover of subunits, some of 
which are prone to oxidative damage[29] a thought that becomes interesting in the light of 
the recently observed accumulation of oxidatively damaged complex I subunits in the brains 
of patients with Parkinson disease[34]. 
 
Assembly chaperones NDUFAF1, NDUFAF2 and Ecsit facilitate the assembly process 
The biogenesis of the OXPHOS system comprises a complex series of processes. Expression 
of the mtDNA-encoded subunits, expression and import of the nuclear-DNA encoded 
subunits, addition of prosthetic groups, insertion of the subunits into the mitochondrial 
inner membrane, assembly of the holocomplexes, and the final formation of supercomplexes 
are all processes that are tightly regulated by the actions of numerous ancillary proteins[35]. 
Although the list of proteins known to be involved in these processes is growing rapidly, 
many more factors are expected to be identified. For instance, assembly of complex IV (of 
the OXPHOS system) is known to proceed through a series of intermediates that involve a 
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number of chaperones[36]. Complex IV consists of only thirteen subunits but requires more 
than fifteen different components for its coordinated assembly into a mature complex[35]. 
Complex I assembly, on the contrary, involves 45 subunits that are believed to assemble in a 
similar fashion involving many more ancillary factors. However, so far, four proteins are 
suggested to be involved in human complex I assembly and/or stabilization exerting 
chaperone-like functions, i.e., NDUFAF1 (CIA30), NDUFAF2 (B17.2L), Ecsit and C6ORF66. 
NDUFAF1 Knockdown of NDUFAF1 expression by means of RNA interference results in 
reduced amounts of fully assembled complex I and impaired enzymatic activity, supporting a 
role for NDUFAF1 in the regulation of assembly and/or stabilization of human complex I 
(Chapter V). However, the absence of accumulating assembly intermediates suggests that 
NDUFAF1 may be involved in the stabilization rather than in active combination of assembly 
intermediates. NDUFAF1 associates with two high-molecular weight protein complexes of 
approximately 600 and 700 kDa (Chapter V). The ~700-kDa complex seems to accumulate 
when membrane arm assembly is hampered, e.g., by mutation of a subunit of the membrane 
arm (patient with an ND5 mutation). Likewise, levels of the ~600-kDa complex increase 
when peripheral arm assembly is hampered (i.e. in a patient with an NDUFS8 mutation). 
The NDUFAF1-associated ~700-kDa complex disappears when mitochondrial translation is 
inhibited and depletion of mtDNA-encoded (ND) subunits occurs. The transient 
reappearance of the complex after release of inhibition of mitochondrial protein synthesis 
suggests that i) NDUFAF1 binds to a mtDNA-encoded (ND) subunit either directly or 
indirectly present in the ~700-kDa complex, and that ii) NDUFAF1 is required by this 
complex to proceed with assembly (Chapter V). A role for NDUFAF1 in assembly of (part 
of) the membrane arm corresponds with the function that was initially proposed for its 
counterpart CIA30 in Neurospora crassa[37]. Representing either an active role in assemble 
to facilitate the combination of assembly intermediates, or a stabilizing role to prevent 
degradation of assembly intermediates, remains subject to debate. 
The sizes of the NDUFAF1 complexes of ~600 kDa and ~700 kDa have recently been 
clarified as being in the ~500–850-kDa range[27], which is also in concordance with the 
NDUFAF1-associated complexes described by Dunning et al.[21]. By means of co-
immunoprecipitation studies and immunodepletion analysis they found that NDUFAF1 
associates transiently with assembly intermediate complexes of ~460 and ~830 kDa that 
contain mtDNA-encoded subunits ND1, ND2 and ND3 of the membrane arm, as well as 
various nuclear DNA-encoded subunits (including NDUFA6, NDUFA9, NDUFB6, NDUFS3 
and NDUFS7). Analysis of newly translated mtDNA-encoded subunits in a patient with an 
NDUFAF1 mutation, revealed that ND2 was absent, while ND1 appeared to stall transiently 
in an ~400-kDa subcomplex, before disappearing completely, too[21]. These findings 
correspond with the noticed absence of accumulating assembly intermediates after 
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knockdown of NDUFAF1 by RNA interference (Chapter V). It seems that lack of NDUFAF1 
leads to loss of the ~460-kDa assembly intermediate that contains ND2, thereby preventing 
combination with an assembly intermediate containing ND1 and the concomitant formation 
of the ~830-kDa subcomplex, and hence assembly of the holocomplex[21]. Taken together, 
NDUFAF1 is probably involved in the early assembly or stabilization of a subcomplex of the 
membrane arm containing ND2 and ND3 enabling association with an assembly 
intermediate containing ND1, which leads to the formation of an ~830-kDa intermediate 
subcomplex. Finalizing assembly of the peripheral arm would initiate its release from the 
complex[21]. The role of chaperone NDUFAF1 has been integrated in the model of complex I 
assembly depicted in Figure 2. 
NDUFAF2 Lack of putative assembly chaperone NDUFAF2 leads to disturbance of 
complex I assembly, demonstrated by reduced amounts and activity of complex I and 
accumulation of low-molecular weight complex I subcomplexes, corresponding with 
assembly intermediates 2–5 of the model for human complex I assembly (Chapter VII). 
NDUFAF2 has exclusively been found associated with an ~830-kDa subcomplex of complex 
I (Chapter VII)[23,27,29]. This ~830-kDa subcomplex (or ~800-kDa subcomplex), mentioned 
earlier as a late assembly intermediate of complex I, specifically accumulates in patients with 
mutations in the subunits NDUFS4, NDUFS6 and NDUFV1 and appears to lack subunits of 
the tip of the peripheral arm, i.e. NDUFV1–3, NDUFS4 and NDUFS6 (Chapter VI)[19,23,29]. 
For these patients increased protein levels of NDUFAF2 have been observed[27]. 
Transduction experiments of fibroblasts with a baculoviral NDUFAF2-GFP construct 
revealed the presence of NDUFAF2 associated with the 830-kDa subcomplex not only in a 
disturbed state of complex I assembly (i.e., in patient cells with a mutation in of one of the 
above mentioned subunits), but also in a healthy state of complex I assembly (Fig 3, R. 
Janssen unpublished results). This supports the view that the 830-kDa subcomplex 
accumulating in patients is not an artifact of destabilized complex I but in fact represents a 
stalled intermediate of complex I assembly, as is proposed by Lazarou et al.[29]. To re-
evaluate the possibility of NDUFAF2 association with low-molecular weight assembly 
intermediates, mitochondrial protein translation was inhibited by chloramphenicol 
treatment of fibroblasts from an NDUFS4 patient and a healthy control, prior to NDUFAF2-
GFP transduction, to consequently accumulate NDUFS3-containing low-molecular weight 
subcomplexes[30]. Directly after release of inhibition and concurrent resumption of complex I 
assembly, NDUFAF2 associated with the accumulating 830-kDa subcomplex in the patient 
cells, whereas no association with low-molecular weight assembly intermediates was 
observed (R. Janssen unpublished results). These findings strongly suggest a role for 
NDUFAF2 restricted to the late stages of complex I assembly. 
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Regarding the lack of in-gel activity of the 830-kDa subcomplex (Chapter VI) and the 
subunits it is missing, it can be hypothesized that NDUFAF2 associates with the ~830-kDa 
assembly intermediate, facilitates the incorporation of the NADH dehydrogenase module of 
complex I or at least an essential part of its functional structure and releases the complex 
when its fully assembled state is reached. The role of chaperone NDUFAF2 has been 
integrated in the model of complex I assembly depicted in Figure 2. 
 
 
 
 
 
Figure 3. Association of NDUFAF2 with an assembly intermediate complex. 
NDUFS4 patient (P(S4)) and healthy control fibroblasts (C2) were transduced with 
baculoviral constructs NDUFAF2-GFP (AF2) and COX8-GFP (COX8), and subsequently 
subjected to BN-PAGE analysis and western blotting. Using an anti-EGFP polyclonal 
antibody, association of NDUFAF2-GFP with the 830-kDa subcomplex of complex I is clearly 
detected in the NDUFS4 patient cells (left panel). For comparison, the same blot was incubated 
with anti-NDUFA9 antibody to show fully assembled complex I in control cells and the 830-
kDa subcomplex in the NDUFS4 patient (right panel). A closer look at a longer exposure of the 
blot (see enlargement) reveals the presence of the 830-kDa subcomplex in control cells as well 
(indicated by the arrow), albeit weakly detectable. At the bottom of the blot unbound 
NDUFAF2-GFP and COX8-GFP is detected. untr: untransduced; AF2: NDUFAF2-GFP 
transduced; COX8: COX8-GFP transduced; CI: fully assembled complex I; 830kD-sub: 830-
kDa subcomplex of complex I 
 
 
Ecsit Recently, a third putative assembly chaperone, named Ecsit, has been found 
interacting with NDUFAF1, by means of tandem affinity purification (TAP) of mitochondrial 
lysates of HEK293 cells expressing TAP-tagged NDUFAF1 protein[38]. In previous studies, 
Ecsit has been described as a cytosolic signaling protein essential for inflammatory response 
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(the Toll pathway of innate immunity) and the BMP (bone morphogenetic protein) pathway 
of embryonic development[39,40]. Ecsit associates with the high-molecular weight NDUFAF1-
containing complexes in the range of ~500–850 kDa. Protein knockdown of Ecsit 
established by RNA interference resulted in specifically disturbed complex I assembly 
and/or stability and accumulation of NDUFS3-containing assembly intermediate complexes 
in the range of ~500 kDa[38]. Furthermore, Ecsit knockdown resulted in severely decreased 
NDUFAF1 protein levels and corresponding NDUFAF1 complexes in the range of ~500–850 
kDa, indicating a chaperone-like function for Ecsit in stabilizing these complexes. It can be 
concluded that Ecsit is required for correct complex I assembly and/or stability and may 
represent a link between mitochondrial functioning, immune response and embryonic 
development. 
C6ORF66 The C6ORF66 gene, encoding a calmodulin-binding protein (HRPAP20), has 
been reported as another putative complex I assembly chaperone[24]. In two complex I-
deficient patients carrying C6ORF66 mutations, pathogenicity was proven as complex I 
activity was restored by complementation with wild-type C6ORF66 cDNA. The protein 
awaits functional characterization yet. 
 
Structural dependence of complex I on supercomplex formation 
It has been argued that fully assembled complex III is required to maintain complex I, since 
loss of assembled complex III has been found to lead to reduced levels of complex I[41]. 
Disturbed assembly of complex III due to loss of the mtDNA-encoded subunit cytochrome b 
causes a severe reduction in the level of fully assembled complex I. Although complex I was 
assembled initially, its stability was severely hampered. In addition, if complex III activity is 
impaired, for instance, by complex III-specific inhibitor antimycin A, complex III assembly 
remains unaffected and normal complex I levels are observed[41]. Conversely, physical 
absence of complex I seems not to have drastic influences on complex III assembly and/or 
stability. However, complex I deficiency combined with a moderate complex III deficiency 
has been observed for patients with mutations in the complex I subunits NDUFS2 and 
NDUFS4[8]. Protein levels of complex III are clearly lowered for NDUFS2 patients, while 
several NDUFS4 patients show a slight decrease in protein levels of assembled complex III, 
as well as in spectrophotometrically measured enzymatic activities (Chapter VI). 
Two explanations can be argued, one, complex I naturally occurs in the form of 
supramolecular structures, named supercomplexes, which are composed of several OXPHOS 
complexes. When these supercomplexes can not be formed by the physical absence of 
complex III, complex I is susceptible to degradation. And two, complex III actively 
participates in the assembly process of complex I by an yet undetermined mechanism[41]. 
The complex III dimer may act as a scaffold to facilitate complex I assembly, possibly by 
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stabilizing unassembled structures[29]. Counting in favor of the latter explanation, is the 
observation that complex I chaperone NDUFAF2 associates with a supercomplex, consisting 
of the complex III dimer and the ~830-kDa subcomplex of complex I, which is also 
accumulating in patients with mutation in the NDUFS4, NDUFS6 and NDUFV1 subunits (R. 
Janssen unpublished results)[23,29]. The same association has transiently been detected in 
mitochondria of healthy control fibroblasts[29]. These findings imply that complex I does not 
need to be fully assembled before it associates with other complexes into supercomplexes 
and that these complexes (i.e. the complex III dimer) may even participate in the assembly 
process itself. Complex IV has also been implicated in stabilization of complex I, and may be 
needed for complex I assembly and/or stability in a similar way as complex III[42]. 
 
 
Intracellular consequences of complex I deficiency 
Indicators of mitochondrial disease 
To elucidate the pathology of complex I deficiency it is important to examine its biological 
consequences at a cellular level. When a key component of the OXPHOS system, e.g. 
complex I, is missing or defective, electron transfer is hampered and ATP production is 
impaired. Disturbance of the OXPHOS system evokes a series of metabolic alterations that 
result in a variety of clinical symptoms. An important intracellular alteration is the change in 
mitochondrial membrane potential. A complex I defect can hamper proton transport across 
the mitochondrial inner membrane, which as a result gets depolarized. Defective complex I 
will also affect the NADH oxidation rate leading to an excess of mitochondrial NADH and a 
lack of NAD+. The increased NADH/NAD+ ratio delivers feedback inhibition of the TCA cycle 
and the pyruvate dehydrogenase complex (PDHc), resulting in an increase in mitochondrial 
pyruvate levels. Subsequently, excess of pyruvate is converted in the cytoplasm either into 
lactate by lactate dehydrogenase (LDH) or into alanine by transamination. As a final 
consequence elevated levels of lactate, pyruvate and alanine occur in body fluids, i.e. in 
blood, urine and frequently also in cerebrospinal fluid (CSF)[43]. Many patients suffering 
from mitochondrial disease have lactic acidemia (i.e. elevated blood lactate levels), which is 
not only an indicator of an OXPHOS defect, but the lactate itself can have deleterious effects. 
Another consequence of complex I deficiency is the generation of free radicals, superoxide in 
particular. Decreased complex I activity as well as decreased amounts of fully assembled 
complex I correlates with increased intracellular superoxide levels, as has been established 
in a cohort of 21 patients with isolated complex I deficiency[44]. As also known for cultured 
skin fibroblasts treated with rotenone, increased superoxide production in complex I-
deficient patient fibroblasts is a primary consequence of (partial) inhibition of complex I 
activity[45]. Although superoxide and its derived reactive oxygen species (ROS) play 
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important roles in a variety of signaling processes at physiological concentrations[46], they 
have deleterious effects for the cell at pathological concentrations. How, in fact, high ROS 
levels exert influence on the integrity and functioning of the OXPHOS system or 
mitochondria in general, remains subject of debate. 
Complex I deficiency can also influence mitochondrial morphology. It is hypothesized that 
complex I, when assembled with other the OXPHOS complexes in supramolecular 
structures, contributes to the unique shaping of the mitochondrial inner membrane and 
cristae[47]. Loss of fully assembled complex I could therefore lead to disturbance of 
mitochondrial inner membrane integrity and thereby change total mitochondrial 
morphology. These changes in mitochondrial morphology could finally induce apoptosis. 
 
Cell physiological changes in a complicated case of complex I deficiency 
In Chapter VII the cell physiological consequences of complex I dysfunction due to lack of 
assembly chaperone NDUFAF2 have been described. The patient with the contiguous gene 
deletion, which lacks NDUFAF2, exhibits extraordinarily high cellular superoxide levels in 
fibroblasts compared to other complex I-deficient patients. The patient‘s superoxide level 
extended up to 354% of normal control levels, which correlates inversely with the low 
amount of fully assembled complex I observed in its fibroblasts. By comparison, cellular 
superoxide levels measured in the 21 complex I-deficient patients (with or without 
established mutations) ranged from 104% to 353% of normal control levels, whereas levels 
for 13 patients with established mutations in complex I subunits encoded by the nuclear 
DNA ranged from 104% to 295% of normal control levels[44]. Nonetheless, the high 
superoxide level and low amount of fully assembled complex I in the patient‘s fibroblasts 
satisfy the inverse relationship between superoxide production and amount of fully 
assembled complex I in fibroblasts of patients with isolated complex I deficiency, which has 
been reported by Verkaart et al.[44]. 
Changes in mitochondrial membrane potential, 91% of normal control levels, and NAD(P)H 
levels, 180% of normal control levels, are comparable to other complex I-deficient patients, 
i.e., ~92% of normal control levels for mitochondrial membrane potential[48] and a range 
from 112% to 191% of normal control levels for NAD(P)H oxidation[49]. 
Mitochondrial parameters as superoxide production and membrane potential are regarded 
as key indicators of mitochondrial health and metabolic activity. Accurate determination of 
these parameters in living cells is of great importance in addressing many research 
questions[48]. 
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Future perspectives 
Currently, the list of genes responsible for human complex I deficiency is still growing, now 
including all genes encoding ‗core subunits‘, continuing with the genes encoding ‗accessory 
subunits‘ and starting with the genes encoding assembly factors (e.g., NDUFAF1, NDUFAF2, 
and C6ORF66). The intricate process of complex I assembly is starting to unravel with the 
characterization of the first few known complex I assembly factors, as NDUFAF1, NDUFAF2 
and Ecsit, supported by the current identification of patients with corresponding disease 
causing genotypes. This will open new avenues for identification of assembly factors and 
possibly explain many more yet unsolved cases of isolated complex I deficiency. Since 
NDUFAF1 and NDUFAF2 were found while associating with assembly intermediate 
complexes, examination of the composition of these subcomplexes, for instance by means of 
mass spectrometry, would present a worthwhile approach to identify new chaperones of 
complex I assembly. 
Characterizing additional functions of the accessory subunits and assembly chaperones of 
complex I is an interesting course to explore functional relationships with other intra- and 
extramitochondrial metabolic pathways. To illustrate, the NDUFA13 subunit, which is also 
known as GRIM-19, was originally identified as a critical regulatory protein for interferon-
beta and retinoic acid-induced cell death, providing a link with the mitochondrial apoptosis 
pathway[50]. In line with this, apoptosis-inducing factor (AIF) is suspected of having a role in 
the biogenesis and/or maintenance of complex I[51] and subunit NDUFS1 is recognized as a 
critical, first substrate for cleavage upon caspase activation during execution of apoptosis[52]. 
All these findings are posing complex I as a participant in apoptosis. Furthermore, there is 
credible evidence that the NDUFAB1 subunit functions as a soluble acyl carrier protein in the 
mitochondrial matrix, providing a link with mitochondrial type II fatty acid synthesis[53,54]. 
Close connections with the mitochondrial translation and import pathways have been 
suggested through subunits NDUFA2 and NDUFA11 that share a high degree of homology 
with, respectively, components of the mitochondrial ribosome, MRPL43 and MRPS25[22], 
and the mitochondrial protein import machinery, Tim proteins 17, 22 and 23[55]. Finally, 
assembly chaperone Ecsit may embody the link between complex I and pathways of the 
immune response. 
Mitochondrial parameters as membrane potential, mitochondrial morphology and 
superoxide production are regarded as key indicators of mitochondrial health and metabolic 
activity. Accurate determination of these parameters in living cells is besides gaining insight 
in its molecular background, of great importance for elucidation of the pathology of 
OXPHOS disorders. 
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At present, a remedy for OXPHOS disorders, and complex I deficiency in particular, is not 
on hand. Many clinical trials of treatment with a diversity of supplements have been 
performed in the past with varying success. Incidental successes have been established with 
administration of creatine providing energy and modestly increasing muscle strength and 
with supplementation of antioxidants, in the form of ‗cocktails‘ of vitamins or cofactors such 
as ubiquinone, idebenone, riboflavin, lipoic acid, thiamine, vitamin E and vitamin K. 
Antioxidants may scavenge harmful free radicals and/or enhance the efficacy of the 
OXPHOS system. Orally administered ubiquinone (Q) can be taken up by mitochondria, but 
only to a limited extent. MitoQ, a lipophilic triphenylphosphonium (TPP+) cation conjugated 
to ubiquinone, is a compound that selectively targets ubiquinone to mitochondria[56]. When 
the ubiquinone is reduced to its active ubiquinol redox form it can protect mitochondria 
against oxidative damage, after which it is recycled back to its active form by the 
mitochondrial respiratory chain[56]. In the past, some cases of mitochondrial myopathy 
caused by complex I deficiency have shown normalization of complex I activity along with 
clear clinical improvement upon prolonged riboflavin therapy[57-59]. Administration of 
metabolites and cofactors is especially important in disorders due to primary deficiencies of 
specific compounds, such as carnitine and coenzyme Q (ubiquinone). Unfortunately, most 
studies on the effects of supplements have produced mixed results, because of divergent 
responses to the supplements among patients. The heterogeneous nature of (the molecular 
defects underlying) OXPHOS disorders is a likely explanation for the divergent 
responsiveness among patients with mitochondrial disease. 
Genetic-based strategies are more promising treatment approaches that are currently being 
developed for patients with mtDNA defects. One such procedure is ‗gene shifting‘, i.e., 
decreasing the ratio of mutant to wild-type mitochondrial genomes, which is applied in 
patients with a pure mitochondrial myopathy. This can be achieved in various ways[5]. First, 
satellite cells with low levels of mutated mtDNA are stimulated to proliferate after which 
they are fused with mature muscle fibers, reducing the overall proportion of mutant mtDNA 
to sub-threshold levels[60,61]. Second, inhibition of replication of mutant mtDNA by selective 
hybridization of peptide nucleic acids (PNAs) favors propagation of wild-type mtDNA and 
causes the proportion of mutant mtDNA to drop below the pathological threshold[62]. Third, 
import of specific restriction endonucleases can selectively degrade mutant mtDNA[63]. 
Fourth, inducing mitochondrial fusion can lead to reorganization of the heterogeneous 
distribution of mutant mtDNAs among mitochondria, thereby dropping the proportion of 
mutant mtDNA below the pathological threshold. 
Other experimental treatments concerning ‗gene therapy‘ that are currently under 
development include allotopic expression of mitochondrial genes transferring a wild-type 
version of a mutated mitochondrial gene to the nucleus[64,65] and xenotopic 
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expression expressing cognate proteins from mitochondrial or nuclear genes from other 
organisms. Nuclear transfer is a technique that can be used to prevent the transmission of 
mtDNA disease. The strategy involves the transfer of nuclear DNA from an oocyte with 
mutant mtDNA to an enucleated oocyte from a female with normal mtDNA. The 
transmitochondrial oocyte can be fertilized in vitro and implanted in the uterus[66]. 
In conclusion, with our expanding knowledge of the OXPHOS system, and mitochondrial 
function in general, it more and more tends to appear in the center of a complex 
constellation of biochemical pathways, serving (almost) every cell of the body. This, once 
again, emphasizes the importance of finding a cure for mitochondrial disease. 
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Oxidative phosphorylation (OXPHOS) is the final biochemical pathway of energy (ATP) 
production in the cell. Defects of the OXPHOS system are amongst the most frequent inborn 
errors of metabolism and result in many, often devastating diseases affecting different 
organs and tissues. The OXPHOS system consists of five multiprotein complexes that are 
built out of 89 structural protein components, which are encoded by both the mitochondrial 
and nuclear DNA. Correct biogenesis and functioning of the OXPHOS system is dependent 
on the finely tuned interaction between the nuclear and the mitochondrial genomes. As a 
consequence, disturbances of the system can be caused by numerous genetic defects and can 
manifest in a variety of metabolic alterations that result in a plethora of clinical symptoms. 
In Chapter II we give an overview of the many genetic defects underlying OXPHOS 
deficiencies and discuss how the four different types of inheritance autosomal recessive or 
dominant, X-linked and maternal or mitochondrial contribute to the heterogeneity of 
OXPHOS disease and possibly can be supportive of linking clinical diagnosis to molecular 
defects. 
The most common cause of OXPHOS disease is isolated complex I deficiency. Complex I is 
the largest and most complicated of five complexes and represents the main entrance of the 
OXPHOS pathway. Structure, function and biogenesis of mitochondrial complex I is 
reviewed in Chapter III, as well as the pathology of complex I deficiency. Complex I 
deficiency is the underlying defect of a heterogeneous group of clinical phenotypes, 
comprising single-organ conditions as well as multisystemic syndromes. Mutations 
responsible for complex I deficiency can be found in many genes encoding structural 
subunits (encoded by the mitochondrial as well as the nuclear DNA), assembly factors, or 
proteins otherwise involved in the biogenesis or functioning of complex I, or of its cofactors 
(e.g. FMN). Additionally, complex I deficiency occurs as in many devastating 
neurodegenerative disorders, such as Parkinson disease and Alzheimer disease. 
The biogenesis of complex I is an intricate process of assembly of 45 individual subunits into 
a membrane-bound multiprotein structure. This process is suspected of being facilitated by 
the action of several (yet to be characterized) assembly chaperones. In Chapter IV we 
report the identification of the first human complex I assembly factor, NDUFAF1, which is 
the human homologue of assembly chaperone CIA30 of the fungus Neurospora crassa. We 
present the genomic sequence of the NDUFAF1 gene and demonstrate that expression of the 
NDUFAF1 protein is ubiquitous with a slightly higher expression in heart, kidney, lung and 
liver. Mutational analysis of the NDUFAF1 gene in 13 patients with an isolated complex I 
deficiency resulted in the detection of four new single nucleotide polymorphisms (SNPs), but 
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no functional mutations were found. Nevertheless, we propose the NDUFAF1 gene as a 
candidate for complex I deficiency. Characterization of the function of NDUFAF1 in the 
assembly process of complex I and the investigation of its involvement in complex I 
deficiency is described in Chapter V. By means of subcellular fractionation and 
immunofluorescence microscopy, mitochondrial localization of NDUFAF1 is demonstrated, 
which is consistent with an in silico prediction of an N-terminal mitochondrial targeting 
sequence. Knockdown of NDUFAF1 expression established by RNA interference leads to 
reduced amounts of complex I and impaired enzymatic activity. Furthermore, we 
demonstrate that NDUFAF1 associates with two high-molecular weight complexes, one of 
which (the larger) seems to accumulate when membrane arm assembly is hampered, and 
disappears when mtDNA-encoded subunits are depleted by inhibition of mitochondrial 
translation. This NDUFAF1-containing complex transiently reappears when assembly 
resumes. These findings suggest that NDUFAF1 facilitates assembly and/or stability of 
complex I, possibly through associating with an assembly intermediate complex by binding 
to a mtDNA-encoded subunit. 
The assembly process of mitochondrial complex I is currently believed to proceed through a 
series of distinct assembly intermediates by combining evolutionarily conserved functional 
modules. Disturbances of the process by, for instance, mutation of subunits can lead to 
accumulation and/or depletion of several assembly intermediate complexes, as a result of 
which so-called assembly profiles can be constituted. In Chapter VI we describe how 
mutations in different complex I subunits affect the integrity of complex I and interpret the 
assembly profiles it brings forth. In six patients with complex I deficiency caused by 
mutations in nuclear DNA-encoded subunits (NDUFS2, NDUFS4, NDUFS7, NDUFS8) we 
show reduced levels of fully assembled complex I and complex I in-gel activity that correlate 
with the low spectrophotometrically measured complex I enzyme activities. These results 
suggest that disturbance of the assembly process or the stability of complex I, caused by 
mutation of the mentioned subunits, is the direct cause of the decreased complex I activities 
in these patients. However, some patients with unknown mutations show no correlation 
between their low complex I activities and the levels of the fully assembled complex I, which 
can be indicative of a catalytic defect. Mutations may occur in genes involved in the 
activation of complex I or in the synthesis one of its cofactors (FMN, FeS clusters). In the 
patients with mutations in the nuclear DNA-encoded subunits accumulation of low-
molecular weight subcomplexes containing the NDUFS3 subunit occurs in different 
patterns. These NDUFS3-containing subcomplexes fit well within a recently proposed model 
of complex I assembly and likely represent true intermediates of assembly rather than 
instability or degradation products. In patients with mutations in the NDUFS4 subunit, an 
additional subcomplex of ~830 kDa (~800 kDa in Chapter VI), that shows no in-gel activity, 
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accumulates instead of fully assembled complex I. This suggests that NDUFS4 is 
incorporated at a late stage in the assembly process. In addition to the complex I deficiency, 
a moderate complex III deficiency has been observed for patients with NDUFS2 and 
NDUFS4 mutations. 
In Chapter VII a unique case of complex I deficiency is described. A patient presenting 
with an apparently mitochondrial encephalomyopathy carries a homozygous triple gene 
deletion on chromosome 5 encompassing the NDUFAF2, ERCC8, and ELOVL7 genes. The 
genes encode the human complex I assembly factor 2, also known as B17.2L, a protein of the 
nucleotide excision repair (NER) machinery, and a putative elongase of very long-chain fatty 
acid (VLCFA) synthesis, respectively. The patient‘s fibroblasts demonstrate a NER defect 
that is characteristic of Cockayne syndrome type A and that can unequivocally be ascribed to 
the deletion of the ERCC8 gene. Unfortunately, due to the low expression level of ELOVL7 in 
human fibroblasts, specific changes in endogenous fatty acid levels as a consequence of the 
ELOVL7 deletion could not be assessed in the patient‘s fibroblasts. By use of a baculoviral 
complementation assay with wild-type NDUFAF2, the loss of the NDUFAF2 gene has been 
proven to cause the complex I deficiency. Lack of NDUFAF2 protein leads to disturbance of 
complex I assembly, which is demonstrated by reduced amounts and activity of complex I 
and accumulation of small assembly intermediates. Furthermore, investigation of cell 
physiological consequences reveals increased intracellular superoxide and mitochondrial 
NAD(P)H levels, and decreased mitochondrial membrane potential. All observed cell 
physiological alterations are restored upon complementation with wild-type NDUFAF2. 
Chaperone NDUFAF2 exclusively associates with the ~830-kDa subcomplex (~800 kDa in 
Chapter VI) that accumulates specifically in patients with mutations in the subunits located 
in the tip of the peripheral arm (NDUFS4, NDUFS6, NDUFV1) and that corresponds to a late 
assembly intermediate of complex I. It can be hypothesized that NDUFAF2 associates with 
the ~830-kDa assembly intermediate, facilitates the incorporation of the NADH 
dehydrogenase module of complex I and releases the complex when its fully assembled state 
is reached. 
Finally, the stepwise, de novo, assembly of complex I is discussed in Chapter VIII. The 
proposed roles of assembly chaperones NDUFAF1 and NDUFAF2 are integrated in a revised 
model of the complex I assembly pathway. The alternative assembly mechanism of dynamic 
exchange of subunits is reflected shortly, as is the role of a third putative assembly 
chaperone, named Ecsit, and the importance of complex III for complex I assembly. 
To understand the pathology of complex I deficiency it is important to not only elucidate the 
molecular background, but also to examine its physiological consequences at a cellular level. 
Mitochondrial parameters as membrane potential, mitochondrial morphology and 
superoxide production are regarded as key indicators of mitochondrial health and metabolic 
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activity. In conclusion, elucidating the mechanisms underlying the biogenesis and 
functioning of complex I and expanding our knowledge of the pathogenesis of complex I 
deficiency will be of utmost importance for performing accurate diagnostics and ultimately, 
for development of future therapeutic treatment. 
 
Samenvatting 
205 
 
Samenvatting 
 
Voor het dagelijks functioneren van ons lichaam is energie nodig, veel energie! Deze energie 
wordt geproduceerd in de vorm van ATP in de vele ‗mini-energiecentrales‘, de 
mitochondriën, die zich in vrijwel elke cel van ons lichaam bevinden. Oxidatieve 
fosforylering (OXFOS) is de laatste biochemische stap in het productieproces van ATP. In 
het kort houdt dit in dat oxidatie van energierijke producten van de stofwisseling 
(metabolieten) gevolgd door een serie biochemische reacties, er toe leidt dat zuurstof wordt 
gereduceerd tot water en ADP wordt omgezet in het energierijke ATP. Dit proces wordt 
uitgevoerd door vijf eiwitcomplexen die zich in de binnenmembraan van de mitochondriën 
bevinden. Deze eiwitcomplexen vormen samen met twee elektronendragers (ubiquinon en 
cytochroom c) het OXFOS systeem en zijn opgebouwd uit 89 verschillende 
eiwitcomponenten (of subunits). Het DNA dat de code (ook wel gen genoemd) bevat voor de 
aanmaak van deze eiwitten bevindt zich voornamelijk in de celkern. Daarnaast hebben de 
mitochondriën een eigen DNA molecuul dat voor enkele van deze eiwitten codeert. Door een 
fout in het DNA, een mutatie genoemd, wordt een defect eiwit aangemaakt dat op zijn beurt 
een defect in het OXFOS systeem kan veroorzaken. Een defect OXFOS systeem kan 
vervolgens tot een verstoring van het ATP-productieproces leiden met uiteindelijk een 
energietekort tot gevolg. Defecten van het OXFOS systeem, OXFOS deficiënties, behoren tot 
de meest voorkomende aangeboren stofwisselingsstoornissen en komen tot uiting in de 
vorm van vaak zeer ernstige ziekten, die veelal een vroege dood inleiden. Vooral organen die 
een hoog energieverbruik hebben, zoals de spieren en de hersenen, zijn aangedaan, maar 
ook afwijkingen aan de ogen, de lever, de nieren en het spijsverteringsstelsel kunnen 
voorkomen. 
Een correcte opbouw en het goed functioneren van het OXFOS systeem is afhankelijk van de 
nauwkeurig afgestemde samenwerking tussen het mitochondriële en het kern-DNA. 
Derhalve kunnen verstoringen van het systeem veroorzaakt worden door tal van genetische 
defecten die een reeks van metabole en biochemische veranderingen in de cel teweeg kunnen 
brengen en die in een diversiteit aan klinische symptomen tot uiting kunnen komen. In 
Hoofdstuk II wordt een overzicht gegeven van de vele genetische defecten die aan de basis 
liggen van OXFOS deficiënties en wordt bediscussieerd hoe de vier verschillende typen van 
overerving autosomaal recessief of dominant, X-gebonden en maternaal of 
mitochondrieel bijdragen aan de diversiteit van OXFOS ziekten en mogelijk een handvat 
kunnen bieden voor het koppelen van een klinische diagnose aan een moleculair defect. De 
meest voorkomende oorzaak van OXFOS ziekten is geïsoleerde complex I deficiëntie. 
Complex I is de grootste en meest gecompliceerde van de vijf eiwitcomplexen en belichaamt 
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de belangrijkste toegangspoort van het OXFOS proces. Zowel de structuur, de functie en de 
vorming van mitochondrieel complex I, alsook de pathologie van complex I deficiëntie, 
worden besproken in Hoofdstuk III. Complex I deficiëntie is het achterliggende defect van 
een heterogene groep klinische fenotypen die bestaat uit zowel één-orgaan aandoeningen als 
multisystemische syndromen. Mutaties die complex I deficiëntie veroorzaken, kunnen 
gevonden worden in de genen die coderen voor subunits (gecodeerd door zowel het 
mitochondriële als het kern-DNA), assemblage factoren of eiwitten die op andere wijze 
betrokken zijn bij de opbouw of het functioneren van complex I of zijn cofactoren (FMN). 
Complex I deficiëntie komt ook voor in vele, ernstige neurodegeneratieve aandoeningen, 
zoals de ziekten van Parkinson en Alzheimer. 
De vorming van complex I is een gecompliceerd proces van assemblage van 45 individuele 
subunits tot één membraangebonden eiwitstructuur. Dit proces wordt waarschijnlijk 
gecoördineerd en vergemakkelijkt door de tussenkomst van enkele (nog te karakteriseren) 
assemblage chaperonnes. In Hoofdstuk IV wordt de identificatie van de eerste humane 
assemblage factor van complex I, NDUFAF1, gerapporteerd. NDUFAF1 is de humane 
homoloog van assemblage chaperonne CIA30 van de schimmel Neurospora crassa. Naast 
het presenteren van de genomische sequentie van het NDUFAF1 gen wordt getoond dat 
expressie van het NDUFAF1 eiwit in alle weefsels plaats vindt, met een enigszins hogere 
expressie in het hart, de nieren, de longen en de lever. Mutatieanalyse van het NDUFAF1 gen 
in dertien patiënten met geïsoleerde complex I deficiëntie resulteerde in de detectie van vier 
nieuwe single nucleotide polymorfismen (SNPs), maar functionele mutaties werden niet 
gevonden. Toch kan NDUFAF1 beschouwd worden als een kandidaat gen voor complex I 
deficiëntie. De karakterisering van de functie van NDUFAF1 in het assemblage proces van 
complex I wordt beschreven in Hoofdstuk V. Met behulp van subcellulaire fractionering en 
immuunfluorescentie microscopie wordt mitochondriële lokalisering van NDUFAF1 
aangetoond, wat consistent is met een in silico voorspelling van de aanwezigheid van een N-
terminale mitochondriële targeting sequentie. Knockdown van NDUFAF1 expressie, 
gecreëerd d.m.v. RNA interference, leidt tot een verminderde hoeveelheid complex I en 
verlaagde enzymactiviteit. Verder wordt getoond dat NDUFAF1 associeert met complexen 
van hoogmoleculair gewicht, waarvan één (de grootste) lijkt te accumuleren als 
membraanarm assemblage verhinderd wordt en verdwijnt als depletie van mitochondrieel 
DNA-gecodeerde subunits plaats vindt, t.g.v. remming van mitochondriële translatie. Dit 
NDUFAF1-bevattende complex komt tijdelijk opnieuw op wanneer assemblage zich hervat. 
Aan de hand van deze bevindingen kunnen we veronderstellen dat NDUFAF1 de assemblage 
en/of de stabiliteit van complex I bevordert mogelijk door te associëren met een 
assemblage intermediair via binding met een mitochondrieel DNA-gecodeerde subunit. 
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De huidige opvatting is dat het assemblage proces van mitochondrieel complex I via een 
aantal duidelijk onderscheidbare assemblage intermediairen verloopt door evolutionair 
geconserveerde functionele modules te combineren. Verstoringen van het proces, door 
bijvoorbeeld mutatie van subunits, kan leiden tot accumulatie en/of depletie van enkele 
assemblage intermediairen, waardoor zogenaamde assemblage profielen kunnen worden 
samengesteld. Hoofdstuk VI beschrijft hoe mutaties in verschillende complex I subunits 
de integriteit van complex I beïnvloeden en beschouwt de hieruit voortvloeiende assemblage 
profielen. Zes bestudeerde complex I-deficiënte patiënten met mutaties in kern-DNA-
gecodeerde subunits (NDUFS2, NDUFS4, NDUFS7, NDUFS8) vertonen verminderde 
hoeveelheden volledig geassembleerd complex I en verlaagde in gel complex I activiteiten, 
die correleren met de lage, spectrofotometrisch gemeten complex I enzymactiviteiten. Deze 
resultaten veronderstellen dat verstoring van het assemblage proces of de stabiliteit van 
complex I, veroorzaakt door mutatie van genoemde subunits, het directe gevolg is van de 
verlaagde complex I activiteiten in deze patiënten. Echter, sommige patiënten met 
onbekende mutaties vertonen geen correlatie tussen complex I activiteit en de hoeveelheid 
volledig geassembleerd complex I, wat mogelijk duidt op een katalytisch defect. Mutaties die 
hiervoor verantwoordelijk zijn, kunnen gezocht worden in genen die betrokken zijn bij de 
activering van complex I of bij de synthese van één van zijn cofactoren (FMN, FeS clusters). 
In patiënten met mutaties in de kern-DNA-gecodeerde subunits vindt accumulatie van 
subunit NDUFS3-bevattende subcomplexen van laagmoleculair gewicht plaats in 
verschillende patronen. Deze subunit NDUFS3-bevattende subcomplexen passen goed 
binnen een nieuw model van complex I assemblage en belichamen waarschijnlijk ‗ware‘ 
assemblage intermediairen en niet instabiliteits- of afbraakproducten. In patiënten met 
mutaties in de NDUFS4 subunit accumuleert een additioneel subcomplex van ~830 kDa 
(~800 kDa in Hoofdstuk VI), dat geen in gel activiteit vertoont, in plaats van volledig 
geassembleerd complex I. Dit suggereert dat de NDUFS4 subunit in een laat stadium van het 
assemblage proces wordt geïncorporeerd in het complex. Voor patiënten met NDUFS2 en 
NDUFS4 mutaties is naast complex I deficiëntie een gematigde complex III deficiëntie 
waargenomen. 
In Hoofdstuk VII wordt een unieke casus van complex I deficiëntie behandeld. Een patiënt 
met een ogenschijnlijk mitochondriële encefalomyopathie draagt een homozygote 
drievoudige gendeletie op chromosoom 5, die de NDUFAF2, ERCC8 en ELOVL7 genen 
omvat. Deze genen coderen respectievelijk voor de humane complex I assemblage factor 2 
(ook bekend onder de naam B17.2L), een eiwit van de nucleotide excision repair (NER) 
machinerie en een elongase van de zeer-lange-keten-vetzuursynthese. De patiëntfibroblasten 
vertonen een NER defect dat karakteristiek is voor Cockayne syndroom type A en dat 
ontegenzeggelijk kan worden toegeschreven aan de deletie van het ERCC8 gen. Als gevolg 
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van het lage expressie niveau van ELOVL7 in humane fibroblasten kunnen er geen specifieke 
veranderingen in de endogene vetzuurniveaus worden vastgesteld in de fibroblasten van de 
patiënt. Hierdoor kan er (nog) geen specifiek defect in de vetzuursynthese worden 
toegeschreven aan de deletie van het ELOVL7 gen. Met een baculovirale complementatietest 
met gebruik van wildtype NDUFAF2 is aangetoond dat de complex I deficiëntie wordt 
veroorzaakt door verlies van het NDUFAF2 gen. Gebrek aan het NDUFAF2 eiwit leidt tot 
verstoring van complex I assemblage, dat aangeduid wordt door een verlaagde hoeveelheid 
en activiteit van complex I en accumulatie van assemblage intermediairen. Bovendien laat 
onderzoek naar de celfysiologische consequenties zien dat intracellulaire superoxide 
productie en mitochondriële NAD(P)H niveaus verhoogd zijn en dat de mitochondriële 
membraan potentiaal verlaagd is. Alle waargenomen celfysiologische veranderingen worden 
hersteld na complementatie met wildtype NDUFAF2. 
Chaperonne NDUFAF2 associeert uitsluitend met het ~830-kDa subcomplex (~800 kDa in 
Hoofdstuk VI), dat specifiek accumuleert in patiënten met mutaties in de subunits die zich in 
de top van de perifere arm bevinden (NDUFS4, NDUFS6, NDUFV1) en dat correspondeert 
met een late assemblage intermediair van complex I. We kunnen veronderstellen dat 
NDUFAF2 associeert met de ~830 kDa-assemblage intermediair, vervolgens de incorporatie 
van de NADH-dehydrogenase module bevordert en het complex pas verlaat als de volledig 
geassembleerde vorm bereikt is. 
Ten slotte wordt de stapsgewijze de novo assemblage van complex I bediscussieerd in 
Hoofdstuk VIII. De vermeende rollen in het assemblage proces voor chaperonnes 
NDUFAF1 en NDUFAF2 worden geïntegreerd in een herzien model van de complex I 
assemblage route. Het alternatieve assemblage mechanisme van dynamische uitwisseling 
van subunits wordt kort behandeld, alsook de rol van een derde assemblage chaperonne, 
genaamd Ecsit, en de invloed van complex III op complex I assemblage. 
Om de pathologie van complex I deficiëntie te begrijpen is het van belang niet alleen de 
moleculaire basis in kaart te brengen, maar ook de fysiologische consequenties op cellulair 
niveau te onderzoeken. Mitochondriële parameters als membraan potentiaal, 
mitochondriële morfologie en superoxide productie worden gezien als graadmeter voor 
mitochondriële gesteldheid en metabole activiteit. Tot besluit, het ophelderen van de 
mechanismen die schuilgaan achter de opbouw en het functioneren van complex I, en het 
uitbreiden van onze kennis van de pathogenese van complex I deficiëntie, zal van uiterst 
belang zijn voor het uitvoeren van accurate diagnostiek, en uiteindelijk, voor de ontwikkeling 
van toekomstige therapeutische behandeling. 
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‗sequencen‘, waarin met name Roel een belangrijk deel voor zijn rekening heeft genomen. De 
‗weefselkweek‘ en ‗spiergroep‘ wil ik bedanken voor hun ondersteuning van mijn onderzoek 
door het aanleveren van de patiëntencellen en het uitvoeren van enzymactiviteitsmetingen. 
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